Mycronic receives order for an advanced mask writer

Mycronic AB (publ) has received an order for a mask writer from the Prexision series for display applications from an existing customer in Asia. The order consists of a Prexision-10 mask writer, limited to production of up to generation 8 photomask size. The system can later be upgraded to a full scale Prexision-10 production system. The order for the limited Prexision-10 system is valued between USD 30–35 million and delivery is scheduled for the fourth quarter of 2020. Mycronic’s Business Area Pattern Generators provides mask writers for manufacturing photomasks in several fields of application. These consist of display manufacturing (TV, smartphones and tablets) and applications in the multi-purpose market, a broad segment which includes such applications as electronic packaging, microelectromechanical systems (MEMS) and touchscreen functions. ”With this size-limited Prexision-10 system the customer will be able to produce photomasks for generation 8 and later upgrade to generation 10 photomask size. This is an attractive way for the customer to add production capacity at a later point in time, when required” says Charlott Samuelsson, Sr VP Pattern Generators at Mycronic. For further information, please contact:Charlott SamuelssonSr VP Business Area Pattern GeneratorsTel: +46 709 844 282charlott.samuelsson@mycronic.com Sven ChetkovichActing Director IR & Corporate CommunicationsTel: +46 70 558 39 19sven.chetkovich@mycronic.com (Torbjorn.wingardh@mycronic.com) The information in this press release was published on July 15, 2019, at 12:00 p.m. About MycronicMycronic AB is a Swedish high-tech company engaged in the development, manufacture and marketing of production equipment with high precision and flexibility requirements for the electronics industry. Mycronic headquarters are located in Täby, north of Stockholm and the Group has subsidiaries in China, France, Germany, Japan, Singapore, South Korea, the Netherlands, United Kingdom and the United States. Mycronic AB (publ) is listed on NASDAQ Stockholm. www.mycronic.com

Orders and revenue growth with sustained high profitability

The order volumes for compressors increased in the quarter while orders for vacuum equipment decreased. The industrial assembly tools and solutions business saw a somewhat lower equipment demand from the motor vehicle industry. For power equipment, such as generators and pumps, the order volumes increased strongly. “The demand for our products remained high and the service business continued to grow in all business areas”, said Mats Rahmström. Orders received in the second quarter grew to MSEK 26 565 (25 120), an organic growth of 2%. Revenues were MSEK 25 580 (24 461), up 1% organically. Excluding items affecting comparability, the adjusted operating profit increased 2% to MSEK 5 622 (5 485), corresponding to a margin of 22.0% (22.4). The return on capital employed increased further to 33% (31). During the quarter, Atlas Copco acquired nine companies and during 2019, up until today, 16 acquisitions have been closed. “Acquiring the right companies as well as investing in research and development has played an important part in making Atlas Copco what it is today”, said Mats Rahmström. “We know that diversity makes us stronger and when we bring new companies in we want them to keep their unique traits and what made them successful to begin with. I am happy to welcome these new members to the Group and look forward to leveraging their ideas, new technologies and service opportunities, with the existing strengths of Atlas Copco. That combination will bring true value to our customers”. Looking ahead, in the near-term, the demand for Atlas Copco’s products and services is expected to be somewhat lower than the level in the second quarter.

Svenska Aerogel Holding AB (publ) appoints Gert Sköld as new CFO

Gert Sköld is currently CEO, and previously CFO, of Scandinavian Track Group AB and has extensive experience from leading positions within, among others, ABB, Siemens and Sandvik where he was responsible for Business Development, Finance, IT and project management for a business area of SEK 38 billion with global activity. Gert is 53 years old and holds both a Master of Science in Industrial Engineering and Management and an MBA in International Marketing. Tor Einar Norbakk, CEO says: “We are very pleased to welcome Gert to Svenska Aerogel. His experience from the manufacturing industry, global operations,  leading and motivating employees will be very important for our further success and growth.” “I would also like to thank Stefan Kaiser for his efforts during this important period in Svenska Aerogel's history where we went from a research company to a successful listing on Nasdaq First North. We wish him good luck in the future.” Gert Sköld says: “Svenska Aerogel is a company working at the technology edge and is currently in a very exciting phase in the transition from research to production and commercialization. I look forward to support the company in its next development stage” For further information, please contact: Tor Einar Norbakk, CEO Svenska Aerogel +46 70 616 0867 toreinar.norbakk@aerogel.se Svenska Aerogel has developed Quartzene, the Next Generation aerogel.  Quartzene is an additive material for products in thermal insulation, paint&coatings and filtration. Svenska Aerogel Holding AB is listed on Nasdaq First North. Certified Adviser is FNCA info@fnca.se +46 8 528 003 99. This information is published by Svenska Aerogel through the agency of CEO Tor Einar Norbakk on July 15 2019, at 1 pm.

BioArctic’s co-founder received AAIC Lifetime Achievement Award

Stockholm, Sweden, July 15, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced that on Sunday, its co-founder, Lars Lannfelt, professor in geriatrics at Uppsala University and researcher, received one of the world’s most prestigious awards in Alzheimer’s disease research. The award is called the “Khalid Iqbal Lifetime Achievement Award in Alzheimer’s Disease Research” and was given out during the ongoing Alzheimer’s Association International Conference® (AAIC®) 2019 in Los Angeles, USA. The award recognizes individuals whose contributions have shown a lasting impact on the field and whose body of work has demonstrated a lifetime commitment towards progress against Alzheimer's and dementia. Earlier this year, Professor Lannfelt was also the recipient of the Swedish Alzheimer’s Foundation’s Grand Research Prize. The motivation for this international award, according to the Alzheimer’s Association, is Professor Lannfelt’s discoveries of mutations leading to understanding of the origins of Alzheimer’s disease and his following research, which has led to the drug candidate BAN2401. In March this year, BioArctic’s partner Eisai initiated a global confirmatory Phase 3 study with BAN2401 in patients with early Alzheimer’s disease. This phase 3 study is based on the positive results from the Phase 2b study in 856 patients, which showed slowed clinical progression, clearance of amyloid beta in the brain and effects on neurodegenerative biomarkers, as well as good tolerability, after 18 months treatment. “I am deeply grateful to receive the Khalid Iqbal Lifetime Achievement Award in Alzheimer’s Disease Research from the Alzheimer Association. My thanks goes to the families and patients with Alzheimer’s disease, who have contributed so much by participating in the research,” said Lars Lannfelt at the award ceremony. He continued, “I would also like to thank the large number of skilled collaborators I have had during the years, and the international Alzheimer research scientific community.” Professor Lannfelt received the award in Los Angeles from Dr. Khalid Iqbal himself, one of the co-founders of the Alzheimer’s Association International Conference. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. For more information, please contact: Gunilla Osswald, PhD, CEO, BioArctic ABE-mail: gunilla.osswald@bioarctic.seTelephone: + 46 8 695 69 30 This information was submitted for publication at 5:00 p.m. CET on July 15, 2019. Notes to editors About Professor Lars Lannfelt Professor Lannfelt was born in 1949 and received his medical degree in 1978, becoming a specialist in psychiatry in 1987 and in geriatrics in 2001. He received his PhD from Karolinska Institute in 1990 and became an associate progressor in neurodegeneration at Karolinska Institute in 1993. He went on to become Professor in Geriatrics at Uppsala University in 2001 and Senior Professor in 2016. He has been a member of the Royal Swedish Academy of Sciences since 2004. Professor Lannfelt co-founded BioArctic AB in 2003 and was the Chairman of the Board of Directors until September 2017. He has been a member of the Board since September 2017 and is currently Senior Vice President in the company with responsibility for University Collaborations. About BAN2401 BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between BioArctic and Eisai. BAN2401 has a unique binding profile and selectively binds to and eliminates soluble, toxic amyloid-beta aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in Alzheimer’s disease. As such, BAN2401 has the potential to have an effect on the disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic in December 2007. In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for BAN2401. Currently, a global confirmatory Phase 3 clinical study (Clarity AD) of BAN2401 in patients with early Alzheimer´s disease is underway. According to Eisai, the final readout of the primary endpoint of the study is targeted for 2022. About the Alzheimer’s Association International Conference® The Alzheimer’s Association International Conference® is the largest and most influential international meeting dedicated to advancing dementia science. Each year, AAIC® convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that'll lead to methods of prevention and treatment and improvements in the diagnosis of Alzheimer’s disease. About BioArctic AB BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com .

IRLAB reports top line results from Phase IIa study with IRL790

Analysis of UDysRS, the primary efficacy variable, showed no statistical difference between IRL790 and placebo in the per protocol analysis set (PPAS) or full analysis set (FAS). The other two prespecified assessments indicated that IRL790 reduced dyskinesias. Dyskinesia assessment using MDS-UPDRS (question 4.1+4.2) showed an improvement by IRL790 treatment (p=0.03 PPAS, p=0.07 FAS) as compared to placebo. Also, the patient reported diaries showed that IRL790 treatment, compared to placebo, significantly reduced the daily time with troublesome dyskinesias in ON state (p=0.03 PPAS, p=0.03 FAS). IRL790 was well tolerated in the study. The mean dose of IRL790 at end of treatment was 16.2 mg daily. Three patients prematurely discontinued treatment, two due to adverse events, one treated with IRL790 and one with placebo, and one IRL790 treated patient due to withdrawal of consent. Any adverse event was reported by 78 % of placebo treated patients and 74% of IRL790 treated patients. The most common adverse events reported by system organ class (SOC) were nervous system disorders reported by 42% of placebo treated patients and 49% of IRL790 treated patients. There were 3 Serious Adverse Events (SAEs), none related to IRL790 treatment, 2 occurred during the screening period before randomization and 1 was reported for a patient treated with placebo. Cardiovascular assessments including blood pressure, heart rate, and ECG, showed no clinically relevant changes due to IRL790 treatment. Assessment of other motor symptoms of Parkinson’s disease using MDS-UPDRS part II+III, MDS-UPDRS off-time assessment as well as 24-hour diaries showed that patients treated with IRL790 maintained their general motor functions and had no increase in OFF time. Joakim Tedroff, CMO at IRLAB, commented “Dyskinesia is a burdensome symptom for patients with Parkinson’s disease as it is affecting their everyday lives and limits optimization of L-Dopa treatment. The patient reported outcome in this study suggest that adding IRL790 to their otherwise stable anti-parkinsonian treatment can improve the quality of daily motor function by reducing troublesome dyskinesias. This outcome was also independently reflected in the UPDRS ratings but not in the UDysRS ratings. This discrepancy needs to be investigated further. Importantly, the excellent safety and tolerability profile observed for IRL790 treatment in this study provides additional reassurance that IRL790 is safe to use in this vulnerable patient population and supports a careful assessment of the continued clinical development of IRL790.” Nicholas Waters, CEO at IRLAB, commented “We are pleased that the study is completed. Given the ambiguity between UDysRS and the other two methods used to assess dyskinesias, further analyses aiming to clarify the underlying reasons will be prioritized to optimize the clinical path forward. Next planned clinical study with IRL790 is in psychosis associated with Parkinson’s disease, PD-P, while continuing CMC development and long-term toxicological studies”. The company will continue and complete analysis of the current Phase II study data. The full results of the study will be published in an international scientific journal. About the study IRL790C003 (ClinicalTrials.gov Identifier: NCT03368170) The Phase IIa study was randomized, double-blind, placebo-controlled and run at 16 sites in the UK and 4 sites in Sweden. 106 patients with Parkinson’s disease and dyskinesia (involuntary movements) were screened for participation in the study and 75 patients, fulfilling inclusion criteria, were randomized to four weeks of treatment, 39 patients with IRL790 and 36 patients with placebo. 42 patients were male and 33 female and the mean age of the patients in the study was 66.6 years. Average duration of Parkinson’s disease was 10.7 years. IRL790 was taken twice daily (b.i.d.) as adjunctive treatment to the patients’ regular and stable antiparkinsonian medication. The first two weeks of treatment comprised titration of placebo or IRL790 (10 to 20 mg daily) to the individually preferred and tolerated dose then used for the remaining two weeks. Tolerability and safety were continuously monitored. About FAS and PPAS The Full Analysis Set (FAS) consisted of all randomised and treated patients who received one or more doses and who provided post baseline data. The Per Protocol Set (PPS) consisted of patients from the FAS but excluded those with major protocol violations. About IRL790 IRL790 is under development for the treatment of levodopa (L-dopa) induced dyskinesias (PD-LIDs), and psychosis in Parkinson’s disease (PD-P). Dyskinesias are involuntary movements that often follows treatment with L-dopa. In pre-clinical studies, IRL790 reduces involuntary movements that occurs after a period of treatment with L-dopa. Additionally, in pre-clinical studies, IRL790 has shown antipsychotic properties. The company believes that IRL790 thus has the potential to simultaneously treat both dyskinesias and psychosis in Parkinson’s disease. About Unified Dyskinesia Rating Scale (UDysRS) The Unified Dyskinesia Ratings Scale (UDysRS) evaluates the involuntary movements that can be associated with long-term treatment with dopaminergic medication. The UDysRS has four parts:          I.            Historical Disability (patient perceptions) of ON-Dyskinesia impact        II.            Historical Disability (patient perceptions) of OFF-Dystonia impact       III.            Objective Impairment (dyskinesia severity, anatomical distribution over seven body regions, and type (choreic or dystonic) based on four activities observed or video-recorded      IV.            Objective disability based on Part III activities About Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a standardized and validated estimation scale developed for assessment of symptoms in Parkinson's disease. The instrument has been tested for good reliability and validity and consists of the following four parts: Part I – Non-Motor Aspects of Experiences of Daily Living Part II – Motor Aspects of Experiences of Daily Living Part III – Motor Examination Part IV – Motor complications of therapy Each section has questions that rate the symptoms from 0 to 4 where higher values indicate more severe symptoms. About patient completed 24-hour diaries Clinical diaries are a standardized method for patients to assess their health status. Patients log their motor status every 30 minutes for 24 hours. Patients record whether their motor status is “OFF”, “ON" or “ON with troublesome dyskinesias”. “OFF” denotes stiffness, marked decrease of mobility or immobility. “ON” denotes good or practically normal mobility, “ON with troublesome dyskinesias” is when the patient is troubled by involuntary twisting and turning movements. Additionally, sleep time is recorded. In this study patients completed two 24-hour diaries before randomization and two 24-hour diaries during the last week of the four-week treatment period.

Interim Report for January – June 2019

January – June 2019 compared with January – June 2018 (unless otherwise stated) · The loan portfolio has increased by 26.4 % to SEK 5,625 million since the start of the year · Operating profit increased by 33.6 % to SEK 136.2 million · Net profit increased by 34.0 % to SEK 105.1 million · Earnings per share increased to SEK 4.73 (3.65) · Cost/income ratio decreased to 37.8 % (40.2) · Total capital ratio has decreased to 15.7 % (17.4) since the start of the year · Return on equity amounted to 34.3 % (29.9) · Adjusted return on equity amounted to 31.7 % (29.9)  April – June 2019 compared with April – June 2018 · Operating profit increased by 32.3 % to SEK 70.6 million · Net profit increased by 32.6 % to SEK 54.6 million · Earnings per share increased to SEK 2.45 (1.91) · Cost/income ratio decreased to 37.6 % (40.1) Significant events, January – June 2019 · Within the segment Ecommerce Solutions an agreement with Estonia’s largest online retailer Hansapost has been signed, and several Nordic retailers have also chosen to extend their existing agreements · New agreements for continuing sale of past due loans have been signed in several markets · TF Bank has established lending operations in Austria within the segment Consumer Lending Presentation for investors, analysts and mediaA live conference call will be held on 16 July at 08:15 CET , where CEO Mattias Carlsson and CFO Mikael Meomuttel will present the report and answer questions. The presentation material is written in English while the conference call will be held in Swedish. To participate, call +46 (0)8 5664 2704 or +44 (0)33 3300 9261. International investors will have an opportunity to ask questions in English during the Q&A session. A recording of the conference call, including the presentation material, will be available on the bank’s website, https://www.tfbankgroup.com/en/section/investor-relations/. For further information, please contact:Mikael Meomuttel, CFO and Head of Investor Relations +46 (0)70 626 95 33 TF Bank in briefTF Bank is an internet-based niche bank offering consumer banking services and e-commerce solutions through a proprietary IT platform with a high degree of automation. The platform is designed for scalability and adaptability to different products, countries, currencies and digital banking solutions. TF Bank carries out deposit and lending activities for about 1 million consumers in Sweden, Finland, Norway, Denmark, Estonia, Latvia, Lithuania, Poland, Germany and Austria through subsidiary, branch or cross-border banking. In its Ecommerce Solutions segment, TF Bank offer next-generation payment and checkout solutions for online retailers in the Nordics, Estonia and Poland. TF Bank is listed at Nasdaq Stockholm.  This is information which TF Bank is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided for publication, through the agency of the contact person set out above, on 16 July 2019 at 07:00 CET. 

Interim Report January – June 2019

KEY HIGHLIGHTS · Strong sales performance · Continued high fibre costs · Ramp-up of KM7 proceeding according to plan · Divestment of a majority share of Bergvik Skog Öst, to be completed in the third quarter QUARTERLY DATA · Net sales were up by 7% to SEK 6 293 million (5 898) as a result of positive currency effects, higher sales volumes and increased sales prices. · Adjusted EBITDA* was SEK 539 million (671), impacted by higher costs for raw materials and start-up effects for KM7. · Operating profit was SEK 194 million (-174). · Net profit was SEK 182 million (-133). · Earnings per share amounted to SEK 0.88 (-0.64). Q3 OUTLOOK · Market conditions expected to remain good for liquid packaging board and cartonboard. · Weaker market conditions for some segments. · Increased price pressure expected. · Total cost for fibre is expected to flatten out at the current high level.     COMMENTS BY CEO “We deliver a solid result despite continued high fibre costs and start-up effects for KM7”High demand for sustainable packaging solutions continued to drive growth. Net sales in the second quarter improved by 7%, positively affected by currency, higher sales volumes and price increases. We deliver a solid result despite continued high fibre costs as well as start-up effects for KM7 of approximately SEK 190 million. Production availability has been satisfactory during the quarter and sales volumes were up compared to same period last year. Operational efficiency is improving, supported by our production excellence programme and group-wide safety initiative, but lost production volumes have affected us during the first half of the year. The ramp-up of the new board machine KM7 at Gruvön is proceeding as planned. During the second quarter we delivered on important milestones and since the end of June the machine is producing liner for customers. The next step will be to introduce coated material, and in October we aim to have certification material sent to customers. For the full year we estimate the negative start-up effects for KM7 on EBITDA to total SEK 500 million. As communicated, we will divest a majority share of Bergvik Skog Öst to the pension company AMF and have agreed on a 15-year long agreement regarding the supply of wood corresponding to approximately one tenth of our total wood supply. We have thereby secured a long-term, competitive and stable wood supply from this forestland. The transaction is planned to be completed on 30 August and will result in a positive cash effect of around SEK 7.9 billion. The balance sheet will thereby be substantially strengthened, enabling investments and acquisitions for a continued profitable growth. BillerudKorsnäs’ market position and know-how offers fantastic opportunities to grow within packaging solutions. We are investing in innovation of new products and believe that the fastest way to market is through collaboration. An example of our way of working is the joint venture that we have formed with ALPLA, where we share the joint vision to develop a fully bio-based and recyclable paper bottle in the near future. Carlsberg and Absolut have already signed up to take part in the commercialisation of the paper bottle. Long-term demand for fibre-based packaging is being driven by the mega trends of urbanisation, digitalisation, globalisation and sustainability. Country by country, decisions are being taken to reduce the use and litter of plastic. In Europe, our largest market, the EU has adopted a directive on single-use plastics which constitutes a great opportunity for us to replace plastic packaging in many applications and contribute to a more sustainable consumer behaviour. For the third quarter we expect the market conditions for our liquid packaging board segment, constituting around one third of our sales, to remain good and within this segment we have secured a number of long-term contracts. However, uncertainty in the containerboard market has increased somewhat and we expect weaker market conditions and increased price pressure for some of our smaller segments. To mitigate the effects and safeguard our results we will continue to focus on growth in areas where we are strong and to continue our programmes for operational efficiency and cost savings. The total cost of fibre is expected to flatten out at the current high level in the second half of the year. BillerudKorsnäs is well positioned to capture customer demand for innovative and sustainable packaging. Our strategy is based on profitable growth by challenging conventional packaging. We will continue to focus on a successful ramp-up of KM7, safety, production stability, efficiency improvements and innovation. Petra Einarsson, President and CEO      SALES AND RESULTS Net sales for the second quarter increased by 7% to SEK 6 293 million (5 898) as a result of positive currency effects, higher sales volumes and increased sales prices. The currency effect on net sales amounted to SEK 148 million. Adjusted EBITDA decreased to SEK 539 million (671), negatively affected by higher raw material costs and start-up effects for KM7 of approximately SEK 190 million, partly offset by increased sales and lower scheduled maintenance shutdown costs compared with the second quarter last year. The implementation of IFRS16 affected adjusted EBITDA positively by SEK 27 million in the second quarter, see note 1. Costs affecting comparability amounted to SEK -40 million (483) and reported in Other, were related to released provisions for staff changes, demolition of old buildings and decontamination as well as costs for the new board machine in Gruvön. Costs affecting comparability for the second quarter of 2018 included provisions totalling SEK 452 million and were related to strengthened workplace efficiency and environment and unified accounting principles related to spare parts and consumables. MARKET DEVELOPMENT AND OUTLOOK Market conditions for liquid packaging board and cartonboard remained good during the second quarter, while the uncertainty in the global container market increased. The market for sack and kraft paper has weakened. For the coming quarter, market conditions are expected to remain good for liquid packaging board and cartonboard, stable for semi-chemical fluting and white kraftliner and challenging for sack and kraft paper. The market pulp price index (PIX) has declined from USD 1 105 at the end of March to USD 1 000 at the end of June.      For further information, please contact:Ivar Vatne, CFO, +46 8 553 335 07Lena Schattauer, Head of Investor Relations, +46 8 553 335 10     This information constituted inside information prior to publication. This is information that BillerudKorsnäs AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07.00 CET on 16 July 2019.

INTERIM REPORT January – June 2019

January–June 2019* · Rental income increased 16 percent on the basis of a growing property portfolio. The increase for the comparable portfolio was 4.2 percent. · Net operating income increased 19 percent, of which just under 5 percent in the comparable portfolio. · The surplus ratio was strengthened by nearly two percentage points. This was largely attributable to effects from acquired properties, but also to a higher surplus ratio in the comparable portfolio. · Profit from property management increased 26 percent, primarily driven by increased rental income. · Unrealised changes in value amounted to MSEK 725, which corresponds to an increase of 2.0 percent, of which 1.2 percent arose in the second quarter. · Profit after tax rose 13 percent, with the increase in the second quarter amounting to 19 percent. · The property value increased 8 percent. · Net asset value (EPRA NAV) increased to slightly more than SEK 81 per share. · On the balance-sheet date, earnings capacity amounted to MSEK 1,438, compared with MSEK 1,360 at year-end. *Comparative figures for income items refer to value for the period January-June 2018 and for balance sheet items as of December 31, 2018. SIGNIFICANT EVENTS DURING AND AFTER THE QUARTER · Acquisitions were completed in Sweden and Finland:           - In Eskilstuna, Sweden, possession was taken in June of three properties including schools and public-sector offices with an underlying property value of MSEK 650.          - In Mariestad, Sweden, possession was taken in June of a property comprising 25 buildings, primarily used for schools and adapted housing, with an underlying property value of MSEK 274.           - In Espoo, Finland, possession was taken in June of a school with an underlying property value of MSEK 245.           - In Espoo and Helsinki, Finland, possession was taken in July of a portfolio of four public-sector offices. The underlying property value is MSEK 465. · A non-cash issue of 1,760,000 ordinary shares was conducted at the beginning of July, when a retirement home in Nacka was acquired from ICA-handlarnas Förbund with an underlying property value of MSEK 156. · Henrik Melder is the new country head of Hemfosa’s operations in Norway, where he will focus on realizing the development potential in the existing portfolio. · Essi Sten was employed as the new country head of Hemfosa’s operations in Finland to enable more rapid growth. · A three-year green bond loan in an amount of SEK 1.3 billion was issued in June at a margin of 240 bps. COMMENTS FROM THE CEO– High activity level We maintained a high level of activity at Hemfosa during the quarter, completing several attractive acquisitions in all three markets. At the same time, our talented property management organization is working to take care of our important tenants and to welcome the new ones we have received through our acquisitions. We continued to strengthen the organization and recruited new country heads for our Norwegian and Finnish operations, as well as a business development head. With the right team structure in place, higher earnings capacity and a stable financial position, we are well positioned for continued profitable growth. During the spring and summer, we completed acquisitions at a high pace in Sweden, Norway and Finland. The properties we acquired complement our portfolio well, with prime locations and stable community players as tenants. Several of the properties include potential future projects in the form of extensions and new builds on associated land – completely in line with our strategy to create value through acquisitions, improvements and projects. Intensified collaborationIn Norway, the acquisition in the Oslo region entails synergies with the existing portfolio and intensified collaboration with parties that include NAV (Norwegian Labor and Welfare Administration), one of Hemfosa’s larger tenants. In Sweden, through acquisitions in such locations as Eskilstuna, Mariestad, Motala and Nacka, we have expanded our collaboration with municipalities and county councils, as well as major private community players, such as Vardaga. For Hemfosa, it is important to establish relations with parties such as these, since we know that our tenants are keen to deepen collaboration that works well. We have many examples of how Hemfosa has been able to grow further with its tenants when they have chosen to expand their operations, much thanks to our skilled, local property management organization. Against this background, we are particularly pleased that the acquisitions in Finland have led to the establishment of collaboration with the major municipalities of Espoo and Helsinki, as well as pre-school operator Touhula. With the acquisitions in recent months of an amount corresponding to slightly more than MSEK 750, we have significantly strengthened Hemfosa’s Finnish portfolio, bringing its total value to nearly SEK 3 billion. Team structure completeIn Hemfosa’s growth strategy, we have an explicit focus on growth in Finland, where we foresee favourable opportunities for further acquisitions. With a country head in place in Finland after the summer, we will be able to gear up the business further. An anticipated increase in the transfer of ownership of community service properties from government and municipalities to private operators will create opportunities for further transactions in the Finnish market. We have also recruited a new country head in Norway, who will take over when Simon Venemyr Ottersland’s consultancy contract expires. With our new country head in place, we will strengthen competence related to early phases and projects, something that will greatly benefit us in our Norwegian operations, where we foresee major development potential in our existing portfolio. In conjunction with these changes, we have also acquired Simon’s minority participations in the Norwegian business. During the quarter, we also recruited a new business development head, who will be a major force in accelerating the work with municipalities and concepts. With these employees on board, together with our existing staff, we have established the team structure that we need to further develop Hemfosa and achieve our goals. Healthy acquisition capacityDuring the quarter, we took the step of strengthening our financing capacity to enable further acquisitions. In May, Hemfosa issued a green bond of SEK 1.3 billion, which attracted a large amount of interest among investors. This is a type of financing that is appropriate for Hemfosa’s operations within community service properties and is an effective complement to our other financing. I am very satisfied with Hemfosa’s performance during the first half of 2019. We have a clear direction on our journey of profitable growth, with our sights set on a property portfolio of SEK 50 billion within five years. And with the successful transactions we have completed so far this year, we are taking important steps toward this goal. We also have a healthy breadth in our project business, with several exciting projects in the planning phase and in progress, as well as a good pipeline moving forward. There is tremendous energy and commitment in the organization and we are looking forward to an equally exciting second half of 2019. Caroline Arehult, CEO

Ra Pharmaceuticals and Camurus Announce Exclusive License Agreement for FluidCrystal® Extended Release Formulation of Zilucoplan

FluidCrystal® extended release formulation of zilucoplan achieved rapid and sustained pharmacodynamic inhibition of complement C5 in non-human primates, supporting at least once weekly dosing Cambridge, Mass., and Lund, Sweden — 16 July 2019 — Ra Pharmaceuticals, Inc. (Nasdaq: RARX) and Camurus AB (Nasdaq STO: CAMX) today announced an exclusive worldwide license agreement for the use of Camurus’s proprietary FluidCrystal® (FC) technology to develop, manufacture, and commercialize a long-acting formulation of zilucoplan, Ra Pharma’s complement component 5 (C5) inhibitor in development for the treatment of multiple complement-mediated disorders. "Ra is committed to delivering convenient and accessible products for managing C5-mediated diseases. Building on the strength of our daily formulation, which offers a quick, low volume injection and room temperature storage, the FluidCrystal® extended release (XR) formulation of zilucoplan has the potential to control disease for at least seven days from a single subcutaneous dose without the need for intravenous loading, on-body infusion devices, tissue-degrading enzymes, or permeation enhancers. The promising data from our pre-clinical studies conducted with Camurus, the potential for cost-effective manufacturing, and Camurus’s proven late-stage regulatory experience with FluidCrystal® were compelling reasons to add the FluidCrystal® technology into our zilucoplan XR life-cycle extension program,” said Doug Treco, Ph.D., President and Chief Executive Officer of Ra Pharma. In pre-clinical testing, a single dose of the FC XR formulation of zilucoplan in non-human primates rapidly achieved and maintained target levels of complement inhibition for at least seven days without the need for an intravenous loading regimen. “The partnership with Ra Pharma follows the successful completion of a feasibility study of the FluidCrystal® extended release zilucoplan injection, which met formulation, pharmacokinetic, and tolerability target specifications,” said Fredrik Tiberg, President & CEO of Camurus. “We look forward to the next phase of our collaboration with Ra Pharma and initiating clinical development of a new promising product candidate based on our unique FluidCrystal® technology.” Under the agreement, Camurus will receive an upfront payment of $2 million and is eligible to receive up to $14.5 million in development milestones and other license payments, up to $55 million in sales milestones, and tiered single digit royalty payments on product sales related to the FC XR formulation of zilucoplan. About ZilucoplanRa Pharma is developing zilucoplan and zilucoplan extended release (XR) for generalized myasthenia gravis (gMG), immune-mediated necrotizing myopathy (IMNM), and other tissue-based, complement-mediated disorders with high unmet medical need. The product candidates are designed for convenient subcutaneous (SC) self-administration. Zilucoplan is an investigational, synthetic, macrocyclic peptide discovered using Ra Pharma's powerful proprietary drug discovery technology. The peptide is designed to bind complement component 5 (C5) with sub-nanomolar affinity and allosterically inhibit its cleavage into C5a and C5b upon activation of the classical, alternative, or lectin pathways.  About FluidCrystal® Injection DepotThe FluidCrystal® injection depot delivers therapeutic levels of drug substance over selected extended periods – from days to months – from a single injection. The FluidCrystal® injection depot offers a liquid solution that transforms into a controlled release, biodegradable liquid crystal gel matrix in situ on contact with minute quantities of aqueous fluid at the injection site. Medicines based on the FluidCrystal® injection depot can be administered by the patients themselves or by healthcare professionals, without time-consuming and complicated reconstitution procedures. The technology is validated by approvals of Buvidal® in the EU and Australia and by the Brixadi™ tentative approval in the US and has been studied in more than 20 completed clinical trials. FluidCrystal® is a registered trademark of Camurus AB.  About Ra PharmaceuticalsRa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on leading the field of complement biology to bring innovative and accessible therapies to patients with rare diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade. For more information, please visit: www.rapharma.com.  About CamurusCamurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.   Contact: Ra Pharmaceuticals, Inc.Investors:Ra Pharmaceuticals, Inc.Natalie Wildenradt, 617-674-9874nwildenradt@rapharma.com Media:Argot PartnersDavid Rosen, 212-600-1902david.rosen@argotpartners.com Camurus ABFredrik Tiberg, President & CEO, Head of R&DTel. +46 (0)46 286 46 92 (mailto:)fredrik.tiberg@camurus.com  (mailto:)  Fredrik Joabsson, Chief Business Development OfficerTel. +46 (0)70 776 17 37ir@camurus.com This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the managing director, at 8:00 am CET on 16 July 2019.  

Integrum Continues to Strengthen its Position as the Leader in Osseointegration at the Amputee Coalitions National Conference 2019

Integrum, the world leader in osseointegrated prosthetics for amputees is excited to announce its inaugural participation as an exhibitor at the 2019 Amputee Coalition’s National Conference in San Antonio, Texas held July 25th-27th, 2019. Integrum has been a gold sponsor to the American Amputee Coalition since January 2019. The American Amputee Coalition is a non-profit organization dedicated to enhancing the quality of life for amputees and their families through support, education and advocacy. The Amputee Coalition reaches over 500,000 people within the limb loss community. Rickard Branemark, MD, PhD, Chairman and Founder of Integrum, Research Scientist at the Biomechatronics Group at MIT, and one of the most experienced osseointegration orthopedic surgeons in the world will participate in a panel discussion, Giants of Osseointegration, on Friday July 26th from 4-6 p.m. In addition to having Dr. Branemark at Integrum’s booth (Booth 310), Rick Cicero, an OPRA Osseointegrated (above knee and elbow) Peer Mentor will be present to answer questions and demonstrate the difference the OPRA System can make to over 1,500 amputees and specialist participating in this Conference. The Amputee Coalition’s National Conference provides Integrum with a strategic opportunity to announce new opportunities for people to receive osseointegration in the U.S. and promote existing centers using the OPRA System, eliminating the need to travel abroad. Over the past 6-7 years the introduction and consideration of osseointegration as a viable option for specific amputees within the limb loss community has continued to establish itself in the U.S. market. This rapidly developing treatment for amputee care gained a considerable boost when the FDA awarded Integrum an HDE approval for the OPRA System in July 2015. The subsequent years have seen the Department of Defense and the University of California San Francisco complete the majority of procedures with the OPRA System since that time. The work completed at these centers has helped provide valuable insight and the time for Integrum to continued and enhance the approach, explanation, education and demonstration of the surgical procedures and rehabilitation protocols to facilitate hospital acceptance of this option for Limb Loss Restoration in the challenging and evolving U.S. health care system.             “I recall 20 years ago learning about the potential option of osseointegration as a solution for limb loss. I thought to myself that will never happen! Given the number of OI amputees that will be present at the conference as well as some of the announcements that will be made during the conference… Osseointegration is here!” Says: Kurt Collier, Certified Prosthetist and Amputee (29 years). VP of Prosthetics, Integrum Inc.

INTERIM REPORT JANUARY - JUNE 2019

Stockholm July 16, 2019 Kai Wärn, President and CEO:“We delivered a good performance during the second quarter. All divisions improved operating income, which for the Group increased by 10% to SEK 2,125m (1,925). Restructuring activities and efficiency improvements, as well as price increases were executed. Cost increases from tariffs and raw materials were balanced by positive currency effects. The improved operating result was despite a slow start of the lawn and garden season. Net sales for the Group decreased by 7% in the second quarter, adjusted for changes in exchange rates, whereof 4 percentage points were related to the exit of the Consumer Brands business. The strong first quarter with high sell-in volumes followed by a slow start of the lawn and garden sell-out season in the second quarter resulted in lower net sales within the Husqvarna Division. However, operating income for the division increased by 5%, driven by price increases as well as continued efficiency and restructuring savings.  The Gardena Division had yet another solid quarter as retailers have been conscious to fully stock-up after the strong and extended season of last year. Operating income developed well due to strong product mix as well as efficiency and restructuring savings, and exceeded last year’s high reference.  The Construction Division delivered growth in the quarter, driven by a continued strong development in Europe. This growth combined with efficiency savings and price increases supported an increased operating income.   Since we initiated our restructuring measures last year and increased our focus on the profitable growth divisions, we have made significant progress. Our last 12 month operating margin amounts to 8.9%, increasing from 7.9% as at the end of 2018, excluding items affecting comparability. Operating cash flow in the first half year improved to SEK 2,519m (733), driven by higher operating income and positive changes from operating working capital compared to last year. To continue to execute on our profitability improvement trajectory, whilst investing in strategic growth initiatives, remains our top priority for 2019. We will continue to build on our strengths in prioritized customer segments and product categories.” Second quarter 2019 · Net sales amounted to SEK 13,789m (14,270), corresponding to a decrease of 7%, adjusted for changes in exchange rates. Exit of Consumer Brands business had a negative effect of approximately 4 percentage points, adjusted for changes in exchange rates. · Operating income increased by 10% to SEK 2,125m (1,925). · Operating margin improved to 15.4% (13.5). · Operating cash flow increased to SEK 3,959m (2,059). · Earnings per share after dilution amounted to SEK 2.63 (2.41). TELEPHONE CONFERENCEA combined press and telephone conference, hosted by Kai Wärn, President and CEO, and Glen Instone, CFO, will be held at Husqvarna Group’s office, Regeringsgatan 28, Stockholm at 10:00 CET on July 16, 2019. To participate, please dial +46 (0) 8 566 184 30 (Sweden) or +44 (0) 8 448 228 902 (UK) ten minutes prior to the start of the conference. Conference ID: Husqvarna or 9480637#. The conference call will also be audio cast live on www.husqvarnagroup.com/ir. A replay will be available later the same day. CONTACTS– Glen Instone, CFO, Senior Vice President, Finance, IR & Communication, +46 72 716 5032– Johan Andersson, Director, Group Corporate Communications and Investor Relations, +46 702 100 451 This press release contains insider information that Husqvarna AB is required to disclose under the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the contact person set out above, at 08.00 CET on July 16, 2019.

Itiviti works with Bloomberg to further facilitate transition for SSEOMS clients

This collaboration includes sharing key SSEOMS platform information, and goes further to enable pre-integration of key Bloomberg products, including the Bloomberg Market Data Feed (B-PIPE) and DASH Enterprise, a solution which helps sell-side firms realize efficiencies on their sales and trading desks.  “Itiviti recognizes that migrating to a new execution and order management platform is a complex undertaking which requires detailed preparation, and we are delighted to work closely with Bloomberg to streamline this process,” said Linda Middleditch, EVP, Head of Product Strategy, Itiviti Group. ”Our multi-asset OMS provides a great solution for the Bloomberg SSEOMS clients, who will benefit from the significant investment we are making in the platform to accommodate their needs. It is an incredibly exciting time for these clients to join Itiviti.” Itiviti also announces two significant additions to its sell-side product team: Implementation Engineer Alex Bloomfield and Project Manager Kevin Jackson are now joining from Bloomberg’s SSEOMS organization. With 15 years of experience from working on the SSEOMS platform between them, Alex and Kevin bring to Itiviti an in-depth knowledge of sell-side technology infrastructure and user requirements. “Our recruitment of Alex and Kevin further demonstrates Itiviti’s commitment to a smooth, efficient transition for SSEOMS clients, and our determination to be the partner of choice for firms as they move ahead to a next-generation execution and order management platform,” commented Linda Middleditch. Itiviti’s sell-side trading solution platform provides access to cross-asset orders from a global network of clients, a feature-rich OMS, and advanced tools for fast and reliable execution and middle office workflows. It is highly customizable for accommodating customer-specific messaging, order flows and user preferences.  Itiviti’s OMS is easily integrated with third party systems and existing trading infrastructure. It is used by more than 10,000 sales-traders worldwide to quickly onboard clients, manage orders in real-time through a shared order book, route execution to any venue, customize commission schemes and automate post-trade tasks to secure bookings and regulatory compliance. For further information, please contactRob Mackay, CEO, Itiviti, Tel: +44 20 7942 0946, Email: rob.mackay@itiviti.comLinda Middleditch, EVP, Head of Product Strategy, Itiviti Group, Tel +44 796 82 126 24, Email: linda.middleditch@itiviti.com  Christine Blinke, EVP, Head of Marketing & Communications, Itiviti Group, Tel. +46 739 01 02 01, Email: christine.blinke@itiviti.com  About ItivitiItiviti enables financial institutions worldwide to transform their trading and capture tomorrow. With innovative technology, deep expertise and a dedication to service, we help customers seize market opportunities and guide them through regulatory change.  Top-tier banks, brokers, trading firms and institutional investors rely on Itiviti’s solutions to service their clients, connect to markets, trade smarter in all asset classes by consolidating trading platforms and leverage automation to move faster. A global technology and service provider, we offer the most innovative, consistent and reliable connectivity and trading solutions available. With presence in all major financial centers and serving around 2,000 clients in over 50 countries, Itiviti delivers on a global scale. For more information, please visit www.itiviti.com or follow Itiviti on social media: Twitter @Itiviti AB , Facebook @ItivitiAB , and LinkedIn . Itiviti is owned by Nordic Capital.

Interim report January - June 2019

New sales record and increased profit Second quarter April – June 2019 · Net sales amounted to 282.1 MSEK (236.1), which is an increase by 19.5 percent compared to the corresponding quarter last year. At comparable exchange rates[1] and adjusted for acquisitions, sales increased by 5.8 percent. · Operating profit increased by 12.1 percent to 56.1 MSEK (50.0). · Result after tax increased by 5.4 percent to 54.2 MSEK (51.4). · Earnings per share amounted to 0.83 SEK (0.79) before and after dilution. · The cash flow from operating activities increased to 43.2 MSEK (24.6). · Dividends to the shareholders were paid to the amount of 97.8 MSEK (90.6). · Net debt[1] at June 30 amounted to 192.3 MSEK (-13.5). Cash and cash equivalents amounted to 108.1 MSEK (95.8). Liabilities to credit institutions amounted to 149.9 MSEK (109.3). · On May 24 the Board of Directors announced that Tomas Blomquist has been appointed as new CEO for Biotage effective November 6. Six months January - June 2019 · Net sales amounted to 530.1 MSEK (444.1), an increase by 19.4 percent compared to the corresponding period last year. At comparable exchange rates1) and adjusted for acquisitions, net sales increased by 7.2 percent. · Operating profit increased by 15.6 percent to 105.9 MSEK (91.6). · Result after tax increased by 5.6 percent to 101.7 MSEK (96.3). · Earnings per share amounted to 1.56 MSEK (1.49). · The cash flow from operating activities amounted to 55.7 MSEK (52.7).  · The acquisition of PhyNexus Inc. was completed on January 15. The purchase price amounted to approx. 21.3 MUSD (approx. 190.6 MSEK[2]), of this sum approx. 4.8 MUSD (approx. 43.2 MSEK) in cash payment and approx. 6.6 MUSD (approx. 58.6 MSEK) in newly issued shares in Biotage was paid in connection with closing. The remaining approx. 10.0 MUSD (approx. 89.3 MSEK) is expected future additional purchase price payments based on future results. · The issue of consideration shares for the acquisition increased the number of shares in Biotage from 64,714,447 to 65,201,784, which has resulted in a dilution of 0.7 percent for existing shareholders.  [1] See definition on pp. 18-20[2] Based on an exchange rate SEK/USD of 8,93 Comments by CEO Torben Jörgensen Biotage follows up the strong first quarter with yet another record quarter concerning sales and earnings. The reported sales increased by no less than 19.5 percent compared with the second quarter 2018. At comparable exchange rates and adjusted for acquisitions, sales increased by 5.8 percent in the quarter isolated, while the corresponding figure for organic growth reaches 7.2 percent for the first six months. This means that Biotage is approaching its financial target; an average annual organic sales growth of 8 percent measured over a three year period. The increased sales have effect on profitability and Biotage is growing with increased profitability. The gross margin for the quarter as well as for the six months period exceeds our strategic goal of 60 percent. For the quarter the gross margin increased to 62.3 percent. The operations in Asia continue to show strong growth. Biotage’s initiative with direct sales in India is so far very successful with a sales increase of over 30 percent compared with the corresponding quarter last year. We have been successful especially in organic chemistry and we now have the three largest local Indian contract research organizations in our line of business as our customers. Also the operations in China are growing beyond expectations and here we are especially pleased that the sales of our products in analytical chemistry are gaining momentum. During the quarter we entered into an OEM collaboration with Shandong Yingsheng Biotechnology Co., Ltd. and the first deliveries of systems and consumables for analytical chemistry within the framework of this collaboration were made at the end of the quarter. The Americas is still our single biggest geographical market and after a period with lower sales than expected in the US it is satisfying to see that in the second quarter sales are back on track. Sales in the Americas region, including the US, Canada and Latin America, increased by almost 30 percent compared to the preceding quarter this year. This is partly due to the improved situation concerning recruitment of sales staff in the US, at the end of the quarter we for the first time in a long time no longer had any vacancies in this sales force. The sales in the EU and EMEA decreased by 5 percent adjusted for acquisitions compared to the corresponding quarter last year, which is not at all up to our expectations, but over the first six months of the year the EU and EMEA still grew by a little over 6 percent. The operating margin (EBIT) is rounded to 20 percent both for the quarter and for the six months period and now amounts to 18.1 percent on a rolling average for the last three years, to be compared with Biotage’s profitability target of an average of 20 percent over a three year period. During the latter part of the quarter we carried out launches of new products primarily for environmental applications, developed at our new unit in Salem, New Hampshire, where we are also working intensely with production transfers of other Biotage products, including products gained in the acquisition of PhyNexus in January. The integration of PhyNexus proceeds according to plan and currently beta testing of a new instrument generation for automated purification of plasmids is in progress, estimated to be launched later this year. During the quarter Biotage has also launched software updates for the flash purification system Biotage® Selekt that further strength the competitive advantages of this system and the associated consumables Biotage® Sfär. The sales of Biotage® Selekt are gaining momentum and we are seeing an increased use of our systems not least in the US pharma industry. The demand for our systems is increasing also in the area of industrial products, where we see a broad increase all the way from pilot to production scale. As previously announced Biotage’s Board of Directors has recruited a replacement for me and I am very pleased with the selection of Tomas Blomquist as new CEO of Biotage AB. Blomquist takes up his duties on November 6, 2019 and then takes over the responsibility for the Group. He has recently served as Vice President EMEA Cardiometabolic at Abbott. I look forward to the second half of 2019 with confidence. Coming financial reports The interim report for the third quarter 2019 will be published on Nov 5, 2019.The year-end report for 2019 will be published on February 7, 2020. All reports are available at Biotage’s website from the above dates.  This report has not been reviewed by the company’s auditor.   Uppsala July 16, 2019   Torben JörgensenPresident and CEO   For further information, please contact: Torben Jörgensen, President and CEO, phone: +46 707 49 05 84Erika Söderberg Johnson, CFO, phone: +46 707 20 48 20   This information is information that Biotage AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on July 16, 2019. About BiotageBiotage offers efficient separation technologies from analysis to industrial scale and high quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage’s products are used by government authorities, academic institutions, contract research and contract manufacturing companies, pharmaceutical and food companies, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 440 employees and had sales of 911 MSEK in 2018. Biotage is listed on NASDAQ Stockholm. Website: www.biotage.com

STENOCARE to establish the world’s first hybrid, in-door cultivation facility for production of premium medical cannabis at scale

Raising the bar: For more than a year, STENOCARE has been pursuing innovative ways to combine the benefits of scale from green-house cultivation of medical cannabis with the advantages of highly controlled production. In pursuit of this, STENOCARE has selected a global leader in its field, Havecon Horticultural Projects (Netherlands) to co-develop a unique technology/facility that meets extreme demands for control of light, climate and 100% pesticide free in-door cultivation, at scale. This includes 24/7 environmental control through application of “pharma-standard” technology involving air filtration, active climate control with positive pressurized rooms, water treatment and continuous monitoring of all relevant quality parameters and processes. Ready in Q1-2020: The project is now ready to commence. Therefore, STENOCARE has today entered into a turnkey construction contract with Havecon to build the first such facility in the world. The commercial terms and technical specifications remain undisclosed for competitive reasons, yet the parties announce that the construction will commence shortly, and the facility is expected to be ready for cultivation in Q1-2020. In the meantime, STENOCARE will continue its already initiated initial cultivation in order to secure the ability to produce with consistency. Cultivation is developed in close cooperation with and based upon intense tech-/knowledge transfer from our partner and shareholder, CannTrust in order to set new standards for best-of-breed cultivation. Independent Premium Brand: The decision to establish premium manufacturing at scale is a natural consequence of STENOCARE’s recent announcement that it has commenced its cultivation of medical cannabis on Danish grounds and marks the next step towards establishing STENOCARE as a frontrunner and global premium brand in medical cannabis. Funding: STENOCARE has decided to establish a 15mDKK unsecured debt facility with 1,5% in monthly interest (accrued, no compound interest) which along with cash at hand will finance the contract. The loan is provided by a consortium of not closely related private individuals and can be repaid or converted, depending upon STENOCARE’s future decisions in relation to funding of its further growth and expansion. Thomas Schnegelsberg, CEO of STENOCARE, comments: “Our Production Director, Søren Kjær, has been working intensively with the specialists at our partner, Havecon Horticultural Projects to arrive at today’s important announcement that we will establish a highly innovative and industry leading cultivation facility. This will play an important role in establishing STENOCARE as a leader in premium medical cannabis”. Henk Verbakel, CEO of Havecon, comments: “We were impressed and excited from our first contact with STENOCARE. We have established over 10 projects for medicinal/medical cannabis cultivation worldwide but have never before seen such ambition to create a hybrid that lives up to the benefits of scale from traditional greenhouses while maintaining the benefits of quality from cleanroom type manufacturing. Together with STENOCARE, we have developed just that. I am very proud”. This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on July 16, 2019.

Turkcell adopts DOCOMO Digital’s AI-driven solutions to drive further growth in its digital services business

Turkcell, Turkey’s dominant telecom carrier has partnered with DOCOMO Digital, the preeminent mobile commerce enabler to bring the power of artificial intelligence to further fuel the growth of its digital services business. Turkcell and DOCOMO Digital have been working closely for the past five years to ensure that nearly 34 million mobile subscribers, both pre and post-paid, can pay for popular apps and digital content in a secure and convenient way through their monthly phone bills or top-ups. Now with DOCOMO Digital’s AI-powered “Billing Risk Manager”, Turkcell can dynamically forecast, manage and mitigate direct carrier billing-related bad debt. The tool enables Turkcell to adjust user spending and subscriptions based on real-time monitoring of user behavior. The tool’s simulator model continually learns and adjusts bad debt thresholds based on transactions data and Turkcell policies, thereby helping Turkcell plug revenue leakage from its OTT business. "Turkcell has always been a frontrunner in the adoption of leading-edge technology, and our latest partnership with DOCOMO Digital once again demonstrates our ability to bring the best of digital services to our subscribers, underpinned by robust risk management. This will further accelerate the uptake of apps and digital content.”, said Onur Güven, Director of Customer & Product Management at Turkcell Payment Services or Paycell. “DOCOMO Digital is committed to removing friction from mobile commerce for our partners like Turkcell and we believe Billing Risk Manager will help bolster Turkcell’s digital business with more robust risk management in the direct carrier billing area.”, said Dheeraj Soni, President of DOCOMO Digital’s Payments business. About Turkcell Turkcell is a converged telecommunication and technology services provider, founded and headquartered in Turkey. It serves its customers with voice, data, TV and value-added consumer and enterprise services on mobile and fixed networks. With more than 33 million subscribers and 20,000 employs, Turkey’s dominant telecom operator has rapidly been expanding in the region with strategic partnerships. Turkcell's shares have been traded on the Borsa Istanbul (BIST) and New York Stock Exchanges (NYSE) since July 11, 2000, and it is the only Turkish company to be listed on the latter exchange. For more information, visit https://www.turkcell.com.tr/

AAK’s Interim report for the second quarter 2019 – strong profit growth and strategic launch of our portfolio for plant-based alternatives

AAK Group ·  Total volumes for the second quarter amounted to 565,000 MT (550,000), organic growth of 3 percent (6). ·  Operating profit, including a positive currency translation impact of SEK 19 million, reached SEK 518 million (454), an improvement of 14 percent. ·  Net result amounted to SEK 362 million (310), an improvement of 17 percent. ·  Earnings per share increased by 18 percent, to SEK 1.42 (1.20). ·  Cash flow from operating activities amounted to SEK 408 million (396). ·  Return on Capital Employed (ROCE), R12M, was 15.5 percent (15.8 at December 31, 2018). Business areas ·  Food Ingredients – operating profit improved by 18 percent to SEK 346 million (292). ·  Chocolate & Confectionery Fats – operating profit reached SEK 177 million (169), an improvement of 5 percent. ·  Technical Products & Feed – operating profit reached SEK 35 million (32), an improvement of 9 percent. CEO’s commentsOur strong profit growth continued in the second quarter with Food Ingredients as the main driver. Chocolate & Confectionery Fats and Technical Products & Feed also contributed nicely. Organic volume growth was 3 percent (6) where Chocolate & Confectionery Fats had the strongest growth, reporting an increase of 15 percent. Operating profit amounted to SEK 518 million, an improvement of 14 percent compared to last year and an all-time high operating profit for a second quarter. Earnings per share increased by 18 percent with a good operating cash flow in the quarter. Food Ingredients continued its strong trend with an improved operating profit of 18 percent. Dairy, Bakery and Foodservice led the way, but there was good contribution from Special Nutrition as well. The strongest regional developments were in the US, North Latin America and Asia. Chocolate & Confectionery Fats had another stable quarter and we continue to see a strong demand for high-end solutions. The strongest developments were in Europe and South Latin America. As expected, lower than normal raw material yields continued to impact operating profit negatively. Our investment projects to increase capacity and strengthen our supply chain are progressing according to plan and are expected to be completed by year-end. Business area Technical Products & Feed improved its operating profit by 9 percent despite a very strong performance in 2018. The continued good momentum was particularly driven by the feed business. Some key strategic events during the quarter include the launch of AkoPlanet™, our new portfolio with tailor-made solutions for food manufacturers developing plant-based alternatives within the meat, dairy and ice cream segments. We have also launched COBAO™ Pure, a breakthrough chocolate solution that delivers significantly improved bloom-retarding effects, delays migration, and extends shelf life. We offer plant-based, healthy, high value-adding oils and fats solutions by using our customer co-development approach and we see favorable underlying trends in our markets. Thus, we continue to remain prudently optimistic about the future. Press and analyst conferenceThe Interim report for the second quarter 2019 will be presented today, July 16, 2019 at 1 p.m. CET at a press and analyst conference. For participation, please see instructions under the Investor tab at the AAK website, www.aak.com. For further information, please contact:Fredrik NilssonCFOMobile: +46 708 95 22 21 E-mail: fredrik.nilsson@aak.com   (fredrik.nilsson@aak.com) This information is information that AAK AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Act. The information was submitted for publication, through the agency of the contact person set out above, at 11:00 a.m. CET on July 16, 2019.   AAK is a leading provider of value-adding vegetable oils & fats. Our expertise in lipid technology within foods and special nutrition applications, our wide range of raw materials and our broad process capabilities enable us to develop innovative and value-adding solutions across many industries – Chocolate & Confectionery, Bakery, Dairy, Special Nutrition, Foodservice, Personal Care, and more. AAK’s proven expertise is based on more than 140 years of experience within oils & fats. Our unique co-development approach brings our customers’ skills and know-how together with our own capabilities and mindset for lasting results. Listed on Nasdaq Stockholm and with our headquarters in Malmö, Sweden, AAK has more than 20 different production facilities, sales offices in more than 25 countries and more than 3,700 employees. We are AAK – The Co-Development Company. 

Interim report January – June 2019 Sweco AB (PUBL)

April – June 2019 · Net sales increased to SEK 5,214 million (4,916) · EBITA decreased to SEK 422 million (464), margin 8.1 per cent (9.4) · EBIT decreased to SEK 398 million (459), margin 7.6 per cent (9.3) · Profit after tax decreased to SEK 281 million (330), corresponding to SEK 2.39 per share (2.78) January – June 2019 · Net sales increased to SEK 10,315 million (9,544) · EBITA increased to SEK 953 million (872), margin 9.2 per cent (9.1) · EBIT increased to SEK 935 million (866), margin 9.1 per cent (9.1) · Profit after tax increased to SEK 672 million (628), corresponding to SEK 5.73 per share (5.28) · Net debt decreased to SEK 2,324 million (2,588) · Net debt/EBITDA decreased to 1.2 x (1.4) Comments from President and CEO Åsa Bergman: Sweco continues to develop positively, in line with the trend from recent quarters. EBITA increased around SEK 54 million and organic growth amounted to around 5 per cent, both after adjustment for calendar effects. The improved performance is driven by positive fee development and an increased number of employees, supported by a solid order backlog. Nominally, reported EBITA and net sales were negatively impacted by approximately SEK 97 million due to less available calendar hours compared to last year.   In particular, Finland, Belgium and Norway performed strongly, combining good organic growth with profitability improve­ments. At the same time, Sweden continues to deliver industry leading profitability, combined with solid organic growth. Sweco announced two strategically important add-on acquisitions during the quarter. MLM Group in the UK, adding 460 experts primarily within the building and infrastructure sectors. Imp GmbH in Germany, adding 380 experts primarily within power transmission. Both acquisitions are in line with our strategy of developing local market leadership in our eight core markets in Northern Europe. Sweco is Europe’s market leading architecture and engineering consultancy. Together with our clients, we plan and design sustainable communities and cities of the future. Customer focus, internal efficiency and having the best people is at the core of Sweco’s decentralised operating model. We aim to continue our trajectory of profitable growth, both organically and through add-on acquisitions. Overall, the market for Sweco’s services is good and largely unchanged to recent quarters. Essentially all Business Areas are experiencing a good market for Sweco’s services in the infrastructure, water and industry segments. Demand for services in the real estate segment remains good in most countries, with the exception of the UK and residential construction in the Nordics, where demand remains weak.

Gasum Group Financial Result Q2 2019 – Expansion of gas infrastructure

Key financial indicators January 1 to June 30, 2019:•  Group revenue increased by 6% and totaled €632.5 million (H1/2018: €597.5 million)•  Operating profit totaled €76.3 million, flat year on year (€76.3 million)•  Balance sheet total increased to €1,574.4 million (December 31, 2018: €1,526.6 million) following the introduction of the new IFRS 16 standard•  The Group’s financial position remained strong in the reporting period, with the equity ratio being 43.9% (December 31, 2018: 43.7%) Key financial indicators \\[][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][][]\ 1,000 €\ [1–6/2019] [1–6/2018] [Change] [2018][ Revenue] [632.5] [597.5] [5.9%] [1,177.4][ Operating profit] [76.3] [76.3] [0.0%] [124.2][ Operating profit (%)] [12.1%] [12.8%]   [10.5%][ Equity ratio %] [43.9%] [44.0%]   [43.7%][ Return on equity (%)*] [12.0%] [13.3%]   [13.3%][ Return on investment (%)*] [8.6%] [9.3%]   [9.2%][ Balance sheet total] [1,574.4] [1,465.9] [7.4%] [1,526.6][ Net interest-bearing debt] [573.9] [558.9] [2.7%] [562.7][ Gearing ratio %] [83.3%] [86.7%]   [84.7%][ Net debt/EBITDA* **] [2.8] [2.9]   [2.9][ Personnel at year-end] [364] [432] [-15.7%] [434] \  * Annualized  ** Current period restated without the IFRS 16 effects  Reference period information does not include IFRS 16 effects\ Gasum Group CEO Johanna Lamminen comments on the first half of 2019: ”Our financial performance was in line with our expectations during H1. Our revenue increased to €632.5 million, up 6% year on year (€597.5 million) and our operating profit for the period under review was €76.3 million (€76.3 million), which was flat compared to a year earlier.  During H1, we took our strategy steadfastly forward and together with our personnel updated our strategic targets for future years. Demand for cleaner energy solutions is showing strong growth in industry and total gas sales volumes are projected to further increase. As a low emission fuel, the role of gas will increase in the future, above all in maritime transport and heavy-duty road transport as action to curb climate change calls for a transition to cleaner solutions. Gasum’s associated company Manga LNG Oy’s LNG terminal in Tornio, Finland was opened in early June. The new terminal is a response to growing demand for low-emission LNG and strengthens security of LNG supply in the northern parts of the Nordic countries. The terminal will significantly support the competitiveness of the region by ensuring the availability of an affordable, low-emission form of energy to meet the demands of local industry as well as maritime and heavy-duty road transport. During the period under review, we entered into significant partnerships in different businesses, of which the most important are two liquefied natural gas supply contracts to industry: Forchem Oy’s tall oil distillery in Rauma and Eastman Chemical Company Oy’s production site in Oulu. Gas offers industrial operators a good alternative to achieve emissions targets. Growing the road fuel gas market and increasing biogas production are key elements in Gasum’s strategy. We have acquired the Mäkikylä biogas plant in Kouvola, Finland from Kouvola Vesi Oy. The transaction enables us to invest in the expansion of the Mäkikylä plant with the aim of increasing biogas production and modernizing the processes at the plant to bring them into line with today’s requirements. During the period under review, we also madean investment decision to construct a biogas plant at Munkkaa in conjunction with the Lohja waste management center. On completion, the plant is expected to produce more than 40 GWh of biogas and 50,000 tonnes of organic fertilizers a year. During the period under review, we opened three gas filling stations to meet the needs of heavy-duty transport and three filling stations for passenger cars. In addition, other operators are also building new gas filling stations, which will further complement the filling station network. Adding to the network of gas filling stations promotes the circular economy and supports national emissions reduction targets by helping Nordic transport to switch over to using cleaner fuel solutions.” Link to the Gasum Group financial result Q2 2019 > 

Changes in Management Team: Alma Media appoints Vesa-Pekka Kirsi as Senior Vice President of Alma Markets and member of the Group Executive Team of Alma Media

Alma Media Corporation Stock Exchange Release 16 July 2019 at 2 p.m. (EEST)  CHANGES IN MANAGEMENT TEAM: ALMA MEDIA APPOINTS VESA-PEKKA KIRSI AS SENIOR VICE PRESIDENT OF ALMA MARKETS AND MEMBER OF THE GROUP EXECUTIVE TEAM OF ALMA MEDIA   BA Vesa-Pekka Kirsi (b. 1969) has been appointed as Senior Vice President of Alma Markets and a member of Group Executive Team. He will take the position September 1st 2019 at the latest.  Kirsi has been working in various business management positions since 2011 at Fonecta, and most recently as the Business Unit Director of Fonecta’s B2B business unit. He has previously led positions in international business, sales and marketing including Tanla Solutions, Openbit Ltd. and Nokia.  - Kirsi’s versatile experience in international business management and in digital new business development provides a good ground for leading our highly profitable and growing Alma Markets business segment, Alma Media President and CEO Kai Telanne says.  -Well managed Alma Media is a company already long way in its digital transformation. The solid growing and international Alma Markets is the most interesting part of the Alma Media. I will take up the challenge with relish as well as a great opportunity, says Vesa-Pekka Kirsi.  For more information: Kai Telanne, President and CEO, Alma Media, tel: +358 10 665 3500  Alma Media Corporation Elina Kukkonen Communications Director   Distribution:  NASDAQ Helsinki, main media, www.almamedia.com  

Catena Media resolves upon a new directed issue of shares as a prepayment to the final payment for U.S. assets acquired in December 2016

As announced on 14 December 2016 , Catena Media acquired regulated affiliate assets in the regulated online casino and poker markets in the U.S. states of New Jersey and Nevada. In addition, the Company acquired a range of unregulated assets which were expected to generate revenues when additional U.S. states regulate online casino and poker. As announced on 19 October 2018 , following the development of additional states regulating online casino and poker, and the PASPA-ruling opening up for sports betting, Catena Media agreed with the sellers to amend the agreement and the earn-out structure, including a prepayment of the final earn-out, based on the first six (6) months of the third and final earn-out period. The prepayment to the final earn-out amount is USD 13,047,315. The maximum amount of the total final earn-out correspond to USD 45 million. The board of directors of the Company has, in accordance with the agreement and under the authorization in the articles of association of the Company, resolved upon a directed share issue of 1,440,454 shares to the seller of the assets which corresponds to seventy (70) percent of the abovementioned prepayment. The remaining part of such prepayment has been paid in cash.   The subscription price amounts to SEK 60.30 per share, corresponding to the volume-weighted average price for Catena Media’s share on Nasdaq Stockholm during a period of 30 trading days up to and including 29 April 2019.    Through the share issue, the number of ordinary shares in Catena Media increases by 1,440,454 shares from 56,989,144 shares to 58,429,598 shares and the share capital increases by EUR 2,160.68 from EUR 85,483.72 to EUR 87,644.40. For further information, please contact:  Per Hellberg, CEO, Catena Media plcPhone: +46 709 10 74 10, E-mail: per.hellberg@catenamedia.com                  Åsa Hillsten, Head of IR & Communications, Catena Media plc Phone: +46 700 81 81 17, E-mail: asa.hillsten@catenamedia.com The information was submitted for publication, through the agency of the contact persons set out above, on 16 July 2019 at 17.40 CET. 

Handelsbanken’s Interim Report january – june 2019

Summary January – June 2019, compared with January – June 2018 · Operating profit increased by 1% to SEK 11,460m (11,381). · The period’s profit after tax decreased by 3% to SEK 8,973m (9,235). · Earnings per share decreased to SEK 4.61 (4.75). · Return on equity decreased to 12.8% (13.8). · Income climbed by 1% to SEK 22,075m (21,959). Adjusted for capital gains during the previous year, income grew by 5%. · Net interest income increased by 3% to SEK 15,998m (15,552). · Net fee and commission income increased by 4% to SEK 5,207m (5,012). · The C/I ratio went down to 44.9% (46.5). · The credit loss ratio was 0.06% (0.04).  · The common equity tier 1 ratio decreased to 17.1% (21.4). Summary of Q2 2019, compared with Q1 2019 · Operating profit fell by 12% to SEK 5,350m (6,110). Adjusted for the first quarter’s reversal of the provision to Oktogonen, operating profit rose by 1%.  · The period’s profit after tax decreased by 11% to SEK 4,217m (4,756). Adjusted for Oktogonen, profit after tax increased by 3%.  · Earnings per share decreased to SEK 2.17 (2.45). Adjusted for Oktogonen, earnings per share increased by 3%.  · Return on equity went down to 12.3% (13.4%, although 11.6% after adjustment for Oktogonen).  · Income increased by 5% to SEK 11,284m (10,791).  · Net interest income increased by 2% to SEK 8,064m (7,934). · Net fee and commission income grew by 7% to SEK 2,695m (2,512).  · The C/I ratio went up to 48.8% (40.8%, although 48.5% after adjustment for Oktogonen).  · The credit loss ratio was 0.07% (0.05). The slide presentation for today’s press conference will be available at 6:45 a.m. CET at handelsbanken.com/ir   For further information, please contact:Carina Åkerström, President and Group Chief ExecutiveTel: +46 (0)8 22 92 20 Rolf Marquardt, CFOTel: +46 (0)8 22 92 20 Lars Höglund, Head of Investor RelationsTel: +46 (0)8 701 51 70, laho01@handelsbanken.se This information is of the type that Handelsbanken is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication through the agency of the contact person set out above, at 6:45 a.m. CET on 17 July 2019.  For more information about Handelsbanken, please go to: handelsbanken.com

Aker Solutions ASA: Second-Quarter and Half-Year Results 2019

2Q 2019 Financial Highlights · Revenue NOK 7.5 billion · EBITDA NOK 623 million · EBITDA margin 8.3% · EBITDA ex. special items NOK 629 million · EBITDA margin ex. special items 8.4% · Earnings per share ex. special items NOK 0.56 · Order intake NOK 3.8 billion · Order backlog NOK 29.5 billion Improved operations, cost reductions and generally higher activity helped support margins.  "While the market remains very competitive, we are delivering our fifth consecutive quarter with revenue growth and we are still seeing high tendering activity in our target markets," said Luis Araujo, chief executive officer of Aker Solutions. Orders totaled NOK 3.8 billion in the quarter, bringing the backlog to NOK 29.5 billion. This was down from NOK 33.3 billion at the end of the previous quarter, reflecting the timing of new awards. The company is continuing to grow internationally and has won key orders in targeted growth regions. Orders in the quarter included several umbilical contracts for key customers totaling around NOK 1 billion. Aker Solutions was awarded an umbrella contract for engineering services for feasibility studies, conceptual, FEED and detailed design for Petronas. The company also won a new frame agreement for subsea trees for a customer based in Norway. Aker Solutions won 46 front-end orders in the period, bringing the total for the first half of the year to 74, compared with 73 in the same period last year. Nearly a third of those orders were from outside the Norwegian continental shelf. "We continue to see demand for studies and front-end work for larger and more complex projects," said Araujo. "This puts us in a strong position to secure more work in future phases." In the first half of the year, 17 concept studies led to front-end engineering and design (FEED) work and two of the FEEDs led to fully-fledged project work.  Finances were strong, with a liquidity buffer of NOK 7.2 billion at the end of the quarter.  Revenue and EBITDARevenue rose to NOK 7.5 billion in the quarter from NOK 6.3 billion a year earlier, driven by generally higher market activity and continued good progress on a number of key projects. Earnings before interest, taxes, depreciation and amortization (EBITDA) were NOK 623 million, compared with NOK 439 million a year earlier.  The EBITDA margin was 8.3 percent versus 7 percent a year earlier. Excluding special items, the margin was 8.4 percent compared with 7.1 percent a year earlier. EBITDA for 2Q 2019 includes NOK 146 million of lease effects from the new IFRS 16 accounting standard, while comparative figures have not been re-stated. The 2Q EBITDA margin, excluding IFRS 16 and special items, was 6.4 percent.  Aker Solutions has two reporting segments: Projects and Services. Revenue in Projects rose to NOK 6 billion in the quarter from NOK 4.9 billion a year earlier. Excluding special items, EBITDA margin was 7.9 percent in the quarter (including IFRS 16 effects)  versus 6.7 percent a year earlier. Revenue in Services rose to NOK 1.5 billion in the quarter from NOK 1.3 billion a year earlier, driven by higher activity and strong operational performance. Excluding special items, the EBITDA margin was 14 percent in the quarter (including IFRS 16 effects) compared with 13 percent a year earlier. OutlookThe market outlook for oil services remains competitive and there is still pressure on pricing. Tendering activity is high in the company’s main markets. Aker Solutions is bidding for contracts totaling about NOK 55 billion. About two-thirds of these are in the subsea area, where the company expects some key projects to be awarded over the next six to 12 months, including in Brazil, Africa and Asia Pacific. Aker Solutions sees overall revenue up by around 10 percent in 2019 from 2018, in particular driven by the high activity levels in the Field Design sub-segment in the first half and continued high tendering activity. The company maintains its outlook for full-year underlying EBITDA margins to be up year-on-year including the effects of IFRS 16. Excluding the effects of IFRS 16, the company expects full-year EBITDA margin around current levels. ENDS

Vitamin K2 technology wins award for Nattopharma pharmaceutical spin-off

Oslo, Norway and Edison, NJ (17 juLY 2019) — Kaydence Pharma, the pharmaceutical company that spun-off from NattoPharma in 2017, received the Start-Up Stadium Award for Therapeutics at the Biotechnology Innovation Organization (BIO) annual international convention held in June in Philadelphia, PA. BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations, offering Kaydence a strong platform for its exclusive focus on developing menaquinone-7 as a pharmaceutical product for vascular and other tissue calcification-related diseases. The Kaydence entry was based on NattoPharma’s substantial body of scientific evidence and intellectual property (IP).   According to BIO, the goal of Start-up Stadium is to increase start-ups’ engagement and visibility with investors, state and regional affiliates, and early-stage companies. The 2019 event saw the most applications ever submitted (150+), across the largest geographical footprint (24 states, 13 countries), with the most judges ever involved between two rounds (60+ total), BIO reports. “Vascular calcification is one of the most serious and life-threatening conditions worldwide, impacting millions. It was gratifying to have panel of pharma-industry experts corroborate a compelling investment case for Kaydence Pharma and our important work, which is to develop novel ground-breaking therapies to help patients prevent and reverse vascular calcification with vitamin K2 as menaquinone-7,” says Daniel Rosenbaum, Kaydence Pharma CEO. Winning companies receive a one-year membership in BIO, a one-hour advisory discussion with two venture capital firms and will be fast-tracked into the final selection phase for up to a $75,000 convertible note as part of the Delaware Innovation Space’s First Fund program.  “NattoPharma is thrilled to see the work we have pioneered since our inception has resulted in the ability to pursue a new drug application in this exciting new venture called Kaydence,” says NattoPharma CEO Kjetil Ramsøy. “As the majority shareholder in Kaydence Pharma, we applaud our colleagues for impressing upon this esteemed audience the importance of their mission and indelible impact vitamin K2 as MK-7 can have on changing the face of global health.” XXX 

Interim Report Second Quarter 2019

CEO comment by Anders Nilsson“In the second quarter of 2019 we took additional steps to focus our geographical footprint by closing the sale in Kazakhstan and announcing the sale of our Croatian business. We also propose an extraordinary dividend of SEK 6 per share to distribute the proceeds from the transactions in Kazakhstan and the Netherlands to our shareholders. The Com Hem integration is well under way and we realized an additional SEK 100 million of synergies, reaching our full year run-rate target of SEK 450 million already after six months. In Sweden, we launched a rebranding campaign of the Tele2 brand and continued to see progress on our fixed mobile convergence (FMC) strategy with 93,000 customers now on FMC offers, paving the way for future revenue growth as we reduce churn and increase pricing power.” Highlights · Revenue of SEK 6.8 billion, representing organic decline of –2 percent · End-user service revenue of SEK 5.1 billion, representing organic decline of –1 percent · Organic growth of 3 percent in underlying EBITDA, excluding IFRS 16, to SEK 2.2 billion for the Group · Organic growth of 3 percent in underlying EBITDA, excluding IFRS 16, to SEK 1.8 billion in Sweden, driven by synergies from the Com Hem merger · Net profit from total operations of SEK 2.1 billion impacted by a SEK 1.6 billion capital gain from the sale in Kazakhstan and a goodwill impairment of SEK –0.5 billion in Estonia · Profit after financial items (EBT) was SEK 0.3 billion (0.7 billion) · Earnings per share after dilution was SEK 2.98 (0.81) · Proposed extraordinary dividend of SEK 6.00 per share to distribute proceeds from asset sales in Kazakhstan and the Netherlands · Equity free cash flow more than doubled to SEK 1.1 billion, driven by the Com Hem merger · Financial guidance unchanged, capex updated to reflect Croatia now reported as a discontinued operation Teleconference and webcastTele2 will host a teleconference and webcast with presentation at 10:00 CEST (09:00 BST, 04:00 EDT) on Wednesday, July 17, 2019. The presentation will be held in English and will also be available as a webcast at Tele2’s website: www.tele2.com Dial-in informationTo make sure you are connected in time for the teleconference, please dial in a few minutes in advance and register your attendance. Use Confirmation Code 3047523. Dial-in numbers:SE: +46 (0) 8 50 69 21 80UK: +44 (0) 2071 928000US: +1 631 510 74 95For more information, please contact:Joel Ibson, Head of Corporate Communications, Phone: +46 766 26 44 00Marcus Lindberg, Head of Investor Relations, Phone: +46 73 439 25 40This information is information that Tele2 AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 07:00 CEST on July 17, 2019.TELE2’S MISSION IS TO FEARLESSLY LIBERATE PEOPLE TO LIVE A MORE CONNECTED LIFE. We constantly strive to be the truly integrated challenger – providing speed, data and video content, no matter where or when. Ever since Tele2 was founded in 1993, we have continued to challenge prevailing norms and dusty monopolies. Today, our award winning networks enable mobile and fixed connectivity, telephony, data network services, TV, streaming and global IoT solutions for millions of customers. We drive growth through customer satisfaction and smart combined offerings. Tele2 has been listed on Nasdaq Stockholm since 1996. In 2018, Tele2 generated revenue of SEK 30 billion and reported an underlying EBITDA of SEK 9 billion. For latest news and definitions of measures, please see our homepage www.tele2.com

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING

NOTICE ETC. Shareholders who wish to attend the Extraordinary General Meeting shall · be entered in the share register maintained by Euroclear Sweden on Friday 16 August 2019, and · give notice of their intention to attend no later than Friday 16 August 2019. Notice to attend is to be made on the company’s website at www.tele2.com, under the heading “Extraordinary General Meeting 2019”, found under the section “Governance”, by telephone to +46 (0)8 42 00 34 32 or by mail to Computershare AB “EGM Tele2”, P.O. Box 610, SE-182 16 Danderyd, Sweden. Shareholders shall in their notice to attend state name, personal identification number or company registration number, address, phone number and number of advisors, if applicable. Shareholders whose shares are registered in the names of nominees must re-register such shares in their own name in order to be entitled to attend the Extraordinary General Meeting. In order for such re-registration, which can be temporary, to be completed on Friday 16 August 2019 the shareholder must inform their nominees well before that day. Shareholders attending by a proxy or a representative should send documents of authorization to the mail address above well before the Extraordinary General Meeting. A template proxy form is available on the company’s website www.tele2.com under the heading “Extraordinary General Meeting 2019”, found under the section “Governance”. Shareholders cannot vote or, in other way, attend the Extraordinary General Meeting by remote access. PROPOSED AGENDA 1. Opening of the Extraordinary General Meeting. 2. Election of Chairman of the Extraordinary General Meeting. 3. Preparation and approval of the voting list. 4. Approval of the agenda. 5. Election of one or two persons to check and verify the minutes. 6. Determination of whether the Extraordinary General Meeting has been duly convened. 7. Resolution on extraordinary dividend. 8. Closing of the Extraordinary General Meeting. RESOLUTIONS PROPOSED BY THE BOARD Dividend (item 7)Following the sale of the company’s equity share in the joint venture between Tele2 and Kazakhtelecom, and the repayment of Tele2’s shareholder loan to the joint venture, and as a consequence of the proceeds received in conjunction with the merger involving Tele2’s operations in the Netherlands, the financial position of the company has been strengthened and the Board therefore proposes, in accordance with the company’s shareholder remuneration framework, that an extraordinary dividend of SEK 6 (six) per share shall be paid. The record date for the dividend payment shall be on 26 August 2019. If the Extraordinary General Meeting resolves in accordance with the proposal, it is estimated that Euroclear Sweden will execute the payments on 29 August 2019. The extraordinary dividend proposed by the Board will not affect the payment of the ordinary dividend resolved by the AGM on 6 May 2019, and for which the record date for the second installment is set to 2 October 2019. The Board’s proposed dividend corresponds to a total amount of SEK 4,126,280,856, based on 687,713,476 outstanding shares as of July 17, 2019 (which excludes 2,628,121 shares held by Tele2). As of 31 December 2018, Tele2’s non-restricted equity amounted to approximately SEK 28,874 million. The Annual General Meeting on 6 May 2019 resolved to pay a cash dividend of SEK 4.40 per share, to be paid in two equal instalments. The first instalment was paid on May 13, 2019 and amounted to SEK 1,512,887,706 in total, and the second instalment is expected to be paid on October 7, 2019 and amount to SEK 1,512,969,647.2 in total, based on 687,713,476 outstanding shares as of July 17, 2019 (which excludes 2,628,121 shares held by Tele2).  The total dividend resolved by the Annual General Meeting is thus expected to amount to SEK 3,025,857,353.2 which reduce the available non-restricted equity by the same amount. Hence, the available amount for distribution in accordance with Chapter 17, Section 3, Paragraph 1 of the Swedish Companies Act, amounts to approximately SEK 25,848 million. Following the Extraordinary General Meeting’s resolution regarding the distribution, the available amount in accordance with Chapter 17, Section 3, Paragraph 1 of the Swedish Companies Act is expected to be reduced by SEK 4,126,280,856 to approximately SEK 21,722 million. MISCELLANEOUS Shares and votesThere are a total number of 690,341,597 shares in Tele2, whereof 22,606,922 Class A shares, 665,835,675 Class B shares and 1,899,000 Class C shares, corresponding to a total of 893,803,895 votes. As at the date on which this notice is disclosed Tele2 holds 729 121 of its own Class B shares and 1,899,000 of its own Class C shares corresponding to 2,628,121 votes which cannot be represented at the Extraordinary General Meeting. AuthorizationThe Board, or the person that the Board will appoint, shall be authorized to make the minor adjustments in the Extraordinary General Meeting’s resolutions as may be required in connection with registration at the Swedish Companies Registration Office and Euroclear Sweden. DocumentationThe reasoned statement of the Board pursuant to Chapter 18 Section 4, and the Board’s report and the Auditor’s statement pursuant to Chapter 18 Section 6, of the Swedish Companies Act (2005:551) are available at the company’s website www.tele2.com under the heading “Extraordinary General Meeting 2019”, found under the section “Governance”. The annual report, including audit report, is available at the company’s website www.tele2.com under the heading “Reports and presentations”, found under the section “Investors”. All documentation are also available at the company’s premises at Torshamnsgatan 17 in Stockholm and will be sent to those shareholders who so request and state their postal address or email address. The documentation can be ordered by telephone at +46 (0)8 42 00 34 32 or at the address Computershare AB “EGM Tele2”, P.O. Box 610, SE-182 16 Danderyd, Sweden. Shareholders’ right to request informationThe Board and the Chief Executive Officer shall, if any shareholder so requests and the Board believes that it can be done without material harm to the company, provide information regarding circumstances that may affect the assessment of an item on the agenda and the company’s relation to other companies within the group. Processing of personal dataFor information on how your personal data is processed, see Tele2’s Privacy notice for General Meetings of Shareholders at www.tele2.com under the heading “Shareholders’ personal data”, found under the heading “The share” under the section “Investors”. Stockholm, July 2019TELE2 AB (PUBL)THE BOARD ___________ Other informationSchedule for the Extraordinary General Meeting:The doors open for shareholders at 12.00 p.m. CEST.The Annual General Meeting commences at 1.00 p.m. CEST. InterpretationThe Extraordinary General Meeting will be held in Swedish. As a service to the shareholders, simultaneous interpretation from Swedish to English will be provided. This service may be requested when attendance to the Extraordinary General Meeting is notified.  ___________

Swedbank has set new financial targets

“Swedbank will continue to be a well-capitalised, low risk bank. The new financial targets will give us even better possibilities to continue to contribute positively to societies where we have operations,” says Göran Persson, Swedbank’s Chair of the Board. Swedbank’s capitalisation will ensure that the bank can withstand changes in economic conditions and maintain a good margin to the regulator’s requirements. Against the backdrop of a higher counter-cyclical buffer in Sweden, a defined benefit pension obligation impacted by market rates, continued loan volume growth and the uncertainty regarding the bank’s work on anti-money laundering, Swedbank has therefore set the following new financial targets:   Dividend policySwedbank’s dividend will correspond to 50 percent of the annual profit attributable to shareholders. The dividend will be decided annually, with respect to the bank’s capital target and the outlook for profitable growth in our home markets. Capital targetSwedbank’s Common Equity Tier 1 capital ratio will exceed the Swedish FSA’s requirement by 100-300bps. The targets of having market leading cost efficiency and a Return on Equity of at least 15 per cent remain. As of the end of the second quarter this year, Swedbank’s Common Equity Tier 1 capital ratio was 16.1 percent, which is 150bps higher than the Swedish FSA’s requirement. “This change will ensure that Swedbank remains one of the strongest banks financially in Europe while continuing to support our customers’ growth,” says Anders Karlsson, acting President and CEO. Contacts:Gregori Karamouzis, Head of Investor Relations, +46 727406338Unni Jerndal, Press Officer, +46 730921180  This announcement involves the disclosure of inside informationSwedbank AB (publ) is required to disclose this information pursuant to Regulation (EU) No 596/2014 on market abuse, the Swedish Securities Markets Act (2007:528), the Swedish Financial Instruments Trading Act (1991:980) and the regulatory framework of Nasdaq Stockholm. This information was sent to be published on 17 July 2019 at 07.00 CET.

Ericsson reports second quarter results 2019

Second quarter highlights   · Sales were SEK 54.8 (49.8) b. Sales adjusted for comparable units and currency increased by 7% driven by growth in Networks in North America and North East Asia. Reported sales grew by 10%. · Gross margin was 36.6% (34.8%). Gross margin excluding restructuring charges was 36.7% (36.7%). · Networks gross margin excluding restructuring charges improved to 41.4% (40.2%) YoY. Sequentially, Networks gross margin decreased from 43.2%, mainly due to costs related to a previously communicated license settlement agreement, negative impact from strategic contracts and lower IPR licensing revenues. · Operating income was SEK 3.7 (0.2) b. and operating margin was 6.8% (0.3%). Operating income excluding restructuring charges was SEK 3.9 (2.0) b. and operating margin excluding restructuring charges was 7.0% (4.1%). · Net income improved to SEK 1.8 (-1.8) b. · Free cash flow before M&A was SEK 2.2 (-0.2) b. Net cash amounted to SEK 33.8 (33.1) b. +--------------------------+-----+-----+------+-----+------+--------+--------+|SEK b. |Q2 |Q2 |YoY |Q1 |QoQ |6 months|6 months|| |2019 |2018 |change|2019 |change|2019 |2018 |+--------------------------+-----+-----+------+-----+------+--------+--------+|Net sales |54.8 |49.8 |10% |48.9 |12% |103.7 |93.2 |+--------------------------+-----+-----+------+-----+------+--------+--------+|   Sales growth adj. for |- |- |7% |- |- |- |- ||comparable units and | | | | | | | ||currency | | | | | | | |+--------------------------+-----+-----+------+-----+------+--------+--------+|Gross margin |36.6%|34.8%|- |38.4%|- |37.5% |34.5% |+--------------------------+-----+-----+------+-----+------+--------+--------+|Operating income (loss) |3.7 |0.2 |- |4.9 |-24% |8.6 |-0.1 |+--------------------------+-----+-----+------+-----+------+--------+--------+|Operating margin |6.8% |0.3% |- |10.0%|- |8.3% |-0.2% |+--------------------------+-----+-----+------+-----+------+--------+--------+|Net income (loss) |1.8 |-1.8 |- |2.4 |-23% |4.3 |-2.5 |+--------------------------+-----+-----+------+-----+------+--------+--------+|EPS diluted SEK |0.51 |-0.58|- |0.70 |-27% |1.21 |-0.83 |+--------------------------+-----+-----+------+-----+------+--------+--------+|EPS (non-IFRS) SEK[1] |0.59 |-0.09|- |0.80 |-26% |1.39 |0.02 |+--------------------------+-----+-----+------+-----+------+--------+--------+|Free cash flow excluding |2.2 |-0.2 |- |4.1 |-45% |6.3 |0.6 ||M&A | | | | | | | |+--------------------------+-----+-----+------+-----+------+--------+--------+|Net cash, end of period |33.8 |33.1 |2% |36.1 |-7% |33.8 |33.1 |+--------------------------+-----+-----+------+-----+------+--------+--------+|Gross margin excluding |36.7%|36.7%|- |38.5%|- |37.5% |36.3% ||restructuring charges | | | | | | | |+--------------------------+-----+-----+------+-----+------+--------+--------+|Operating income (loss) |3.9 |2.0 |89% |5.1 |-24% |9.0 |2.9 ||excluding restructuring | | | | | | | ||charges | | | | | | | |+--------------------------+-----+-----+------+-----+------+--------+--------+|Operating margin excluding|7.0% |4.1% |- |10.4%|- |8.6% |3.1% ||restructuring charges | | | | | | | |+--------------------------+-----+-----+------+-----+------+--------+--------+ [1]  EPS diluted, excl. amortizations and write-downs of acquired intangible assets, and excluding restructuring charges. Potential ordinary shares are not considered when their conversion to ordinary shares would increase earnings per share. Non-IFRS financial measures are reconciled to the most directly reconcilable line items in the financial statements at the end of this report. Comments from Börje Ekholm, President and CEO of Ericsson (NASDAQ:ERIC) Organic sales growth[1] was 7% in the quarter, mainly driven by sales in North America and North East Asia. We see strong momentum in our 5G business with both new contracts and new commercial launches as well as live networks. To date, we have provided solutions for almost two-thirds of all commercially launched 5G networks. 5G momentum is increasing. Initially, 5G will be a capacity enhancer in metropolitan areas. However, over time, new exciting innovations for 5G will come with IoT use cases, leveraging the speed, latency and security 5G can provide. This provides opportunities for our customers to capture new revenues as they provide additional benefits to consumers and businesses. In the quarter, gross margin[2] was unchanged YoY at 36.7%, with improvements in segment Networks being offset by lower margins in Digital Services and Managed Services. Networks had another solid quarter with an organic sales growth[1] of 11% YoY, driven by 4G and 5G investments in North America and North East Asia as well as increased volumes related to strategic contracts. While the strategic contracts will be margin accretive in the long term, the impact on near-term profitability is negative. In the quarter we had a negative impact on gross margin and expect this impact to increase during the second half of the year. In addition, costs related to the previously announced license settlement agreement impacted margins negatively. Despite this, gross margin[2] improved to 41.4% (40.2%) YoY mainly due to increased IPR revenues. To ensure we meet customer requirements for fast and agile deliveries, we have decided to invest in a state-of-the-art 5G production site in the US to complement our global supply chain. In Digital Services we continue to execute on the plan to reach low single-digit margins for 2020. The improvements are not linear and will vary between quarters. Organic sales[1] in Digital Services were down by -3% YoY as a result of rapid decline in legacy products. Gross margin[2] was 37.1% (42.6%). The decline in gross margin was mainly driven by a change in sales mix. The mix may vary between quarters. Our 5G and Cloud native portfolio is gaining customer traction and we are increasing related R&D investments to ensure portfolio readiness. The reshaped BSS strategy is gaining momentum and contracts were signed with several new customers in the quarter. The share of recurrent business is increasing, we are tracking towards having 75% of the 45 critical and non-strategic contracts addressed by year-end and we have cost efficiency programs in place throughout Digital Services. In Managed Services the strategy is to enhance the customer offering by relying more on automation, machine learning and AI, which will longer-term change and improve the margin profile of the business. Near-term margins are negatively impacted by the increase in R&D investments. Organic sales[1] declined by -6%, mainly explained by the negative effect from the customer contract reviews. Gross margin[2] declined to 12.3% (14.0%) YoY, negatively impacted by timing of costs. Organic sales growth[1] in Emerging Business and Other was 24% driven by a continued growth in iconectiv. Operating income[2] improved YoY to SEK -0.7 (-1.2) b. supported by increased profits in iconectiv and the divestment of MediaKind. In this segment we invest in initiatives that aim to scale and help create future business for Ericsson. With the exception of iconectiv, the portfolio is still in an early investment phase. Driven by improved earnings, free cash flow excluding M&A improved to SEK 2.2 (-0.2) b. We are in ongoing settlement negotiations with the United States Securities and Exchange Commission (SEC) and the United States Department of Justice (DOJ) in connection with their previously reported investigation under the U.S. Foreign Corrupt Practices Act (FCPA). We are not able to estimate the length of these settlement discussions. Further, as this is an ongoing legal matter we cannot provide any detail. However, it is our current assessment that the resolution of these matters will result in material financial and other measures, the magnitude and impact of which cannot be reliably estimated or ascertained at this time. We continue to take strategic contracts and the large-scale network deployments expected to commence in parts of Asia, will gradually impact margins negatively in the short term but strengthen our position in the long term. Continued technology and market investments, especially in 5G, automation and AI, are fundamental for long-term competitiveness and a key part of our focused strategy to strengthen our long-term business and path to reaching our targets for 2020 and 2022. Börje Ekholm President and CEO [1] Organic sales growth: Sales growth adjusted for comparable units and currency[2] Excluding restructuring charges Planning assumptions going forward Market related                                                                                                                                 · The Radio Access Network (RAN) equipment market is estimated to increase by 3% for full-year 2019 with 2% CAGR for 2018-2023. (Source: Dell’Oro.) Ericsson related Net sales · Two-year average sales seasonality between Q2 and Q3 is 3%. The current sales level in North America is expected to remain throughout 2019. · The revenues for current IPR licensing contract portfolio is approximately SEK 9 b. on an annual basis. Gross margin · Strategic contracts in Networks, with initially low margins, taken to strengthen the market position, will have a negative impact on gross margin without jeopardizing the 2020 target. The negative impact is expected to increase in 2H 2019. · Large 5G deployments in parts of Asia are expected to commence at the end of 2019 and will gradually impact gross margin negatively in the short term. · The share of services sales in North America is expected to gradually increase, impacting gross margin negatively. · The targeted improvements in Digital Services are not linear and will vary between quarters. Operating expenses · Operating expenses typically decrease somewhat between Q2 and Q3 due to seasonality. · Costs for 5G field trials will continue to impact SG&A . · Networks R&D expenses are expected to flatten out. Restructuring charges · Restructuring charges for full-year 2019 are estimated to be SEK -2 to -4 b. (the previous estimate was SEK -3 to -5 b.). Currency exposure · Rule of thumb: A change of 10% of USD to SEK would have an impact of approximately +/-5% on net sales and approximately +/-1 percentage point on operating margin. NOTES TO EDITORS You find the complete report with tables in the attached PDF or by following this link https://www.ericsson.com/assets/local/investors/documents/financial-reports-and-filings/interim-reports-archive/2019/6month19-en.pdf or on www.ericsson.com/investors Conference calls for journalists, analysts and investors  The company will hold two identical conference calls for journalists, financial analysts and investors. President and CEO Börje Ekholm and CFO Carl Mellander will comment on the report and take questions. The first conference call will begin at 09:00 CEST (08:00 BST in London, 03:00 EDT in New York and 16:00 JST in Tokyo), and the second at 14:00 CEST (13:00 BST in London, 08:00 EDT in New York and 21:00 JST in Tokyo). To join the conference call, please phone one of the following numbers: Sweden: +46 (0) 8 56642651 (Toll-free Sweden: 0200 883 685) International/UK: +44 (0) 333 300 0804 (Toll-free UK: 0800 358 9473) US: +1 631 913 1422 (Toll-free US: +1 855 85 70686) PIN code: For 09:00 CEST call, 77905138# and for 14:00 CEST call, 63330598# Please call in at least 15 minutes before the conference call begin. As there is usually a large number of callers, it may take some time before you are connected. A live audio webcast of the conference call will be available at www.ericsson.com/investors and www.ericsson.com/press  Replay:  Replay of the conference calls will be available from about one hour after each has ended until July 24, 2019. Sweden replay number: +46 (0) 8 519 993 85 International replay number: +44 (0) 333 300 0819 For 09:00 CEST call, 301292129# and for 14:00 CEST call, 301292137# FOR FURTHER INFORMATION, PLEASE CONTACT Contact person Peter Nyquist, Head of Investor RelationsPhone: +46 10 714 64 99E-mail: peter.nyquist@ericsson.com  Additional contacts Stella Medlicott, Senior Vice President, Marketing and CommunicationsPhone: +46 10 713 65 39E-mail: media.relations@ericsson.com Investors Stefan Jelvin, Director, Investor RelationsPhone: +46 10 714 20 39E-mail: stefan.jelvin@ericsson.com  Rikard Tunedal, Director, Investor RelationsPhone: +46 10 714 54 00E-mail: rikard.tunedal@ericsson.com Media Ola Rembe, Vice President, Head of External CommunicationsPhone: +46 10 719 97 27E-mail: media.relations@ericsson.com  Corporate CommunicationsPhone: +46 10 719 69 92E-mail: media.relations@ericsson.com This information is information that Telefonaktiebolaget LM Ericsson is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CET on July 17, 2019.  

Interim report April – June 2019

Significant events during the second quarter  The Annual General Meeting resolved, in accordance with the submitted proposal, to appoint Yvonne Mårtensson as the new Chairman of the Board. SyntheticMR has received clearance from the FDA, for the use of SyMRI together with Siemens systems. SyntheticMR invests in local presence in the US and as part of this, a subsidiary has been registered, SyntheticMR U.S. Inc. At the end of the quarter, a subsidiary manager was recruited to the newly started company in the U.S. The person takes up his position on August 1, 2019. Significant events after the second quarter  Ulrik Harrysson has started his position as CEO as of 1 July 2019. The Board of Directors has decided to postpone the application to change trading list to NASDAQ OMX Stockholm. The company has recently made a CEO change and the resources will be focused on the business operations to further establish the company's products in the global market. CEO comments It is with great enthusiasm and a high level of ambition, that I have now started my position as CEO of SyntheticMR. The company possesses a strong expertise that builds on our unique technology and develops, markets and sells innovative solutions that meet customersneeds. I see great development opportunities for SyntheticMR. Having pre-existing partnerships with the largest players within MRI, means that conditions are good for continuing to strengthen the company's position in the global market. I can report that sales during the second quarter amounted to SEK 12.9 million (SEK 11.1 million), which means an increase of 16%. The growth is attributable to a combination of higher sales through all our partners. Cash flow during the quarter was negative due to the dividend payment of SEK 6.6 million, which was decided at the Annual General Meeting at the end of April. Cash flow from operating activities remains positive, SEK 1.2 million (SEK 4.4 million), and we see continued good cash conversion rate. The collaboration with GE Healthcare is progressing well, with continuing steps in the right direction. During the quarter we have continued positive discussions about widening our partnership further. This means not only increased customer offerings in the existing MAGiC product, but also the opportunity for GE Healthcare to offer additional solutions. MAGiC aims to simplify and shorten the time of an MRI exam, while at the same time maximizing the productivity of the hospital or clinic. GE Healthcare sees that these offerings fit well with the market conditions that emerge primarily in developing countries but also in larger countries in Asia. In our collaboration with Philips, we are working intensively on the required actions to get SyMRI into their global product catalog. It will take some time until we are included there, as this requires an updated agreement as well as long lead times in Philips' internal processes. In the meantime, we are actively working on other sales initiatives, which during the period resulted in the sale of SyMRI to one of Europe's largest university hospitals. In the second quarter, another application was submitted to the FDA regarding the use of SyMRI together with MRI systems from Siemens. The same application was subsequently cleared during the period, which means that SyMRI is now available for clinical use in the US market together with all of our partners.  As previously communicated, we are now accelerating our investments in our own local presence in the US. At the end of the quarter, we have completed the recruitment of the first staff member for our newly started US subsidiary. With the latest approval from the FDA, we now see that it is a good opportunity to increase our local presence and support our partners for increased sales and deployment of SyMRI. SyntheticMR is a growth company and I see great potential in the company's long-term opportunities for increased profitable sales growth. We are now increasing the pace of strengthening the company's position globally. The establishment in the US, the world's largest healthcare market, is a significant step towards that ambition.  Ulrik Harrysson CEO SyntheticMR AB  For additional information, please contact Fredrik Jeppsson, CFO and Head of Investor Realtions, SyntheticMR AB, +46 72 303 13 39 or Ulrik Harrysson, CEO, SyntheticMR AB, +46 70 529 29 87 SyntheticMR AB develops and markets innovative software solutions for Magnetic Resonance Imaging (MRI). SyntheticMR AB product SyMRI® delivers multiple contrast images and quantitative data from a single 6-minute scan – to improve patient throughput and objective decision support for clinicians. SyMRI is CE-marked and FDA 510(k) cleared. SyMRI is a registered trademark in Europe and in the USA. SyntheticMR is listed on the Spotlight Stock Market in Stockholm, Sweden. For additional information, please visit www.syntheticmr.com.  This information is information that SyntheticMR AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on July 17th, 2019

Good growth and improved operating margin

Second quarter · Net sales increased by 11% to SEK 23,544 M (21,140), with organic growth of 3% (5) and acquired net growth of 4% (2) · Strong growth in Americas and Global Technologies, good growth in EMEA and Asia Pacific and growth in Entrance Systems · Three acquisitions signed with combined expected annual sales of about SEK 800 M · Operating income (EBIT)[1] increased by 28% and amounted to SEK 3,733 M (2,911), corresponding to an operating margin of 15.9% (13.8) · Net income[1] amounted to SEK 2,562 M (2,049) · Earnings per share[1] amounted to SEK 2.31 (1.84) · Operating cash flow increased by 27% to SEK 3,636 M (2,855) Sales and income Second quarter First half-year 2018 2019 Δ 2018 2019 ΔSales, SEK M 21,140 23,544 11% 39,690 45,048 14% Of which:Organic growth 954 692   3% 1,659 1,698 4% Acquisitions and 366 790   4% 633 1,478 4% divestmentsExchange-rate 433 922 4% –131 2,182 6% effectsOperating income 2,911 3,733 28% 5,740 6,978 22% (EBIT)[1], SEK MOperating margin 14.2% 16.4% 14.9% 16.0%(EBITA)[1], %Operating margin 13.8% 15.9% 14.5% 15.5%(EBIT)[1], %Income before 2,720 3,462 27% 5,374 6,459 20% tax[1], SEK MNet income[1], 2,049 2,562 25% 4,013 4,780 19% SEK MOperating cash 2,855 3,636 27% 3,431 4,807 40% flow, SEK MEarnings per 1.84 2.31 25% 3.61 4.30 19% share[1], SEK [1] Excluding impairment of goodwill and other intangible assets in Q2 2018, totaling SEK –5,595 M before tax, corresponding to SEK –5,268 M after tax. Comments by the President and CEO Good growth and improved operating marginFollowing a good start to 2019, the positive performance continued during the second quarter. Total sales grew by 11% with an improved operating margin. Sales growth in the quarter was driven by organic growth of 3%, acquired net growth of 4% and positive currency movements of 4%. Growth was strong in Americas (6%) and Global Technologies (5%). Asia Pacific and EMEA reported good growth, while growth in Entrance Systems was stable. Operating income excluding non-comparable items in 2018[2]increased by 13% to SEK 3,733 M, driven by good operating leverage. This contributed to an operating margin improved by 20 basis points. The Group has now offset the previous headwind from the higher raw material costs. Operating cash flow was very strong and improved by 27% to SEK 3,636 M, driven by the improved earnings and positive evolution from working capital. Our cash conversion in the quarter was stable at 105%[2]. Our strategic objectives guide usDemand has generally been good in 2019, but with variations between different markets. In some markets, uncertainty has increased at the same time due to weaker construction indices and geopolitical challenges. To retain our leadership in the short and long term, it is important to be agile and to focus on our strategic objectives. It is encouraging to see how cost efficiency in everything we do is driving results. During the second quarter our efficiency programs and other savings generated more than SEK 200 M in efficiencies. We continuously work to identify opportunities for saving across the entire Group, which is critical for our competitive advantage. We also continue to invest in product leadership through innovation as an enabler of sustainable profitable growth. Our investments in innovation have driven our strong sales growth in electromechanical products during the last year, including 20% growth in the second quarter. Today, we have more than 2,600 people working in R&D and 9,000 patents across our product segments. These resources provide a solid platform for our continuing developments of new solutions that will make life easier and more secure for our customers. Because people are our most important asset, we will continue to invest in training and skills development to stay ahead and lead the development in our industry. Another driver of growth is the increasing demand for sustainable solutions. With our strong range of products that are both environmentally suited and innovative, we are well positioned to capture these opportunities and grow through customer relevance. This will enable us to continue to create shareholder value while contributing to a greener world. Stockholm, 17 July 2019 Nico DelvauxPresident and CEO   Further information can be obtained from:Nico Delvaux,President and CEO, tel. no: +46 8 506 485 82 Erik Pieder,Executive Vice President and CFO, tel.no: +46 8 506 485 72  ASSA ABLOY is holding a telephone and web conference at 09.30 17 July 2019 which can be followed on the Internet at www.assaabloy.com.It is possible to submit questions by telephone on: +46 8–505 583 51, +44 333 300 9266 or +1 833 823 0587  This is information that ASSA ABLOY AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CEST on 17 July 2019. [2] Excluding impairment of goodwill and other intangible assets, totaling SEK –5,595 M and write down of operating assets in China of SEK –400 M in Q2 2018.

Getinge publishes Interim Report for January - June 2019

Getinge is today reporting an increase in organic sales by 4.0% and an increased order intake of 5.2% organically, which means that Getinge’s growth remains higher than the market average. The positive performance in the US is continuing and the net sales in China increased by more than 30%. During the quarter, Getinge launched the steam sterilizer GSS610H and the most recent version of the Servo-u ventilator is now ready for launch on all markets that require CE marking. “I am pleased with the development in the business areas Acute Care Therapies and Life Science in the quarter and that our working capital is continuing to decline despite our growth, which has a positive impact on cash flow, “says Mattias Perjos. “ However, I am not satisfied with the margins, which were impacted by the negative development in the business area Surgical Workflows, and we will intensify our efforts to strengthen the profitability of the operations in general and in Surgical Workflows in particular.” April – June 2019 in brief ·  Net sales increased organically by 4.0% and the order intake rose by 5.2%, despite challenging comparative figures.   ·  Adjusted gross profit amounted to SEK 3,101 M (2,844) and the margin was 49.4% (49.6). IFRS 16 had a positive effect of SEK 29 M on adjusted gross profit.  ·  Adjusted EBITA amounted to SEK 591 M (538) and the adjusted EBITA margin was 9.4% (9.4). IFRS 16 had a positive effect of SEK 4 M on adjusted EBITA.  ·  Adjusted earnings per share amounted to SEK 1.12 (1.21). The effect of IFRS 16 was SEK -0.01 per share.   ·  Introduction of the GSS610H Sterilizer and the upgraded version of the Servo-u ventilator is ready for launch on all markets that require CE marking.   Telephone conference A conference call will be held on July 17, 2019, at 10:00-11:00 CEST hosted by Mattias Perjos, President & CEO, and Lars Sandström, CFO. Please see dial in details below to join the conference: SE: +46 8 519 99 383   UK: +44 33 3300 9035US: +1 844 625 1570 During the telephone conference a presentation will be held. To access the presentation through webcast, please use this link: https://tv.streamfabriken.com/getinge-q2-2019.Alternatively, use the following link to download the presentation: https://www.getinge.com/int/about-us/investors/reports-presentations A recorded version can be accessed for 3 years via: https://tv.streamfabriken.com/getinge-q2-2019 Media contact: Lars Mattson, Head of Investor RelationsTel: +46 (0)10 335 0043Email: lars.mattsson@getinge.com Jeanette Hedén Carlsson, EVP Communication & AcademyTel: +46 (0)10 335 1003Email: jeanette.hedencarlsson@getinge.com This information is such that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, on July 17, 2019, at 08:00 a.m. CEST.

Hunter Group ASA – Appointment of CFO

Oslo, 17. July 2019 Hunter Group ASA (the «Company») is pleased to announce that Mr. Lars M. Brynildsrud has accepted the position as CFO of the Company as from 12 August 2019. Mr. Brynildsrud has more than six years of investment banking experience and has been involved in a wide range of shipping and offshore related capital market transactions.  Most recently Mr. Brynildsrud comes from the position of Vice President, Corporate Finance at Swedbank, a position he has held since 2018. Prior to joining Swedbank, Mr. Brynildsrud was a partner in Pareto Securities working both in Oslo and New York.   Mr. Brynildsrud holds a MSc in finance from the Norwegian School of Economics (NHH), and a BBA from BI Norwegian Business School (BI). As part of his remuneration package Mr. Brynildsrud has been granted 500,000 LTI Options, with a strike price per share equal to the subscription price in the Private Placement completed on 23 May 2019, i.e. NOK 3.65 per share, and with a 12 month vesting period on terms set out in the Company’s LTI rules, as adopted by the Company’s AGM as per 25. April 2019, with effect from the commencement date of employment. Further, as per the date of this release, Mr. Brynildsrud also owns 15,400 shares in the Company. For further information, please contact: Erik Frydendal, CEO +47 957 72 947 E-mail: ef@huntergroup.no This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

REPORT ON THE SECOND QUARTER 2019

· Net sales for the quarter were SEK 5,329 m (5,260); an increase of 1%, of which -7% was organic growth. · Operating profit before depreciation and amortization (EBITDA) for the quarter was SEK 1,100 m (1,048), representing a margin of 20.6% (19.9%). · Operating profit (EBIT) for the quarter was SEK 900 m (919), representing a margin of 16.9% (17.5%). · There were no items affecting comparability in the quarter (-). · Cash flow for the quarter was SEK -742 m (3). Operating cash flow was SEK 1,417 m (943). · Profit for the quarter was SEK 562 m (629). · Earnings per share: SEK 1.90 (2.13).    CONTINUED SOLID EARNINGS AND STRONG CASH FLOW“The first half of 2019 was very much characterized by a continued focus on efficiency improvements and building a foundation for an even more diversified and stronger Dometic. Despite challenging RV markets and negative impact from additional US tariffs, we have managed to keep improving our cost structures and implement processes and best practices across our global organization, while investing in new opportunities. The restructuring program launched in Q4 2018 is proceeding well, with good progress in all regions. We are well on track in expanding our presence in Mexico, and the new site is expected to be finalized in the third quarter. The SKU reduction is progressing at a good pace and we remain confident in terms of our ambition to achieve a 30 percent reduction by the end of the year. We continued to strengthen our organization, and a number of new key positions in the areas of product development and operations were added to accelerate strategic initiatives and the pace of innovation. Net sales growth was 1 percent in the quarter with positive growth in EMEA and Asia, while conditions in Americas and Pacific continued to be challenging. EBIT and EBITDA margins held up well as we have intensified our focus on cost reductions. Given the current market situation, we are looking at additional initiatives in all three regions to protect profitability in the short term, while also building up a more efficient company in the long term. Operating cash flow was SEK 1,417 m, an increase of 50 percent compared with the same quarter last year. Leverage improved from 3.3x by the end of Q2 2018 to 2.8x by the end of Q2 2019. Our strong cash generation and extended debt maturities create good opportunities for additional acquisitions. Short term, we expect organic growth to be slightly positive during the second half of the year compared to the same period last year, despite the continued inventory reduction in primarily the US RV market and the revised full year shipments forecast from -5 to -14 percent published by the US RV Association (RVIA). Given this, and the negative impact from the additional US tariffs, the full year 2019 outlook is revised to negative organic growth and an EBIT margin above 14 percent. Leverage excluding acquisitions is expected to be around 2x by the end of 2019”. Juan Vargues President and CEO PRESENTATION OF THE REPORTAnalysts and media are invited to participate in a telephone conference at 10.00 (CEST) July 17, 2019, during which President and CEO, Juan Vargues and CFO, Per-Arne Blomquist, will present the report and answer questions. Sweden: +46 8 566 42 706UK: +44 333 300 9032US: +1 646 722 4903 Webcast URL and presentation are available at www.dometic.com.   This information is information that Dometic Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on July 17, 2019. FOR FURTHER INFORMATION, PLEASE CONTACTJohan Lundin, Head of Investor Relations & CommunicationsPhone: +46 8 501 025 46Email: ir@dometic.com  ABOUT DOMETICDometic is a global market leader in branded solutions for mobile living in the areas of Food & Beverage, Climate, Power & Control and Other Applications. Dometic operates in the Americas, EMEA and Asia Pacific, providing products for use in recreational vehicles, pleasure and workboats, trucks and premium cars and for a variety of other uses. Our motivation is to create smart and reliable products with outstanding design. We sell our products in approximately 100 countries and we have a global distribution and dealer network in place to serve the aftermarket. Dometic employs approximately 8,000 people worldwide, had net sales of approximately SEK 18.0 billion in 2018 and is headquartered in Stockholm, Sweden.

Finnair Group Half-year Report 1 January – 30 June 2019

Finnair Plc, Stock exchange Release, half-year financial report, 17 July 2019 at 9.00 am. EET  Q2 revenue increased by 10.4 per cent and comparable operating profit was 47.2 million euros Quarterly and full-year figures for 2018 have been restated to reflect the adoption of the IFRS 16 standard, changesin accounting principles relating to aircraft components and the changes in the presentation of profit and loss, balance sheet and cash flow statements. The restated figures were published on 21 March 2019. More information on the restatement is available in Note 20 to the Interim Report. April–June 2019  ·  Revenue increased by 10.4% to 793.0 million euros (718.2)*. ·  Unit revenue (RASK) decreased by 3.8%. Unit revenue at constant currency decreased by 3.7%. ·  Unit cost (CASK) decreased by 1.4%. Unit cost at constant currency excluding fuel decreased by 2.9%. ·  Fuel costs increased by 35.2 million euros (+24.2%) of which the impact of fuel price** was 13 million euros. ·  Some exceptional increase in maintenance costs were booked for the quarter. ·  Comparable operating result was 47.2 million euros (59.1). Operating result was 47.9 million euros (50.8). ·  Net cash flow from operating activities was 176.8 million euros (233.1), and net cash flow from investing activities was -147.0 million euros (-34.6).*** ·  Earnings per share were 0.22 euros (-0.15). ·  Number of passengers increased by 13.1 per cent to 3.9 million (3.5). ·  Available seat kilometres (ASK) grew by 14.8%. ·  Passenger load factor (PLF) was 82.5% (-0.1 points). January–June 2019  ·  Revenue increased by 7.8% to 1,466.0 million euros (1,359.3)*. ·  Unit revenue (RASK) decreased by 4.3%. Unit revenue at constant currency decreased by 4.4%. ·  Unit cost (CASK) decreased by 1.0%. Unit cost at constant currency excluding fuel decreased by 2.9%. ·  Fuel costs increased by 53,0 million euros (+19.4%) of which the impact of fuel price** was 19 million euros. ·  Some exceptional increase in maintenance costs were booked for the quarter. ·  Comparable operating result was 31.0 million euros (73.7). Operating result was 30.3 million euros (67.7). ·  Net cash flow from operating activities was 325.0 million euros (341.1), and net cash flow from investing activities was -217.2 million euros (-91.1).*** ·  Earnings per share were -0.11 euros (-0.07). ·  Number of passengers increased by 9.0 per cent to 7.1 million (6.5). ·  Available seat kilometres (ASK) grew by 12.7%. ·  Passenger load factor (PLF) was 80.5% (-2.2 points). *     Unless otherwise stated, comparisons and figures in parentheses refer to the comparison period, i.e. the same period last year. **   Fuel price including impact of currencies and hedging. *** In Q2, net cash flow from investing activities includes 2.9 million euros of redemptions in money market funds or other financial assets maturing after more than three months. In H1, these decreased in net terms by 55.5 million euros. These redemptions are part of the Group’s liquidity management.   Outlook Guidance issued on 24 April 2019: Global airline traffic is expected to continue growing in 2019. Finnair expects increased competition as capacity is added, particularly on routes linking Europe with Asia as well as in short-haul traffic. The slowdown in the economy of Finnair’s key markets and the continued uncertainties surrounding global trade, including from Brexit, could impact the demand for air travel and cargo. Finnair plans to increase its capacity by approximately 10 per cent in 2019, down from its 14.8 per cent capacity growth in 2018. This growth is mainly focused on the Asian market. Revenue is expected to grow at a somewhat slower pace than capacity in 2019. In line with its disclosure policy, Finnair will issue guidance on its full-year comparable operating result as part of its half-year report in July. New guidance on 17 July 2019: Global airline traffic is expected to continue growing in the latter half of 2019. However, the operating environment is expected to remain volatile also in the second half of the year. The slowdown in the economies of Finnair’s key markets and the continued uncertainties surrounding global trade, including the US-China trade talks and Brexit, could impact the demand for air travel and for cargo. Finnair raises its capacity forecast for 2019 owing mainly to its new service to Beijing Daxing International Airport. Finnair estimates that capacity growth in 2019 will be between 11-12 per cent.  Revenue is expected to grow at a somewhat slower pace than capacity in 2019.  While the current outlook for Finnair’s seasonally strongest third quarter remains robust, we have started to see increased uncertainty especially in cargo demand. Finnair estimates that its comparable operating result will be between 4.5-6.0% of revenue in 2019, assuming no material changes in fuel prices and exchange rates. CEO Topi Manner:   Despite the volatile operating environment in Q2, the number of passengers carried rose to a new Q2 record of 3.9 million passengers, and our market share strengthened in both Asian and European traffic. Global uncertainties, such as Brexit and the US-China trade talks, and the gradual slowdown in the economies of Finnair’s key markets, were reflected in our Q2 performance. At the same time, capacity reductions in European traffic, especially on some Nordic routes, had a minor beneficial effect on the competitive situation. Overall, our passenger traffic performed well, with European traffic growing well in line with our expectations. Cargo and travel services, on the other hand, were suffering from a more difficult market environment. We continued to grow: Our revenue grew by 10.4 percent to 793.0 million euros driven by passenger revenue. Profit developed more moderately and was impacted especially by a 13 million euro increase in fuel price[1]  and an exceptional increase in maintenance costs. Our comparable operating result was EUR 47.2 million in Q2. During the review period, we continued to invest in our customer experience: in June, we opened a new Platinum Wing lounge in Helsinki-Vantaa airport, which has been received enthusiastically by our customers. The expansion of the Business Class lounge will be completed in early autumn. We've made it easier for the customer to buy tickets and services via the renewed Finnair.com website, which has already been opened in over 30 markets. We also completed the installation of wireless internet access for the Airbus narrow-body aircraft. In the annual Skytrax evaluation, Finnair was recognized as the ‘Best Airline in Northern Europe’ for the tenth consecutive year, and for that I want to express my warmest thanks to our passengers and to our personnel, who have paved the way for this recognition. Understanding and nurturing a strong relationship between customer and employee experience is in the core of Finnair’s strategy. Sustainability is also one of the cornerstones of our strategy. During Q2 we made progress towards our goals of halving the use of disposable plastic on our flights by the end of 2022 and reducing waste in general: we renewed the packaging of products sold on European flights, reduced the amount of plastic from travel packages and started recycling of bright PET plastic from our return flights to Helsinki. We are also constantly looking for new ways to improve fuel efficiency and reduce carbon emissions from our flying. Sustainable, profitable growth is our future goal. We will increase capacity in our key markets, either to implement our long-term Asian growth strategy or to exploit short-term tactical growth opportunities. In Asian traffic this can be seen, for example, in the openings of new connections in the second half of the year, and in Europe as route optimization. As the first airline, Finnair will open a direct flight from Europe to Busan, the second largest city in South Korea in the summer of 2020, and in early November 2019 we will open a new connection to Beijing's new Daxing International Airport in addition to the current connection. After that we will operate 10 flights per week to Beijing. In addition, we are extending the summer season route to year-round in Guangzhou, the home hub of our new codeshare partner China Southern. In the foreseeable, more challenging operating environment, we will pay increasing attention to operational efficiency, including cross-unit processes and resource optimisation between traffic planning and flight operations, and putting further focus on reliability. Furthermore, we will increase productivity by simplifying and automating processes, such as customer compensations, and by utilising digitalisation in distribution and customer service.  1. Fuel price including impact of currencies and hedging. Financial Reporting in 2019 The publication dates of Finnair’s financial reports in 2019 are the following:  ·  Interim Report 1 January – 30 September 2019: 22 October 2019  FINNAIR PLCBoard of Directors Briefings  Finnair will hold a results press conference (in Finnish) on 17 July 2019 at 11:00 a.m. at its office located at Tietotie 9, Vantaa. An English-language telephone conference and webcast will begin at 1:00 p.m. Finnish time. The conference may be attended by dialling your local access number +358 9 7479 0361 (Finland), 0200 880 389 (Sweden), 0800 358 6377 (UK) or +44 (0)330 336 9105 (all other countries). The confirmation code is 3916088. To join the live webcast, please register at: https://slideassist.webcasts.com/starthere.jsp?ei=1253101 For further information, please contact:  Chief Financial Officer Mika Stirkkinen, tel. +358 9 818 4960 mika.stirkkinen@finnair.com Director, Financial Communications Mari Reponen, tel. +358 9 818 2037, mari.reponen@finnair.com IR Analyst, Kasper Joukama, tel.+358 9 8181 2004, kasper.joukama@finnair.com

Erlangen University Hospital and Immunovia enter into a collaboration agreement for the collection of pancreatic cancer blood samples for the final steps of IMMray™ PanCan-d development

LUND, SWEDEN― Immunovia AB (publ) (“Immunovia”) today announced that Erlangen University Hospital has become the first cancer center in Germany to join Immunovia’s global network of key opinion leaders in the quest for early diagnosis of pancreatic cancer. Erlangen University Hospital will, in addition to Immunovia’s already existing collaborations, supply freshly collected blood samples for the final two steps to market of IMMray™ PanCan-d. As previously communicated (link to PR June 3, 2019 ) the final two steps towards commercialization remain the same and are the verification and validation of the commercial biomarker signature. The blood samples that will be collected, 100 PDAC and additional controls, are collected from patients referred to surgery with radiologically detected pancreatic lesions. The Principal Investigator at Erlangen Hospital is Prof Dr Christian Pilarsky, Department of Surgery, Erlangen University Hospital. This collaboration will not only add fresh PDAC samples and controls to contribute to Immunovia’s collection criteria of up to 2000 fresh samples needed for the remaining process of assuring commercialization readiness of IMMray™ PanCan-d, but will also add to genetic variability as well. As previously communicated the final steps to market of IMMray™ PanCan-d will have three readouts: 1) yearend 2019 for the commercial test model, 2) Q2 2020 for the verification and 3) Q3 2020 the final read out of the blinded validation of IMMray™ PanCan-d. (link to PR June 3, 2019 ). “Being able to gain access to a sufficient number of newly collected samples is essential for finalizing the validation of IMMray™ PanCan-d to launch in Q3 next year,” comments Mats Grahn, Immunovia CEO. “We are therefore delighted to announce this collaboration with Erlangen which also represents our first collaboration site in Germany, a very important market going forward.”   “Whilst there is a good probability of success with surgical intervention in PDAC, we still lack the kind of reliable non-invasive diagnostic test to complement imaging that IMMray™ PanCan-d represents,” adds Professor Pilarsky. “Therefore, we are pleased to enter collaboration with Immunovia and look forward with interest to the outcome.” For more information, please contact: Julie Silber Investor Relations Director, Immunovia Tel.: +46-79-3486277 Email: julie.silber@immunovia.com (mats.grahn@immunovia.com) This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 a.m. (CET) on July 17, 2019. About ImmunoviaImmunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. About Pancreatic Cancer   Pancreatic Cancer is one of the most deadly and difficult to detect cancers, as the signs and symptoms are diffuse and similar to other diseases. There are more than 40,000 deaths and over 50,000 new cases diagnosed each year in the U.S. alone, and the five-year survival rate for pancreatic cancer is currently 5-9%. It is predicted to overtake colorectal cancer to become the second leading cause of cancer death by 2020. However, because resection is more successful in stage I/II, early diagnosis can significantly improve pancreatic cancer patients’ 5-year survival rates from 5-9% to up to 49%. ###

SKF Half-year report 2019

Gothenburg, 17 July 2019 Alrik Danielson, President and CEO: “Our efforts to keep costs under control are showing results, in a market with lower demand. Operating profit for the second quarter was SEK 2,539 million, including costs for restructuring and impairments of 317 million. The reported operating margin was 11.3% (12.9% last year), with an underlying operating margin of 12.7% excluding costs for restructuring and impairments, the sixth straight quarter above 12%. Net sales were SEK 22.5 billion, a drop in organic sales of 1.6% compared to last year. Sales were relatively unchanged in Europe, slightly lower in Asia and North America and significantly higher in Latin America. Our operating performance was positively impacted by cost reductions and price. Restructuring and impairment costs on the other hand had a negative impact of SEK 317 million. Cash flow from operations was in line with last year. The industrial business had yet another strong quarter with an operating margin of 13.9% (14.7% last year) and an organic growth of 0.6% (10.7% last year). The underlying operating margin was higher than last year, with announced restructuring and impairments impacting the reported result negatively. Sales in Europe, Asia and North America were relatively unchanged but increased in Latin America. The automotive business contributed with an operating margin of 4.8% (8.7% last year). Organic growth was negative 6.8% (+5.2% last year) with significantly lower sales volumes in North America and Asia, lower sales volumes in Europe and significantly higher sales in Latin America. During the second quarter we continued to invest in regionalizing and automating our manufacturing footprint. An investment of SEK 450 million was announced for deep-groove ball bearings. This investment supports our ambitions to adopt a full value chain approach in Asia, where our global product development for deep-groove ball bearings is based. During the quarter we also acquired RecondOil, a cleantech start-up that has developed a unique chemical filtration and reconditioning process that enables a drastic reduction in the consumption of lubrication fluids and oil. RecondOil is a perfect strategic fit with our Rotating Equipment Performance offer and supports our efforts to help customers reduce the environmental impact of their operations. Entering the third quarter of 2019, we expect to see slightly lower volumes for the Group, relatively unchanged for Industrial and lower for Automotive.” Key figures, SEKm  Q2 2019 Q2 2018  Half year 2019 Half year 2018Net sales 22,488 22,620 43,766 43,180Operating profit* 2,539 2,925 5,197 5,550Operating margin*, % 11,3 12.9 11.9 12.9Profit before taxes 2,261 2,783 4,703 5,208Net cash flow after 1,448 2,182 2,132 2,441investments beforefinancingBasic earnings per share 3.32 4.25 7.09 8.02 *including restructuring and impairments Net sales change y-o-y, %, Q2  Organic  Structure  Currency  Total SKF Group -1.6 -2.6 3.5 -0.7Industrial 0.6 -3.8 3.8 0.6Automotive -6.8 0.2 -3.0 -3.6 Net sales change y-o-y, %, Half year  Organic  Structure  Currency  Total SKF Group -0.7 -2.6 4.6 1.3Industrial 1.7 -3.6 4.8 2.9Automotive -6.3 0.0 4.1 -2.2 Organic sales change in local Europe  North Latin Asia  Middlecurrencies, per region y-o-y, %, America  America  East &Q2  AfricaSKF Group -1.7 -3.2 8.8 -2.2 -5.4Industrial +/- +/- ++ +/- ---Automotive -- --- +++ -- +++ Organic sales change in local Europe  North Latin Asia  Middlecurrencies, per region y-o-y, %, America  America  East &Half year  AfricaSKF Group -0.5 -1.7 5.4 -1.2 -6.8Industrial + +/- ++ +/- --Automotive -- --- +++ -- +++ Outlook and guidance Demand for Q3 2019 compared to Q3 2018 The demand for SKF’s products and services is expected to be slightly lower for the Group, including relatively unchanged demand for Industrial and lower demand for Automotive. Demand is expected to be relatively unchanged in Asia, slightly lower in Europe and North America and slightly higher in Latin America. Guidance Q3 2019 · Financial net: SEK -245 million · Currency impact on the operating profit is expected to be around SEK +130 million compared with Q3 2018, based on exchange rates per 30 June 2019. Guidance 2019 · Tax level excluding effect related to divested businesses: around 28% · Additions to property, plant and equipment: around SEK 2,800 million A teleconference will be held on 17 July 2019 at 9:00 (CET): Conference ID: SKF or 3588786Standard International: +44 (0) 2071 928000Sweden: +46 (0)850692180United States: +16315107495 Website: http://investors.skf.com/en/result-centre Aktiebolaget SKF      (publ) The information in this press release is information which AB SKF is required to disclose under the EU Market Abuse Regulation (EU) No 596/2014 The information was provided by the above contact persons for publication on 17 July 2019 at 8:00.

Interim Report January-June 2019

CEO commentsAfter two months as CEO, I am enthusiastically and confidently looking forward to continue developing the company, together with the strong team that has built Mycronic into the company it is today. I am impressed by the capacity for innovation that has contributed to the company’s strong position as a global supplier of world-leading production solutions for electronics and display manufacturing. We have an ability to identify product trends and how these influence future technical solutions, so as to find sub-segments in the electronics industry with faster growth than the industry as a whole. We can then build a strong position in these segments through product development and acquisitions. It was precisely this product development that enabled us during the quarter to launch the Prexision Lite 8 mask writer, which is a complement to the more advanced Prexision-8 and broadens the range of mask writers to address different customer needs. I am pleased to note that sales grew 27 percent during the quarter and it was therefore Mycronic’s strongest quarter ever in terms of sales. We have continued to deliver as planned and feel confident with the goal for 2019 to reach net sales of SEK 4 billion, excluding any acquisitions. Assembly Solutions demonstrated favorable growth during the quarter in both order intake and net sales and delivered improved EBIT. At the end of June, Pattern Generators received an order for two FPS6100 mask writers in the multi-purpose segment. The business area increased both net sales and EBIT, while retaining a robust EBIT margin. Our aftermarket and service offering, which currently accounts for about 30 percent of sales, constitutes a significant and stable source of revenue with healthy profitability. The share of advanced mask writers in Pattern Generators is greater than ever following the system deliveries of recent years to meet the ongoing shift in technology in the display industry. At the same time most customers choose to sign a service agreement to ensure production stability, productivity and a high level of service. For Assembly Solutions, the aftermarket offering constitutes one of the synergies we are striving to realize in our acquired companies, where there is potential to develop the aftermarket and service offering. Mycronic has a solid foundation for continued growth. The global electronics industry is growing and the outlook is favorable for innovative players, such as Mycronic. The company’s strategy stands firm and together with customers and other key stakeholders, we will continue to develop unique production solutions. It is exciting to be a part of the future of the electronics industry, where production equipment must meet customer needs for flexibility, quality and stability while also facilitating the transition to more sustainable electronics production. Anders Lindqvist, President and CEO Financial informationMycronic AB (publ) is listed on NASDAQ Stockholm, Mid Cap, MYCR. The information in this report is published in accordance with the EU Market Abuse Regulation and the Swedish Securities Act. The information was submitted for publication, through the contact persons stated below on July 17, 2019, at 8:00 a.m. Financial reports and press releases are published in Swedish and English and are available on www.mycronic.com. For further information, please contact Anders Lindqvist Torbjörn Wingårdh Sven ChetkovichPresident and CEO CFO Acting Director IR & Corporate Communications+46 8 638 52 00 +46 8 638 52 00 +46 70 558 39 19anders.lindqvist@mycronic.com torbjorn.wingardh@mycronic.com sven.chetkovich@mycronic.com

Sobi publishes report for second quarter 2019

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces its results for the second quarter 2019. Total revenue was SEK 3,163 M (2,289), with 38 per cent revenue growth in the quarter compared with Q2 2018 (32 per cent at constant exchange rates (CER)). Organic growth(1) amounted to 25 per cent compared with Q2 2018. Adjusted EBITA(1,2) was SEK 1,193 M, an increase of 25 per cent, excluding restructuring costs of SEK 157 M related to the reorganisation of R&D. Highlights (April – June) ·  Total revenue of SEK 3,163 M (2,289). 38 per cent revenue growth in the quarter compared with Q2 2018(32 per cent at constant exchange rates (CER)) ·  Adjusted EBITA(1,2) was SEK 1,193 M (951), an increase of 25 per cent ·  Earnings per share (EPS) of SEK 1.70 (2.54) and adjusted EPS(1,2,3) of 2.12 SEK (2.54) ·  Net debt(1 )of SEK 4,403 M at 30 June 2019 (-2,999 at 31 Dec 2018) ·  Sales for Elocta® were SEK 1,127 M (794) and sales for Alprolix® were SEK 382 M (263) ·  Continued strong performance for Gamifant® with sales amounting to SEK 205 M ·  Sales for Synagis® were SEK 148 M ·  Purchase agreement of CHF 515 M (SEK 4,897 M) for emapalumab and related assets was signed ·  Sharpened strategic focus on core areas of Haematology and Immunology, and on late-stage assets. As a consequence Sobi has the intention to discontinue early research and partner programmes outside core areas, generating annual savings of SEK 200-300 M in 2020. Restructuring costs for the quarter amounted to SEK 175 M, whereof SEK 157 M impacted EBITA and SEK 18 M related to impairment of intangible assets ·  New data on emapalumab in patients with macrophage activation syndrome (MAS), a form of secondary HLH complicating systemic juvenile idiopathic arthritis (sJIA), showed that treatment with emapalumab led to a complete response in all six patients with a favourable safety profile · Outlook 2019 updated Financial Summary   Q2 Q2 H1 H1 Full-yearAmounts in SEK M 2019 2018 Change 2019 2018 Change 2018Total revenue 3,163 2,289 38% 6,427 4,253 51% 9,139Gross profit 2,413 1,677 44% 4,907 3,089 59% 6,723Gross margin(1) 76% 73% 76% 73% 74%EBITA(1) 1,037 951 9% 2,546 1,722 48% 3,571EBITA adjusted(1,2) 1,193 951 25% 2,665 1,722 55% 3,571EBITA margin(1) 33% 42% 40% 40% 39%EBITA margin 38% 42% 41% 40% 39%adjusted(1,2)EBIT (operating 677 841 -19% 1,905 1,500 27% 3,122profit)Profit for the 499 685 -27% 1,402 1,200 17% 2,418periodEarnings per share, 1.70 2.54 -33% 4.82 4.45 8% 8.97SEKEarnings per share, 2.12 2.54 -17% 5.14 4.45 16% 8.97SEK adjusted(1,2,3)(1)AlternativePerformanceMeasures (APMs).(2)EBITA excludingnon-recurringitems;restructuring costsof SEK 157 M in Q22019 and gain fromdivestment ofSOBI005 in Q1 2019of SEK 37 M.(3)EPS excludingimpairment ofintangible assetsof SEK 18 M relatedto therestructuring in Q22019.  Guido Oelkers, CEO and President: “Our strong performance continued in the second quarter, with organic growth of 25 per cent taking us to revenue of SEK 3,163 M, adjusted EBITA of SEK 1,193 M and an adjusted EBITA margin of 38 per cent. Announcing the acquisition of emapalumab and related assets, we took further steps to sharpen focus on our core therapeutic areas and on late-stage assets.” Financial outlook 2019 — updated  Sobi expects revenue for the full year to be in the range of SEK 13,000 - 13,500 M(1)(12,500 - 13,000)(2). EBITA for the full year is expected to be in the range of SEK 5,300 - 5,500 M(1)(5,000 - 5,300)(2), excluding restructuring costs. The updated outlook reflects the continued strong product sales in Haemophilia and the promising uptake of Gamifant in the US. (1)At current exchange rates.(2)The initial outlook was first published on 20 February 2019. Telephone conference:Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, today at 09:00 am CEST. The event will be hosted by Sobi’s CEO and President, Guido Oelkers, and the presentation will be held in English. The presentation can be followed live, or afterwards on www.sobi.com. Slides used in the presentation will be made available on Sobi’s website prior to the telephone conference. To participate in the telephone conference, please call: SE: +46 8 505 583 55 UK: +44 33 330 090 30 US: +1 646 7224 957Click here to go to the live webcast.  After the live event the webcast will be available on-demand via the same URL. --- About Sobi™ At Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving. The hard work and dedication of our approximately 1050 employees around the globe has been instrumental in our success across Europe, North America, the Middle East, Russia and North Africa, leading to total revenues of SEK 9.1 billion in 2018. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com. For more information please contact Paula Treutiger, Head of Jörgen Winroth, Senior IR AdvisorCommunication & InvestorRelations+ 46 733 666 599 +1 347 224 0819, +1 212 579 0506paula.treutiger@sobi.com jorgen.winroth@sobi.com  Linda Holmström, CorporateCommunication & InvestorRelations+ 46 708 734 095linda.holmstrom@sobi.com

XVIVO and MyCartis engage to develop a fast diagnostic test to assess the quality of donated organs before transplantation

Despite yearly growing transplantation numbers, organ waiting lists continue to grow. The organ shortage represents a huge burden for the patient, for his or her direct environment, for the healthcare system and for the overall community. Ex vivo evaluation of solid donor organs by normothermic machine perfusion is becoming increasingly established as a tool to increase the number of available organs. XVIVO Perfusion is a leading medical technology company focused on developing optimized solutions for organ, tissue and cell preservation and perfusion in connection with transplantation. Currently, surgeons rely on physiological criteria to determine the fitness of an organ, whereas signs of non-fitness, like inflammation or tissue damage, may remain unnoticed by such means. Biomarker assessment to identify and quantify these unfavorable conditions in a timely manner would help the surgeon in the decision process. The MyCartis EvalutionTM platform is unique in its ability to measure multiple biomarkers simultaneously in a fast and easy way using a workflow that enables repeated testing. In a recent whitepaper, MyCartis demonstrated the successful application of interleukin-1β as an indicator for inflammation in lung organs during perfusion. With results generated within 20 minutes, this test meets the required turnaround time for real-time organ assessment as well as organ follow-up. MyCartis and XVIVO decided to expand the real-time testing panel to also enable the quantitation of organ damage next to the degree of inflammation. Both phenomena are negative indicators for successful transplantation. “Seeing that the unique capabilities of fast, easy and timely biomarker testing of our EvalutionTM platform are recognized in the field of organ transplantation, strengthens our believe that we can play a major role in solving unmet medical needs”, says Wouter Laroy, CSO at MyCartis. “MyCartis’ strong experience in high performant biomarker testing perfectly complements XVIVO’s expertise in donor organ perfusion, a combination that will help save lives of those in need of a new organ”. ”XVIVO believes that adding biomarkers, in addition to measurement of conventional physiological criteria, to determine fitness for transplantation after an EVLP will play an important role in the decision process. We are therefore pleased to announce the collaboration with MyCartis, that can deliver a fast and easy way to measure biomarkers during an EVLP. This new method has the potential to increase the number of donated lungs for transplantation by using EVLP”, says Magnus Nilsson CEO of XVIVO Perfusion AB. July 17, 2019GothenburgMagnus Nilsson, CEOXVIVO Perfusion AB (publ) About MyCartis MyCartis has developed the immune-diagnostic technology, DMAT®, which is integrated in its real-time platform called EVALUTION®. DMAT® delivers an unmatched combination of features, covering multiplexing, assay speed and analytical performance, together with the unique ability to measure antibody binding strength and hence qualify immune responses directly. EVALUTION® uses a 16-channel disposable cartridge. It is currently used in the Life Sciences research context and was validated for many multiplex assays in-house and with partners. MyCartis is a privately held company located in Ghent, Belgium. E-mail: info@mycartis.net. Website: www.mycartis.net About XVIVO Perfusion AB XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424. Tel: 46 31 788 21 50. Fax: 46 31 788 21 69. E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

Good growth in Q2, driven mainly by strong sales in Sweden

Q2 · Net sales reached SEK 6.4 (5.3) million.  · Result after tax came in at SEK -15.7 (-15.5) million.  · Earnings per share, basic and diluted, were SEK -0.11 (-0.17).  · Cash and cash equivalents were SEK 40.8 (3.2) million Significant events in Q2 · Enzymatica signed agreement with German Maren for delivery of enzyme formulation for skin care products. The agreement is worth SEK 120 million over three years. · Enzymatica completed recruitment of patients to a double-blind, placebo-controlled multicenter study in Germany to evaluate the effects of ColdZyme on the common cold. A total of 700 patients were enrolled, of which more than 400 developed colds. At the end of the quarter the last patients had been treated. The results are expected to be ready in the late autumn of 2019. H1  · Net sales reached SEK 19.7 (20.4) million.  · Result after tax came in at SEK -27.9 (-25.7) million.  · Earnings per share, basic and diluted, were SEK -0.20 (-0.28). +-----------------------------------+-----+-----+-----+-----+---------+|Financial ratios   | | | | | |+-----------------------------------+-----+-----+-----+-----+---------+|(SEK THOUSAND) | Q2| Q2| H1| H1|Full year|| | 2019| 2018| 2019| 2018| 2018|+-----------------------------------+-----+-----+-----+-----+---------+|Net sales | 6.4| 5.3| 19.7| 20.4| 52.6|+-----------------------------------+-----+-----+-----+-----+---------+|Gross margin, % | 63| 51| 70| 66| 70|+-----------------------------------+-----+-----+-----+-----+---------+|Operating profit/loss |-15.6|-15.0|-27.5|-24.6| -40.6|+-----------------------------------+-----+-----+-----+-----+---------+|Cash flow from operating activities|-12.3|-16.9|-27.8|-18.4| -28.8|+-----------------------------------+-----+-----+-----+-----+---------+|Average number of employees | 20| 21| 20| 21| 21|+-----------------------------------+-----+-----+-----+-----+---------+   CEO statement: The agreement with Maren provides us with greater opportunities to continue to develop cold products Sales in the second quarter of 2019 totaled SEK 6.4 million, an increase of more than 20% year-on-year. Sales on the Swedish market continued to demonstrate strong growth. Sales of ColdZyme from pharmacies to consumers rose by more than 38% during the second quarter, corresponding to a market share of 6,1% based on MAT – Moving Annual Total. Digital marketing, social media and influencer marketing contributed to the strong increase. Earlier studies have also documented a high re-purchase rate of ColdZyme. At the end of the quarter Enzymatica entered into an agreement with the German cosmetics company Maren for delivery of an enzyme formulation for their skin care products. The value of the agreement is SEK 120 for the coming three-year period. For the first 12 months the value of the order is SEK 15 million, with SEK 3.5–5 million expected in 2019. The agreement with Maren demon-strates the potential of our barrier technology, even for cosmetic applications. The agreement will increase revenue streams and provide us with increased opportunities to develop products for colds and upper respiratory tract infections, which will continue to be our business focus. The activity level within the company is high, with a strong focus on new distributor agreements, clinical studies to strengthen documentation for ColdZyme and marketing initiatives for increased sales of our cold spray. I have every reason to view the future with confidence as the cold season begins in the third quarter.  Fredrik Lindberg, CEO   For questions about this report, please contact: Fredrik Lindberg, CEO, Enzymatica ABTel: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com Therese Filmersson, CFO, Enzymatica ABTel: +46 (0)708-40 72 24 | Email: therese.filmersson@enzymatica.com PublicationThis information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CET on Wednesday, July 17, 2019.

NENT Group traces ‘Manson’s Bloodline’ in next original documentary series

· Four-part series to premiere exclusively on Viaplay on 9 August · Documentary distributed globally by NENT Studios’ DRG · NENT Group to premiere at least 20 original productions every year ‘Manson’s Bloodline’, a documentary series about American cult leader and murderer Charles Manson, will be the next original production from Nordic Entertainment Group (NENT Group). For the first time, Manson’s only living relative tells his unsettling story in the four-part series, which will premiere exclusively on NENT Group’s Viaplay streaming service across the Nordic region on 9 August. Fifty years ago, Charles Manson and his cult committed a series of murders that shocked America and the world. Despite not even being born at the time, Manson’s grandson Jason Freeman has lived in the shadow of the events of 1969 ever since. ‘Manson’s Bloodline’ follows Freeman for 16 months as he struggles with the legacy left by one of the most notorious criminals in American history. ‘Manson’s Bloodline’ is produced by New York-based MY Entertainment and distributed globally by DRG, a NENT Studios company. NENT Studios is NENT Group’s content production and distribution business and comprises 32 companies across 17 countries. NENT Group recently commissioned two seasons of the documentary series ‘American Runestone ’ by Swedish Hollywood superstar Peter Stormare (‘The Blacklist’; ‘Prison Break’). Previous NENT Group original documentaries include ‘Swedish Sin ; ‘Four Hands Menu ’; ‘Couple Thinkers’; and ‘Superswede’. Jakob Mejlhede Andersen, Viaplay Chief Content Officer: “The crimes of Charles Manson have long fascinated and horrified audiences around the world – but what happened next? ‘Manson’s Bloodline’ at last reveals the enormous impact on Manson’s relatives through unprecedented access to his only living descendant. NENT Group continues to expand Viaplay’s offering of unique documentaries that leave no story untold and no viewer unmoved.” About NENT Group’s original productions NENT Group has now launched 46 original productions and is set to premiere a minimum of 20 every year. ‘Swedish Sin ’; ‘Straight Forward ’; ‘Saga’s Stories ’; ‘Wisting ’; ‘The Inner Circle ’; ‘Darkness – Those Who Kill ’; ‘Hidden ’; ‘The Truth Will Out’; ‘Four Hands Menu ’; ‘Pros and Cons ’; ‘Conspiracy of Silence ’; ‘Couple Trouble’; season one  of ‘Rig 45’; ‘The Lawyer ’; ‘Stella Blómkvist ’; seasons one  and two  of ‘ALEX’; ‘Couple Thinkers’; ‘Occupied’; ‘Hassel’; ‘Peppy Pals ’; ‘Superswede’; ‘Veni Vidi Vici ’; seasons one  and two  of ‘Swedish Dicks’; seasons one  and two  of ‘The Great Escape’; and seasons one and two  of ‘Black Lake’ have already premiered. Recently announced originals include ‘American Runestone ’; ‘Home Invasion ’; ‘The Professionals’; ‘Fixi in Playland ’; ‘Shadowplay ’; ‘Box 21 ’; season two  of ‘Rig 45’; ‘The Ambassador ’; ‘Margeaux ’; ‘Cryptid ’; ‘Commando ’; ‘Face to Face ’; ‘Casper Conquers Norway ’; ‘Honour ’; ‘Love Me ’; and ‘Cold Courage ’. As well as breaking Nordic viewing records, NENT Group’s originals are increasingly reaching audiences around the world. Amongst others, ‘ALEX’ has been sold to broadcast and streaming partners in Europe, Asia and the US ; ‘Veni Vidi Vici’ has premiered on Hulu  and is set for a US remake in partnership with Lionsgate ; ‘Swedish Dicks’ has featured on Pop TV  in the US; ‘Black Lake’ has been shown on BBC Four and AMC Networks-backed Shudder ; and the upcoming series ‘Honour ’ has been sold to RTL in Germany and to Belgium’s VRT. In January 2019 , NENT Group announced a UK-based joint venture with award-winning independent studio FilmNation Entertainment to develop, produce and finance premium scripted television content for global audiences. In May 2019 , NENT Group invested in a minority stake in the new US production company Picturestart together with a range of high-profile industry partners. Based in Los Angeles and founded by renowned producer Erik Feig, Picturestart will create, co-finance and produce premium scripted content for young adult viewers around the world. **** NOTES TO EDITORS Nordic Entertainment Group AB (publ) (NENT Group) is the Nordic region’s leading entertainment provider. We entertain millions of people every day with our streaming services, TV channels and radio stations, and our production companies create content that is experienced around the world. We make life more entertaining by telling stories, touching lives and expanding worlds – from live sports, movies and series to music and original shows. Headquartered in Stockholm, NENT Group is listed on Nasdaq Stockholm (‘NENT A’ and ‘NENT B’). Contact us:press@nentgroup.com (or Nicholas Smith, Acting Head of Public Relations; +46 73 699 26 95)investors@nentgroup.com (or Stefan Lycke, Head of Investor Relations; +46 73 699 27 14)Download high-resolution photos: Flickr Follow us:nentgroup.com  / Facebook  / Twitter  / LinkedIn  / Instagram Privacy policy:To read NENT Group’s privacy policy, click here 

Stadshypotek Interim Report January–June 2019

JANUARY–JUNE 2019 COMPARED WITH JANUARY–JUNE 2018Stadshypotek’s operating profit rose by SEK 29m (406), or 0% (7), to SEK 6,252m (6,223). Net interest income grew by SEK 98m (464) to SEK 6,939m (6,841). This is mainly due to higher lending volumes to the private and corporate markets in Sweden. Of the net interest income, SEK 424m (465) was attributable to the branch in Norway, SEK 226m (211) to the branch in Finland and SEK 267m (242) to the branch in Denmark. Excluding the branches, net interest income increased by SEK 99m (296). Net gains/losses on financial transactions increased by SEK 21m to SEK 16m (-5). Expenses increased by SEK 124m (31) to SEK -710m (-586). This increase was mainly attributable to an increase in the sales compensation paid to the parent company for the services performed by the branch office operations on behalf of Stadshypotek in relation to the administration and sale of mortgage loans. Credit losses led to net recoveries of SEK 21m (-14). The credit loss ratio remained unchanged at 0.00% of lending (0.00). LENDINGCompared with the end of the corresponding period of the previous year, loans to the public increased by 5% (8), or SEK 69bn (90), to SEK 1,342bn (1,273). In Sweden, loans to the public increased by 6% (7), or SEK 62bn (67), to SEK 1,146bn (1,084). FUNDINGIssues of Stadshypotek’s benchmark programme loans in Swedish kronor reached a nominal volume of SEK 78.6bn (71.3) during the period. A nominal volume totalling SEK 42.4bn (76.6) matured or was repurchased during the period. The carrying amount of the outstanding Swedish kronor bonds was SEK 479.3bn (450.2) at the end of the period. Issues of bonds under the EMTCN programme totalled EUR 1.25bn (0.2) and GBP 0bn (0.7). The nominal outstanding volume in the programme at the end of the period was EUR 10.4bn (9.8). There were no outstanding volumes in the European commercial paper programme at the end of the period. No issues were made in USD or AUD during the period. The outstanding volume in the US programme totalled USD 3.8bn (3.8) at the end of the period. There is no longer any outstanding volume in AUD. The Norwegian kroner issue was a nominal amount of NOK 5bn (5). The outstanding volume at the end of the period was NOK 24bn (24). CAPITAL ADEQUACYThe total capital ratio according to CRD IV was 21.2% (52.8), while the common equity tier 1 ratio calculated according to CRD IV was 13.2% (31.3). RATINGThe rating was unchanged during the period. +-------------------+-------------+---------+----------+|Stadshypotek       |Covered bonds|Long-term|Short-term|+-------------------+-------------+---------+----------+|Moody’s |Aaa |- |P-1 |+-------------------+-------------+---------+----------+|Standard & Poor’s | |AA- |A-1+ |+-------------------+-------------+---------+----------+|Fitch | |AA |F1+ |+-------------------+-------------+---------+----------+   Stockholm, 17 July 2019 Maria Lidström AnderssonChief Executive This information is of the type that Stadshypotek is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication through the agency of the contact person set out above, at 11,00 CET on 17 July 2019.

Interim Report Second Quarter 2019

Second quarter 2019 Continuing operations   · Order intake 26,031 million SEK · Revenues 26,467 million SEK · Operating profit 5,078 million SEK · Operating margin 19.2% · Adjusted operating profit 4,968 million SEK · Adjusted operating margin 18.8% · Profit after financial items 4,692 million SEK · Earnings per share 2.88 SEK · Cash flow from operations 2,732 million SEK Discontinued operations · Order intake 27 million SEK · Revenues 100 million SEK · Operating profit -67 million SEK Group Total · Order intake 26,058 million SEK · Revenues 26,567 million SEK · Operating profit 5,012 million SEK · Operating margin 18.9% · Adjusted operating profit 4,901 million SEK · Adjusted operating margin 18.4% · Earnings per share 2.83 SEK · Cash flow from operations 2,681 million SEK Additional information may be obtained from Sandvik Investor Relations, phone +46 8 456 14 94 (Ann-Sofie Nordh), +46 8 456 11 94 (Anna Vilogorac). A webcast and teleconference will be held on 17 July 2019 at 14:00 CEST. Information is available at home.sandvik/investors  Stockholm, 17 July 2019 Sandvik Aktiebolag (publ) Björn Rosengren President and CEO This information is information that Sandvik AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at about 11.30 CEST on 17 July 2019.

Alfa Laval AB (publ) Interim report April 1 - June 30, 2019

Summary  Second quarter Order intake decreased by 20 percent* to SEK 10,025 (12,062) million.Net sales increased by 5 percent* to SEK 11,339 (10,475) million.Adjusted EBITA**: SEK 1,870 (1,698) million.Adjusted EBITA margin**: 16.5 (16.2) percent.Result after financial items: SEK 1,832 (1,499) million.Net income: SEK 1,412 (1,117) million.                                          Earnings per share: SEK 3.36 (2.65).Cash flow from operating activities: SEK 609 (1,377) million.Impact on adjusted EBITA of foreign exchange effects: SEK 95 (-80) million.Impact on result after financial items of comparison distortion items: SEK 196 (31) million. First six months Order intake decreased by 3 percent* to SEK 22,238 (22,087) million.Net sales increased by 7 percent* to SEK 21,497 (19,326) million.Adjusted EBITA**: SEK 3,598 (3,195) million.Adjusted EBITA margin**: 16.7 (16.5) percent.Result after financial items: SEK 3,454 (2,968) million.Net income: SEK 2,637 (2,166) million.                                          Earnings per share: SEK 6.26 (5.14). Cash flow from operating activities: SEK 1,584 (2,043) million.Impact on adjusted EBITA of foreign exchange effects: SEK 190 (-45) millionImpact on result after financial items of comparison distortion items: SEK 196 (98) millionReturn on capital employed (%) **: 22.2 (20.8)Net debt to EBITDA, times **/***: 1.30 (1.28)  * Excluding currency effects. ** Alternative performance measures.*** Net debt to EBITDA for Q1 2019 excluding IFRS 16 impact: 0.96. Outlook for the third quarter “We expect demand in the third quarter to be somewhat higher than in the second quarter.” Earlier published outlook (April 24, 2019): “We expect demand in the second quarter to be somewhat lower than in the first quarter.”   The Q2 2019 report has not been subject to review by the company’s auditors.  This information is information that Alfa Laval AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at CET 12.00 on July 17, 2019. For more information, please contact:  Peter Torstensson Senior Vice President, CommunicationsPhone: +46 46 36 72 31Mobile: +46 709 33 72 31peter.torstensson@alfalaval.comGabriella Grotte,Investor Relations ManagerPhone: +46 46 36 74 82Mobile: +46 709 78 74 82gabriella.grotte@alfalaval.com   Alfa Laval AB (publ)PO Box 73SE-221 00 LundSweden  Corporate registration number: 556587-8054 

Half-Year Financial Report 2019

Nordea Bank Abp – Inside information – Half-Year Financial Report   CEO Casper von Koskull’s comments on the results: “The operating environment for Nordea remains stable with continued lending growth, pressurised margins and challenging conditions for our market making activities. Our actions from the past 12 months have, however, led to some encouraging signs of regaining market shares and future cost reductions but it will take time before these increased activity levels are fully reflected in the results. That said, our performance is not satisfactory, and further actions are needed to strengthen the financial results. I am confident that the investments we have made in regulatory and systems infrastructure, together with our committed and skilful employees, will ensure a powerful future development for the bank. Nordea has in recent years de-risked the bank, invested in our digital and compliance platforms, concentrated our operations to the Nordic markets and has entered a new phase of customer focus. The financial environment has also changed with expected lower rates for longer, and we will soon have more clarity on our capital requirements within the banking union. For these reasons Nordea will review its financial targets, including the capital and dividend policy with an expectation to present these after the release of the third quarter 2019 results. As communicated on 30th June 2019, I have decided to retire from Nordea by the end of 2020 and the process to find a successor has been initiated. Further information on timing will be disclosed when available”. Second quarter 2019 vs. Second quarter 2018 (Second quarter 2019 vs. First quarter 2019)   · Net interest income EUR 1,071m, -4%; -1% in local currencies (1%, 2% in local currencies)  · Total operating income EUR 2,141m, -17%; -16% in local currencies (1%, 2% in local currencies) · Total operating income[1] EUR 2,141m, -4%; -3% in local currencies (1%, 2% in local currencies) · Total operating expenses EUR 1,180m, 2%; 3% in local currencies (-19%, -18% in local currencies) · Total operating expenses[2] EUR 1,180m, 2%; 3% in local currencies (-13%, -12% in local currencies) · Profit before loan losses EUR 961m, -33%; -32% in local currencies (45%, 45% in local currencies) · Net loan losses EUR 61m, 3%; 5% in local currencies (45%, 48% in local currencies) · Operating profit EUR 900m, -34%; -33% in local currencies (45%, 45% in local currencies) · Common Equity Tier 1 capital ratio[3],[4] 14.8% vs.19.9% (14.8% vs. 14.6%) · Cost/income ratio 55% vs. 45% (55% vs. 69%) · Cost/income ratio, [1],[2] 55% vs. 52% (55% vs. 64%) · Loan loss ratio of 10 bps vs. 10 bps (10 bps vs. 7 bps) · Return on equity 9.1% vs 14.3% (9.1% vs. 5.5%) · Return on equity[1],[2] 9.1% vs 9.8% (9.1% vs. 6.7%) · Return on equity[1],[2],[5] 8.5% vs 9.4% (8.5% vs. 8.1%) · Diluted EPS EUR 0.17 vs. EUR 0.28 (EUR 0.17 vs. EUR 0.10) Exchange rates used for Q2 2019 for income statement items are for DKK 7.4651, NOK 9.7314 and SEK 10.5170.[1] Excl. Items affecting comparability in Q4 2018: EUR 50m gain from revaluation of Euroclear, EUR 38m after tax, and EUR 36m gain related to sale of Nordea Ejendomme. Q1 2018: EUR 135m gain from valuation model update in Denmark, EUR 105m after tax.[2] Excl. Items affecting comparability in Q1 2019: EUR 95m non-deductible expense related to provision for ongoing AML-related matters. In Q4 2018: EUR 141m loss from impairment of goodwill in Russia.[3] Including profit for the period adjusted by accrued dividend.[4] The capital ratios for 2018 have not been restated due to the changed recognition and presentation of resolution fees (see Note 1 for more information).[5] Adjusted for resolution fees after tax: In Q2 2019 EUR -40m, in Q1 2019 EUR 118m and in Q2 2018 EUR -32m. Income statement Q2 Q1 Local Q2 Local Jan-Jun Jan-Jun Local 2019 2019 Chg curr. 2018 Chg curr. 2019 2018 Chg curr. % % % % % %EURmNet interest income 1,071 1,056 1 2 1,110 -4 -1 2,127 2,226 -4 -3Net fee and commission 743 737 1 1 800 -7 -6 1,480 1,570 -6 -5incomeNet result from items at 283 264 7 7 260 9 8 547 701 -22 -22fair valueProfit from associatedundertakings and jointventures accounted for 24 14 71 71 33 -27 -35 38 61 -38 -42underthe equity methodOther operating income 20 44 -55 -56 375 -95 -95 64 398 -84 -84Total operating income 2,141 2,115 1 2 2,578 -17 -16 4,256 4,956 -14 -13 Staff costs -727 -718 1 2 -730 0 1 -1,445 -1,528 -5 -4Other expenses -304 -594 -49 -48 -350 -13 -12 -898 -853 5 7Depreciation,amortisationand impairmentcharges of tangible and -149 -140 6 7 -74 101 104 -289 -145 99 101intangible assetsTotal operating expenses -1,180 -1,452 -19 -18 -1,154 2 3 -2,632 -2,526 4 6 Profit before loan losses 961 663 45 45 1,424 -33 -32 1,624 2,430 -33 -32 Net loan losses -61 -42 45 48 -59 3 5 -103 -99 4 6Operating profit 900 621 45 45 1,365 -34 -33 1,521 2,331 -35 -34 Income tax expense -219 -178 23 23 -250 -12 -12 -397 -479 -17 -16Net profit for the period 681 443 54 53 1,115 -39 -38 1,124 1,852 -39 -39 Business volumes, keyitems[1] 30 Jun 31 Mar Local 30 Jun Local 2019 2019 Chg curr. 2018 Chg curr. % % % %EURbnLoans to the public 323.8 325.6 -1 0 314.8 3 4Loans to the public, 300.2 300.6 0 0 292.4 3 3excl.reposDeposits and borrowings 176.5 176.3 0 1 176.5 0 1fromthe publicDeposits from the public, 167.0 166.6 0 1 166.3 0 1excl. reposTotal assets 582.9 590.2 -1 570.1 2Assets under management 306.5 300.2 2 307.0 0Equity 31.1 30.5 2 31.9 -3 Ratios and key figures[2] Q2 Q1 Q2 Jan-Jun Jan-Jun 2019 2019 Chg 2018 Chg 2019 2018 Chg % % %Diluted earnings per 0,17  0,10  70  0,28  -39  0,27  0,46  -41 share,EUR EPS, rolling 12 months up 0,58  0,68  -15  0,82  -29  0,58  0,82  -29 toperiod end, EUR Share price[1], EUR 6,39  6,80  -6  8,26  -23  6,39  8,26  -23  Total shareholders' 4,0  3,3  3,7  -1,5  -7,0 return,%Equity per share[1], EUR 7,69  7,55  2  7,90  -3  7,69  7,90  -3 Potential shares 4.050  4.050  0  4.050  0  4.050  4.050  0 outstanding[1], millionWeighted average number 4.032  4.033  0  4.037  0  4.032  4.037  0 ofdiluted shares, mnReturn on equity, % 9,1  5,5  14,3  7,2  11,7 Return on tangible 10,6  6,4  16,5  8,4  13,4 equity, %Return on Risk Exposure 1,7  1,1  3,6  1,4  3,0 Amount, %Return on Equity with 8,5  7,0  13,9  7,7  12,1 periodised resolutionfees,%Cost/income ratio, % 55  69  45  62  51 Cost/income ratio with 58  61  46  59  49 periodised resolutionfees,%Loan loss ratio, basis 10  7  43  10  0  9  8  13 points[3]Common Equity Tier 1 14,8  14,6  19,9  14,8  19,9 capitalratio[1],[4],[5],[6],[7],%Tier 1 capital 17,3  17,1  22,2  17,3  22,2 ratio[1],[4],[5],[7], %Total capital 19,8  19,5  25,4  19,8  25,4 ratio[1],[4],[5],[7], %Tier 1 27,6  27,8  -1  27,2  1  27,6  27,2  1 capital[1],[4],[7],EURbnRisk exposure amount[4], 160  163  -2  123  30  160  123  30 EURbnNumber of employees 29.550  29.284  1  29.271  1  29.550  29.271  1 (FTEs)[1]Economic capital[1],[7], 27,8  28,2  -1  26,5  5  27,8  26,5  5 EURbn[1] End of period.[2] For more detailedinformation regardingratiosand key figures definedasAlternative performancemeasures, seewww.nordea.com/en/investor -relations/.[3] Including Loans tothepublic reported in Assetsheld for sale in Q1 2018.[4] Including the resultforthe period.[5] Changes to theapplicable capitalrequirements regime (formore details, please seechapter Otherinformation).[6] Including profit fortheperiod adjusted byaccrueddividend.[7] The capital ratiosfor2018 have not beenrestateddue to the changedrecognition andpresentationof resolution fees (seeNote1 for more information).   Outlook Key drivers of the outlookThroughout Nordea, we are intensifying our efforts to increase business momentum and each business area has identified a number of initiatives to drive client value and revenue growth. Examples include investments in Private Banking in Norway and Sweden, the integration of Gjensidige Bank, new distribution channels within Asset Management and Wholesale Banking and actions to regain momentum on mortgages, where we are already starting to see results. The key drivers behind the cost efficiency are increased usage of automation and robotics, the shift in our workforce composition through nearshoring to Poland and Estonia and increased use of outsourcing and partnerships of which the recent collaboration with John Hancock to distribute stable return products in the US is an example. We are also simplifying by harmonising products and services and leveraging scale by further consolidating common units, for instance global operations and services. Nordea has in recent years de-risked the bank, invested in our digital and compliance platforms, concentrated the operations to the Nordic markets and has entered a new phase of customer focus. Financial environments have also changed with expected lower rates for longer, and we will soon have more clarity on our capital requirements within the banking union. For these reasons Nordea will review its financial targets, including the capital and dividend policy with an expectation to present these after the release of the third quarter 2019 results. On 18 July 2019, the ECB will publish Nordea’s result of the Comprehensive Assessment (CA) exercise including the Asset Quality Review (AQR) and the ECB stress test. Overall results of the exercise confirm the resilient capital position of Nordea, exceeding all the thresholds defined by the ECB. The outcome of the AQR presents a prudential assessment of current provisions. Nordea has reviewed the results and are comfortable with the current level of accounting provisions. Nordea expects that the prudential outcome of the AQR will be further assessed and discussed in the supervisory dialogue during H2 2019.  CostFor 2021, we expect the cost base in constant currencies to be approximately 3% below the 2018 cost base excluding items affecting comparability in 2018[1] and cash costs are expected to be down by up to 10% in constant currencies over the same period. Costs for 2019 are expected to be lower in constant currencies compared to 2018 excluding items affecting comparability in 2018 and 2019[2] and the total cash cost is expected to be lower in constant currencies over the same period. [1] Goodwill write-down of EUR 141m in Q4 2018[2] Adjusted for the goodwill write-down of EUR 141m in 2018, transaction costs of EUR 90m in 2019, higher resolution fee in 2019 and provision of EUR 95m in Q1 2019 Credit qualityOur expectation for the coming quarters is that net losses will remain low and around the average level for 2018. Capital policyGiven the implementation of transitional arrangements agreed with the ECB following Nordea’s transfer to the Banking Union and with the aim to maintain the same nominal management buffer, the management buffer has been adjusted from a range of 50–150 bps to 40–120 bps. This is mainly a technical adjustment and hence the management buffer remains largely unchanged in nominal EUR amounts. The current level of the management buffer is approximately EUR 2.0bn (120 bps). Nordea aims to achieve a yearly increase in the dividend per share, while maintaining a strong capital position in line with the capital policy. The entire report can be found on the below link on our website.Nordea Group Q2 2019 Report   For further information: Casper von Koskull, President and Christopher Rees, Group CFO,Group CEO, +358 503 821 +45 5547 2377 391        Rodney Alfvén, Head of Investor Sara Helweg-Larsen, Head ofRelations, +46 72 235 05 15   Group Communications, +45 2214 0000 The information provided in this stock exchange release is such that Nordea Bank Abp is required to disclose pursuant to the EU Market Abuse Regulation and was submitted for publication, through the agency of the contact persons set out above, at 06.30 CET on 18 July 2019. We build strong and close relationships through our engagement with customers and society. Whenever people strive to reach their goals and realise their dreams, we are there to provide relevant financial solutions. We are one of the largest banks in the Nordic region in terms of total market capitalization with around 10 million customers. The Nordea share is listed on the Nasdaq Helsinki, Nasdaq Copenhagen and Nasdaq Stockholm exchanges. Read more about us on nordea.com.

Interim report 1 January-30 June 2019

Highlights Second quarter · Net sales increased 20.5 percent to SEK 1,708.8 million (1,417.8). Organic growth amounted to 8.6 percent · Gross profit increased 36.4 percent to SEK 397.6 million (291.5), with a gross margin of 23.3 percent (20.6) · Adjusted EBIT, excluding IFRS 16 effects, increased 39.9 percent to SEK 100.4 million (71.7), and the adjusted EBIT margin increased to 5.9 percent (5.1)*. Adjusted EBIT, including IFRS 16 effects, amounted to SEK 102.3 million, corresponding to an EBIT margin of 6.0 percent · Operating income, excluding IFRS 16 effects, increased to SEK 90.1 million (55.0), corresponding to an operating margin of 5.3 percent (3.9)*. Operating income, including IFRS 16 effects, amounted to SEK 92.0 million, corresponding to an operating margin of 5.4 percent · Operating cash flow amounted to SEK 224.3 million (171.8), corresponding to a cash conversion of 201.1 percent · Net income, excluding IFRS 16 effects, amounted to SEK 44.6 million (32.1)*. Taking IFRS 16 into account, net income amounted to SEK 44.4 million · Earnings per share amounted to SEK 0.48 (0.30) before dilution and SEK 0.48 (0.30) after dilution 1 January-30 June  · Net sales increased 19.9 percent to SEK 2,928.9 million (2,442.9). Organic growth amounted to 8.3 percent · Gross profit increased 38.3 percent to SEK 698.1 million (504.6), with a record-high gross margin of 23.8 percent (20.7) · Adjusted EBIT, excluding IFRS 16 effects, increased 50.2 percent to SEK 153.8 million (102.4), and the adjusted EBIT margin increased to 5.3 percent (4.2)*. Adjusted EBIT, including IFRS 16 effects, amounted to SEK 157.5 million, corresponding to an EBIT margin of 5.4 percent · Operating income, excluding IFRS 16 effects, increased to SEK 126.5 million (25.8), corresponding to an operating margin of 4.3 percent (1.1)*. Operating income, including IFRS 16 effects, amounted to SEK 130.2 million, corresponding to an operating margin of 4.4 percent · Operating cash flow amounted to SEK 240.6 million (221.8), corresponding to a cash conversion of 138.5 percent · Net income, excluding IFRS 16 effects, amounted to SEK 64.0 million (-22.9)*. Taking IFRS 16 into account, net income amounted to SEK 63.3 million · Earnings per share amounted to SEK 0.65 (-0.87) before dilution and SEK 0.65 (-0.87) after dilution Key events during and after the quarter · Acquisition of LampGallerian Växjö AB on 10 May, further strengthening the Group’s leading Nordic online position in home furnishings * 2019 figures are reported excluding the effect of IFRS 16 to facilitate comparison with 2018 figures, as 2018 has not been restated for IFRS 16.** Refer to “Relevant reconciliations of non-IFRS alternative performance measures (APM)” on page 29 of this report for a more detailed description. This information is information that Bygghemma Group First AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 7:00 a.m. CEST on 18 July 2019. Contact informationFor further information, visit www.bygghemmagroup.se or contact: Martin Edblad, acting President and CEOmartin.edblad@bygghemmagroup.se+46 (0)734-24 68 51 Adam Schatz, CFOadam.schatz@bygghemmagroup.se+46 (0)709-32 43 00 Johan Hähnel, Head of Investor Relationsjohan.hahnel@bygghemmagroup. (johan.hahnel@bygghemmagroup.se)se (johan.hahnel@bygghemmagroup.se)+46 (0)70-605 63 34 Conference call in connection with publication of the quarterly reportOn Thursday, 18 July at 10:00 a.m. CEST, Martin Edblad, acting President and CEO, and Adam Schatz, CFO, will hold a conference call concerning the publication of the quarterly report. The call will be held in English. To participate, please call +46 (0)8 505 583 54 or go to the weblink https://tv.streamfabriken.com/bygghemma-group-q2-2019. The presentation is available from Bygghemma Group’s website: http://www.bygghemmagroup.com/investor-relations/presentations About Bygghemma GroupBygghemma Group is the leading online supplier of home improvement products in the Nordic region. We offer our customers a broad product range at attractive prices, with convenient home delivery. We conduct operations in two segments: DIY and Home Furnishing. DIY comprises sales of products from well-known brands for homes and gardens, and Home Furnishing comprises sales of furniture and home decor, mainly under proprietary brands. Bygghemma Group includes a wide range of webstores, such as www.bygghemma.se, www.trademax.se, www.chilli.se and www.furniturebox.se. Bygghemma Group had sales of SEK 5 billion in 2018, has its head office in Malmö and is listed on Nasdaq Stockholm Mid Cap.

Interim Report January-June 2019

”Camurus had a productive quarter with significant progress in the commercial business, start of a pivotal Phase 3 study of CAM2029, and a new FluidCrystal® partnership” Summary second quarter 2019  ·  Net revenues in the quarter were MSEK 11.9 (7.3), whereof product sales MSEK 11.3 (2.9) ·  Half‐year net revenues were MSEK 30.4 (22.3) whereof product sales MSEK 22.3 (5.9) ·  Patients in treatment with Buvidal® increased from approximately 500 to 1,300 patients across 150 clinics ·  Buvidal® launch expanded to Australia and Norway ·  Positive pricing and reimbursement decisions achieved on key markets ·  Phase 3 study of CAM2029 in acromegaly initiated following IND acceptance by the FDA ·  GMP manufacturing of CAM2029 in final prefilled syringe presentation completed ·  Braeburn initiated court proceedings to overturn a 3‐year market exclusivity extending to 30 Nov. 2020 and seek immediate market approval of Brixadi™ (the US trade name for Buvidal®) ·  Fast track (180 days) registration procedure granted for Buvidal® in Israel ·  Clinical data for Buvidal® presented at several international conferences, including ASAM in Orlando, IOTOD in Frankfurt, Albatros in Paris, and CPDD in San Antonio, Texas ·  Positive Phase 3 results from long‐term study of Buvidal® published in the leading journal Addiction Significant event after the period  ·  License agreement with Ra Pharmaceuticals for weekly zilucoplan FluidCrystal® injection depot Financial summary second quarter 2019  ·  Net Revenue MSEK 11.9 (7.3)- whereof product sales MSEK 11.3 (2.9) ·  Operating result MSEK -109.8 (-81.2) ·  Result for the period MSEK -87.6 (-67.5) ·  Earnings per share SEK -1.83 (-1.81), before and after dilution ·  Cash position MSEK 283.1 (199.1) CEO statementDuring the second quarter we reached several important business goals. The launch of Buvidal® for the treatment of opioid dependence was expanded and pricing and reimbursement approvals were obtained in key markets in the EU and Australia. A pivotal Phase 3 study of CAM2029 octreotide SC depot was initiated after IND acceptance by the FDA. In addition, positive results in a research collaboration with Ra Pharma for a new FluidCrystal® based long‐acting formulation of zilucoplan for the treatment of life threatening blood and tissue disorders resulted in a new license agreement, signed after the period. Buvidal® reaching new marketsWe have continued our launch efforts in the first wave markets, Finland, Sweden, Denmark, Germany and the UK. The feedback from patients and healthcare professionals continues to be positive and inspiring, with numerous reports of how Buvidal® is transforming lives of individuals and families with opioid dependence. Additionally, our initial estimates suggest that treatment retention rates on Buvidal® are high – similar or better than in the Phase 3 long‐term safety study [1]. The number of patients in treatment with Buvidal® increased during the period from about 500 to 1,300, across more than 150 clinics. In our first market, Finland, Buvidal® already has a market share of more than 20% of buprenorphine treated patients and about 15% of all treated patients. As expected, the initial uptake has not been as fast on all markets, due to extended pricing and reimbursement processes. However, we made excellent progress during the quarter and received four positive reimbursement decisions from national authorities in key markets, including in Australia and Norway. In addition, more than 30 formularies in the UK have agreed to include Buvidal® on their listings, representing about one third of all patients with opioid dependence. Sales in other geographies continue to increase, with a high interest in both community and criminal justice settings. In addition, launch preparations have also progressed in the second and third wave markets. By the end of the year, we expect Buvidal® to be available on at least 10 markets, representing almost 400,000 patients in treatment for opioid dependence. Approval status in the US and IsraelEarly in the quarter, our partner Braeburn filed an action in the United States District Court for the District of Columbia (District Court), seeking to overturn the earlier decision by the US Food and Drug Administration (FDA) awarding a three‐year period of exclusivity to Sublocade™, which blocks approval of Brixadi™ monthly until November 30, 2020. The District Court held a hearing on the proceedings on July 15th, 2019, and a decision is expected later in the third quarter. A positive outcome at the District Court could potentially give patients in the US earlier access to Brixadi™ weekly and monthly depots for treatment of opioid use disorder. In Israel, our partner Medison was granted fast track (180 days) registration procedure for Buvidal® and is now on track for late 2019 approval. Phase 3 publication in opioid dependenceIn May 2019, detailed results from the global Phase 3 longterm safety study were published online in Addiction1, showing long‐term safety, efficacy and high rates of patient satisfaction with Buvidal®. Clinical results with Buvidal® were also presented at multiple international scientific conferences: ASAM in Orlando, Florida, IOTOD in Frankfurt, Germany, Albatros Addiction Congress in Paris, France, and CPDD in San Antonio, Texas. The presentations included new analysis of Phase 3 data in patients using fentanyl, a growing problem around the world, showing improved outcomes with Buvidal® versus daily standard treatment with sublingual buprenorphine/naloxone. Additionally, two clinical studies of Buvidal® in outpatient and criminal justice settings respectively have been progressing according to plan. Initial results from both studies are expected in the fourth quarter. Preparations for regulatory submission for CAM2038 in chronic painIn the quarter, we also completed a 52‐week Phase 3 long‐term safety extension study of CAM2038 in patients with chronic pain. Data from the study, including pharmacokinetics, are currently being analyzed and the study report is being compiled. Pre‐submission meetings with regulatory authorities in the EU are planned during the autumn, followed by regulatory submissions in the first half of 2020. Based on the product profile and the positive results obtained in the pivotal Phase 3 study, we believe CAM2038 has a significant potential in the chronic pain area. With effective longacting pain relief and reduced risk of misuse, illegal diversion and overdosing, we believe that CAM2038 could become an effective, convenient and potentially safer treatment alternative for patients in need for strong opioid analgesics, such as morphine, oxycodone and fentanyl. According to external assessments, one million patients in the seven largest global markets (7MM) are taking high doses of opioid analgesic drugs, morphine equivalent dose above 100 mg/day. About 2.5 million are estimated to be on doses above 50 mg/day. Phase 3 entry with CAM2029 is a significant milestone for CamurusFollowing the IND acceptance for entering Phase 3 with CAM2029 octreotide subcutaneous (SC) depot, Camurus now has two innovative product candidates in Phase 3 development, each addressing significant unmet medical needs and markets with large potential. With its ready‐for‐use design, enabling convenient once‐monthly dosing and enhanced plasma exposure, CAM2029 has an attractive target product profile with best‐in‐class potential on a global somatostatin analogue market currently worth more than $2.6 billion. The start of the pivotal Phase 3 study of CAM2029 represents an important milestone for Camurus. We will enroll 78 patients in about 50 clinical sites in the US and Europe. The last patient in is expected mid‐2020. In parallel, we will also conduct a Phase 3 long‐term safety study in newly recruited patients and rollover patients from the pivotal study. Both studies are expected to be completed during 2021. Progress in early pipeline and a new promising partnership with Ra PharmaAside from the late stage pipeline progress, we continued advancing our early stage programs, including initiating manufacturing of clinical batches of our CAM2043 weekly treprostinil depot for a planned Phase 2 start in H2 2019. Additionally, formulation optimization was performed for two new long‐acting peptide formulations targeting different endocrine disorders, which we plan to take into clinical development in 2020. In the collaboration with Rhythm, a Phase 2 study of CAM4072, a weekly setmelanotide depot addressing rare genetic obesity disorders is ongoing, and expected to be completed by the end of the year. In parallel, manufacturing preparations are being conducted for a planned Phase 3 start in 2020. After the quarter, following a successful feasibility study, we signed a license agreement with Ra Pharmaceuticals for a zilucoplan FluidCrystal® depot for the treatment of complement component 5 mediated disorders, including generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria. Under the agreement, Camurus will receive an upfront payment of $2 million and is eligible to receive up to $14.5 million in development milestones and other license payments, $55 million in sales milestones and a tiered single‐digit royalty on product sales related to the extended release FluidCrystal® formulation of zilucoplan. Camurus well positioned for the second half of 2019Camurus had a productive quarter with significant progress in the commercial business, start of a pivotal Phase 3 study of CAM2029, and a new FluidCrystal® partnership. With several positive pricing and reimbursement decisions and launch expansion to new markets, we have laid the foundation for a significantly increased patient access to Buvidal® in Europe and Australia. We see a significant commercial opportunity and an increasing external interest for CAM2029 in acromegaly, neuroendocrine tumors and other indications. In addition, we have growing pipeline of attractive product candidates in clinical development, addressing unmet needs of patients with severe and chronic disease. Together with an increasing number of products and technology partnerships, we expect a strong news flow and revenue growth in line our earlier guidance. Fredrik TibergPresident and CEO References1) Frost M, Bailey GL, Lintzeris N. et al, Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder. Addiction 2019;114(8):1416-1426 For more information:Fredrik Tiberg, CEO and Head of ResearchTel. +46 (0)46 286 46 92fredrik.tiberg@camurus.com    Fredrik Joabsson, Chief Business Development OfficerTel. +46 (0)70 776 17 37ir@camurus.com  This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the chief executive officer, 7.00 AM CET on 18 July 2019.

BioArctic and Eisai present new data regarding BAN2401 at the Alzheimer’s Association International Conference 2019

Stockholm, Sweden, July 18, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The presentations were held by BioArctic and its partner, Eisai, at the Alzheimer’s Association International Conference® 2019 (AAIC®) in Los Angeles, USA. BAN2401 was designed and generated to selectively target toxic protofibrils and oligomers, soluble aggregated forms of amyloid beta. The new data included details of the binding profile of BAN2401 and additional analyses from the earlier presented Phase 2b study in 856 patients with early Alzheimer’s disease. All data were consistent with previously presented outcomes from the Phase 2b study. BioArctic presented new data around BAN2401’s binding profile. The new data confirmed BAN2401’s strong binding and high selectivity for protofibrils and oligomers. The poster presentation can be found on BioArctic’s website at www.bioarctic.com.   Eisai presented data on biomarkers of neurodegeneration (cerebral spinal fluid, or CSF, biomarkers), which suggested that treatment with BAN2401 in patients with early Alzheimer’s disease was associated with reduced neurodegeneration at both 12- and 18-months timepoints. CSF biomarker data shows the impact downstream of the amyloid cascade, including a reduction of tau pathology (p-tau) and synaptic function (neurogranin), and a reduction in the increase of axonal degeneration (neurofilament light chain or NfL). These analyses were conducted with a subset of patients from the Phase 2b study where cerebral spinal fluid samples were collected. The findings are consistent with the previously presented positive effects on cognition and on reduction of amyloid beta in the brain with PET imaging. Further, it was observed that the positive impact on neurodegenerative biomarkers was more pronounced in patients who are ApoE4 carriers. This finding is also is consistent with the previously announced results for ApoE4 carriers on cognition and reduction of amyloid beta in the brain with BAN2401. Eisai also presented new data that showed a positive correlation between clinical cognition endpoints and reduction of amyloid beta in the brain after both 12- and 18-months treatment. The analysis was conducted comparing the clinical endpoints ADCOMS, ADAS-Cog and CDR-SB with two approaches to analyze the reduction of amyloid beta in the brain with PET imaging. The subset of patients included in this analysis had assessments from both from the clinical endpoints and PET imaging in the Phase 2b study in early Alzheimer’s disease. Further, increased BAN2401 exposure measured by serum concentrations correlated with larger reductions of amyloid beta in the brain measured by PET. ”The data presented today further demonstrate the uniqueness of BAN2401 and the robustness of the positive Phase 2b data previously presented. We look forward to Eisai´s progression of the confirmatory Phase 3 study in patients with early Alzheimer’s disease,” said Gunilla Osswald, CEO of BioArctic. BAN2401 is being studied by BioArctic’s partner Eisai in a Phase 3 study in patients with early Alzheimer’s disease to confirm the previously announced Phase 2b study results. This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. For more information, please contact:   Gunilla Osswald, PhD, CEO, BioArctic ABE-mail: gunilla.osswald@bioarctic.seTelephone: + 46 8 695 69 30 This information was submitted for publication at 7:00 a.m. CET on July 18, 2019. Notes to editors About BAN2401  BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between BioArctic and Eisai. BAN2401 has a unique binding profile and selectively binds to and eliminates soluble, toxic amyloid beta aggregates (protofibrils and oligomers) that are thought to contribute to the neurodegenerative process in Alzheimer’s disease. As such, BAN2401 has the potential to have an effect on the disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic in December 2007. In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for BAN2401. Currently, a global confirmatory Phase 3 clinical study (Clarity AD) of BAN2401 in patients with early Alzheimer´s disease is underway. According to Eisai, the final readout of the primary endpoint of the study is targeted for 2022. About the collaboration between BioArctic and Eisai  Since 2005, BioArctic has long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the development and commercialization agreement on the BAN2401 antibody, which was signed in December 2007, and the development and commercialization agreement on the antibody BAN2401 back-up for Alzheimer's disease, which was signed in May 2015. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has no development costs for BAN2401 in Alzheimer’s disease.   About BioArctic AB  BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com . About Eisai Co., Ltd. Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. Eisai defines their corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which Eisai calls their human health care (hhc) philosophy. With approximately 10,000 employees working across the global network of R&D facilities, manufacturing sites and marketing subsidiaries, Eisai strives to realize their hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in the strategic areas of Neurology and Oncology. Eisai has been working to establish a social environment that involves patients in each community in cooperation with various stakeholders including the government, healthcare professionals and care workers, and is estimated to have held over ten thousand dementia awareness events worldwide. As a pioneer in the field of dementia treatment, Eisai is striving to not only develop next generation treatments but also to develop diagnosis methods and provide solutions. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Interim report April-June 2019

Second quarter, April-June 2019: · Consolidated net revenues increased to SEK 3,784M (3,630). · Adjusted EBIT increased to SEK 1,561M (1,196). · Net Debt / Cash EBITDA amounted to 4.3x (3.9x). · Portfolio investments amounted to SEK 1,436M (2,385). The return on portfolio investments increased to 15 per cent (14). · Net profit increased to SEK 879M (701), and earnings per share increased to SEK 6.26 (5.33). · Cash flow from operating activities increased to SEK 1,897M (1,679). · Strategic partnership established in Greece through an agreement with Piraeus Bank. · Launch of EUR 60M efficiency improvement programme supporting our 2020 targets. Comment by President and CEO Mikael Ericson “I am pleased that we are able to report another good, solid set of quarterly results, with adjusted EBIT up 31 per cent year-on-year. We note a clear improvement in margins in our credit management service line (CMS) and have delivered a stable ROI of 15 per cent within portfolio investments. This resulted in an EPS of SEK 6.26 and continues the progress required to achieve our 2020 targets.” “During the quarter, we also strengthened our footprint in Southern Europe through the establishment of a strategic partnership with Piraeus Bank in Greece. This means that we’re taking the final step in securing our leading position in all major European markets.” “As part of our efforts to further increase operational efficiency, we are initiating an efficiency improvement programme, targeting a further EUR 60M in bottom line impact in 2020. The programme will include activities such as fully integrating our acquisition of Solvia into our existing Spanish operations and carefully prioritising key projects within areas such as IT to ensure we benefit from the size and scale of our organisation. This will lay the foundations for an even more competitive and efficient Intrum beyond 2020.”For further information, please contact:Viktor Lindeberg, Head of Investor Relations+46 (0) 8 546 102 02 This information is such that Intrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was released for publication, through the agency of the contact person set out above, on July 18, 2019 at 07.00 a.m. CET.

Telia Company Interim report January-June 2019

Second quarter summary · The new lease accounting principles, IFRS 16, have had significant effects on the financial statements for 2019. Comparative information for 2018 has not been restated. See Note 1. · Net sales rose 2.2 percent in reported currency to SEK 21,272 million (20,814). Net sales like for like regarding exchange rates, acquisitions and disposals, declined 4.2 percent. Service revenues like for like regarding exchange rates, acquisitions and disposals, declined 1.4 percent. · Adjusted EBITDA rose 16.7 percent in reported currency to SEK 7,520 million (6,443). Like for like regarding exchange rates, acquisitions and disposals, adjusted EBITDA rose 8.1 percent. Excluding the positive impact from IFRS 16, adjusted EBITDA, like for like regarding exchange rates, acquisitions and disposals, fell 2 percent. The adjusted EBITDA margin rose to 35.4 percent (31.0). · Adjusted operating income fell 12.7 percent to SEK 3,146 million (3,601).  · Total net income decreased to SEK 1,651 million (2,244). Total net income attributable to owners of the parent fell to SEK 1,601 million (2,160). · Free cash flow from continuing and discontinued operations increased to SEK 3,322 million (3,114). Operational free cash flow from continuing operations fell to SEK 2,443 million (2,574). Total cash flow amounted to SEK -12,956 million (-6,832). · Outlook 2019 is unchanged. First half summary · Net sales rose 3.6 percent in reported currency to SEK 42,118 million (40,666). Net sales like for like regarding exchange rates, acquisitions and disposals, fell 3.7 percent. · Adjusted operating income fell 7.8 percent to SEK 6,632 million (7,189). · Total net income rose to SEK 3,451 million (1,644). Total net income attributable to the owners of the parent rose to SEK 3,393 million (1,450). Comments by Johan Dennelind, President & CEO  “Dear shareholders and Telia followers, as expected, the second quarter was an improvement compared to the first quarter, and we see continuous improvement during the rest of the year. The revenue initiatives, both already implemented and the ones coming in the autumn, combined with cost reductions, primarily on resource cost, are the main reasons for why we can reiterate a stronger second half of 2019 than the first half. The trend is right even if the recovery curve is slow primarily due to a soft mobile B2C in Norway and a negative service revenue mix in Finland. The service revenues for the group declined like for like by 1 percent in the second quarter, an improvement from the decline of 3 percent in the first quarter. The adjusted EBITDA like for like and excluding impact from IFRS 16 declined 2 percent, also an improved level from the decline of 4 percent in the first quarter. Our operational free cash flow outlook for 2019 remains at SEK 12-12.5 billion, an increase of between 11-16 percent compared to 2018. For the first half the operational free cash flow was SEK 6.9 billion, in line with the corresponding period 2018. The main drivers relate to the acquisition of Get/TDC and we also have a good start on our working capital initiatives. The somewhat slower start in adjusted EBITDA like for like and excluding impact from IFRS 16 will be compensated in the second half of the year by other cash flow drivers, which means that the cash flow composition will be slightly different from what we originally expected. During the second quarter we have continued to execute on our commercial plans for the year to improve the service revenues. In Sweden we have reshuffled and simplified our mobile product portfolio, making it easier for families to consume and allocate data among each other in the best mobile network in Sweden. So far, the response from customers have been positive. Combined with the recent price adjustments we made in the fixed service portfolio this should contribute to the improved service revenue trends for the second half of 2019. I am very pleased by the enterprise segment showing growth in the second quarter supported by implementation driven revenues on IoT and datacom, where we have secured several large customer contracts, both new and extensions. We are proud to be chosen as the trusted partner and will continue to show leadership in the digital era, where I especially want to highlight the opportunities connected to IoT, where we are clearly very competitive. This quarter we signed yet another big contract in the energy sector, enabling one million E.ON customers to connect to smart electricity meters and we help transportation company Nobina with smart heating of buses. We have also entered several partnerships to explore how 5G can improve our customers’ competitiveness. Overall, we see a slightly better underlying run-rate in B2B for the second half of the year versus the level seen in 2018. The operational expenses in Sweden are still too high. However, given actions already taken as well as additional measures to be implemented in the second half we reiterate our ambition to reach a reduction in operational expenses by 3 percent for 2019. This will primarily be driven by resource costs. For the second quarter trends improved and adjusted EBITDA like for like and excluding impact from IFRS 16 declined by 3 percent versus 6 percent in the first quarter in Sweden. In Finland the mobile service revenues have returned to growth, a trend that should improve further once we have seen the financial impact from the strong order intake in the first half of 2019 in the enterprise segment. After the season ending of Liiga we have managed to maintain a very high share of customers which should indicate a shorter start-up phase in the autumn. We have also accelerated the dismantling of the copper network leading to a sharp decline in our legacy business. There were higher costs due to the growth in our ICT business. This led to a declining adjusted EBITDA like for like and excluding impact from IFRS 16 for the second quarter by 4 percent. In Norway mobile service revenues are still hampered by the subscriber losses we experienced in 2018. We are seeing better trends in mobile customer intake, mainly driven by the enterprise segment. For the consumer segment we need to improve our trends during the rest of the year. In the quarter, we have taken the first convergence initiatives which, albeit early days, look encouraging. The Get performance continues to be stable, with both broadband and TV revenues being flat versus the second quarter of 2018. The pace of synergy realization is increasing as planned and is now at a NOK 200 million full year run-rate and will accelerate further coming quarters. The adjusted EBITDA like for like and excluding impact from IFRS 16 returned to a 1 percent growth in the second quarter.  I have mentioned before that Sweden since the beginning of the year has been enrolled into our new operating model. We are encouraged by the effects and are accelerating the enrollment of the other countries which will all be added within the next 12 months where we will realize OPEX and CAPEX synergy potential of SEK 600-900 million and SEK 500 million, respectively, in the coming years. As anticipated the EU commission pushed the Bonnier Broadcasting approval process into a deeper investigation, a so-called phase two. We have a constructive dialogue with EU commission and continue to believe in an approval in the fourth quarter of 2019. The outlook of a full year operational free cash flow in between SEK 12-12.5 billion is reiterated. After an intense first half year I would like to take the opportunity to thank team Telia for the hard work and relentless push to bring the world closer to our customers, with the best connectivity out there. Have a great summer all of you!” Johan Dennelind, President & CEO  This information is information that Telia Company AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07.00 CET on July 18, 2019. For more information, please contact our press office +46 771 77 58 30, visit our Newsroom  or follow us on Twitter @Teliacompany . Forward-Looking StatementsStatements made in the press release relating to future status or circumstances, including future performance and other trend projections are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Telia Company.    We’re Telia Company, the New Generation Telco. Our approximately 20,000 talented colleagues serve millions of customers every day in one of the world’s most connected regions. With a strong connectivity base, we’re the hub in the digital ecosystem, empowering people, companies and societies to stay in touch with everything that matters 24/7/365 - on their terms. Headquartered in Stockholm, the heart of innovation and technology, we’re set to change the industry and bring the world even closer for our customers. Read more at www.teliacompany.com

Interim report January – June 2019

Stockholm, Sweden, July 18, 2019 Enea® (Nasdaq Stockholm: ENEA) New business generating strong growth and profitability Second quarter 2019 · Revenue amounted to SEK 260.2 (213.4) million, equivalent to a 22 percent increase.  · Operating profit excluding non-recurring items increased to SEK 72.2 (45.9) million, corresponding to an operating margin of 27.8 (21.5) percent. · Operating profit increased to SEK 72.0 (44.0) million, equivalent to an operating margin of 27.7 (20.6) percent.  · Earnings per share increased to SEK 2.71 (1.83).  · Jan Häglund took up position as CEO on 6 May.  · The AGM appointed Anders Lidbeck, formerly CEO, as new Chairman of the Board. Birgitta Stymne Göransson was appointed a new Board member. The Board was given a mandate to issue shares to finance continued growth.  January - June 2019 · Revenue amounted to SEK 501.1 (383.6) million, equivalent to a 31 percent increase · Operating profit excluding non-recurring items increased to SEK 137.9 (81.1) million, corresponding to an operating margin of 27.5 (21.1) percent · Operating profit increased to SEK 134.2 (71.0) million, equivalent to an operating margin of 26.8 (18.5) percent.  · Earnings per share increased to SEK 4.85 (2.77).  Significant events after period end On 9 July, Enea reported that it had signed a multi-year, EUR 21.2 million contract on one of its Key Accounts.  Comments from Jan Häglund, President and CEO Innovation and successful acquisitions pay off Strong growth and profitability Enea’s second quarter 2019 is my first as the company’s CEO and President. I’m delighted to report continued brisk progress, with revenue growth of 22 percent, and an operating margin of 27.7 percent. Our revenue increase was highest in Network Solutions, where new business, mainly in policy and access control, as well as traffic classification, had a positive impact. Enea’s operating profit was up by 64 percent on the corresponding quarter of the previous year, driven by higher sales and good profitability in our new policy and access control business. Our strong earnings also resulted in earnings per share increasing to SEK 2.71 and cash flow before changes in working capital remaining high in the quarter, at SEK 74.5 million. We should note that in the second quarter, profitability is impacted by positive non-recurring effects. Even if we expect to be able to continue our long-term positive earnings trend, we should not anticipate equally high operating margins in forthcoming quarters. We’re retaining our target of achieving growth with an operating margin of over 20 percent. Consolidating our leadership in traffic classification Cyber security remains a dynamic and growing market where Enea enjoys a leading position in the traffic classification technology known as DPI (Deep Packet Inspection). We signed a USD 2.8 million deal with a major US provider of cloud technology and network solutions for business in the quarter. Enea is making a contribution to this customer’s Software Defined Wide Area Networks (SD-WAN) solution. The deal is another example of customers selecting Enea’s software based on our many years’ expertise in key segments like cyber security and network communication. Policy and access control creating new business Enea previously reported the acquisition of a business providing policy and access control products from Atos Convergence Creators. Policy and access control is present in all 4G and 5G systems, bringing users network access and services. This market is forecast to grow as mobile traffic expands, and with operator access to the 5G spectrum. Enea develops and delivers software specialized for cloud-based infrastructure. Enea’s acquisition of a business providing policy and access control products made a positive impact on our profitability in the second quarter. Major contract generates stable revenues in operating systems Enea’s traditional business in real-time operating systems is significant, even if it is a lower share of the company’s total revenue than previously (21 percent in the second quarter). The usage of open source such as Linux is continuing to increase, reducing the demand for proprietary operating systems, where Enea’s real-time operating system OSE is the telecom market leader. In the quarter, we renewed a deal for the years 2019-2022 for operating systems on one of our Key Accounts, worth EUR 21.2 million. This contract extension means an expected loss of revenues from operating systems on this account during coming years. We will be continuing to adapt our focus and costs to match how the market in the operating system segment evolves. Award-winning innovations Enea is an innovator, and we continue to invest a significant revenue share in research and development. Most of the company’s some 650 employees develop software for the systems of tomorrow such as 5G. In the quarter, two of our products won great awards—congestion software for mobile systems and a solution for more efficient data management in future 5G systems. The combination of increasing data traffic volume and the new 5G standard means the market for Enea’s software solutions is growing. We’re a world leader in several key segments, not least managing and optimizing video traffic on mobile networks. New customers in business communication Enea recently launched NFV Access, a product that opens a door to the growing business communication market. NFV Access is a software platform that enables business customers to use various communication and security applications in combination with hardware from an array of independent vendors. We’ve now signed our first contract, and also helped bring the system into commercial operation. Our business model in this segment is based on subscriptions for used units. Accordingly, total revenue will increase as new units are installed, often by SMEs. Future prospects We still take a positive view of the market outlook for software in telecom systems and business networks, although the scale of deals and revenues may vary between individual quarters. We stand on a secure foundation, based on proprietary development and recent years’ business acquisitions. Accordingly, we will continue to invest in own innovation and consider acquisitions that strengthen our market positioning and long-term earnings capacity. Our goal for the full year 2019 is to achieve revenue growth on 2018, and an operating margin of over 20 percent. The full report can be found as an attachment in this press release and published on www.enea.com   Press and analyst meeting Press and financial analysts are invited to a press and analyst meeting where Jan Häglund, President and CEO, will present and comment on the report. Time: Thursday July 18 at 08:30 am CET.Link: https://tv.streamfabriken.com/enea-q2-2019 Phone number:SE: +46 8 505 58365UK: +44 333 300 9265US: +1 833 526 8383  This information is information that Enea AB (publ) is obliged to make public pursuant to the EU Market buse Regulation. The information was submitted for publication, through the agency of the contact person set below, on July 18, 2019 at 7:20 am CET. For more information visit www.enea.com  or contact: Jan Häglund, President and CEOE-mail: jan.haglund@enea.com  Tomas Hasselrot, Director, Marketing and CommunicationTelephone: +46 70 971 6134E-mail: tomas.hasselrot@enea.com About Enea Enea develops the software foundation for the connected society. We provide solutions for mobile traffic optimization, subscriber data management, network virtualization, traffic classification, embedded operating systems, and professional services. Solution vendors, systems integrators, and service providers use Enea to create new world-leading networking products and services. More than 3 billion people around the globe already rely on Enea technologies in their daily lives. Enea is listed on Nasdaq Stockholm. For more information: www.enea.com   Enea®, Enea OSE®, Netbricks®, Polyhedra®, Zealcore®, Enea® Element, Enea® Optima, Enea® LINX, Enea® Accelerator, Enea® dSPEED Platform and COSNOS® are registered trademarks of Enea AB and its subsidiaries. Enea OSE®ck, Enea OSE® Epsilon, Enea® Optima Log Analyzer, Enea® Black Box Recorder, Polyhedra® Lite, Enea® System Manager, Enea® ElementCenter NMS, Enea® On-device Management and Embedded for LeadersTM are unregistered trademarks of Enea AB or its subsidiaries. Any other company, product or service names mentioned above are the registered or unregistered trademarks of their respective owner. © Enea AB 2019

Volvo Group – the second quarter 2019

·  In Q2 2019, net sales increased by 16% to SEK 120.7 billion (103.6). Adjusted for currency movements, net sales increased by 11%. ·  The adjusted operating income amounted to SEK 15,105 M (11,519), corresponding to an adjusted operating margin of 12.5% (11.1). ·  The reported operating income amounted to SEK 15,105 M (12,337). ·  Currency movements had a positive impact on operating income of SEK 1,004 M. ·  Diluted earnings per share rose to SEK 5.47 (4.53). ·  Operating cash flow in the Industrial Operations amounted to SEK 13,867 M (8,322). July 18, 2019 Press and Analyst Conference. An on-line presentation of the report, followed by a question-and-answer session will be webcast starting at 09.00 CET. More information under Investors on www.volvogroup.com Aktiebolaget Volvo (publ) 556012-5790         Investor Relations                                       SE-405 08 Göteborg, SwedenTel +46 31 66 00 00                                    www.volvogroup.com                                                                                                                                                                                                        Contact Media Relations: Claes Eliasson +46 765 53 72 29 Contacts Investor Relations:Christer Johansson +46 31 66 13 34 Anders Christensson +46 31 66 11 91Johan Bartler +46 739 02 21 93 This information is information that AB Volvo (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 07.20 CEST onJuly 18, 2019 For more information, please visit volvogroup.com/press   The Volvo Group is one of the world’s leading manufacturers of trucks, buses, construction equipment and marine and industrial engines. The Group also provides complete solutions for financing and service. The Volvo Group, which employs 105,000 people, has production facilities in 18 countries and sells its products in more than 190 markets. In 2018 the Volvo Group’s sales amounted to about SEK 391 billion (EUR 38.1 billion). The Volvo Group is a publicly-held company headquartered in Göteborg, Sweden. Volvo shares are listed on Nasdaq Stockholm.

Volvo Group and Samsung SDI enter strategic alliance for electromobility

The alliance will cover joint development of battery packs specifically developed for Volvo Group’s truck applications. Samsung SDI intends to provide battery cells and modules to meet the demand for the Volvo Group’s electric trucks. The intention is that Volvo Group will utilize Samsung SDI’s battery pack technology for assembly in Volvo Group’s manufacturing operations. “Volvo Group is one of the world’s largest manufacturers of commercial vehicles. With electromobility the increasing needs for transport will be done in a cleaner and quieter way which opens up new possibilities for our customers and society as a whole. The alliance with Samsung SDI is an important next step on our journey towards offering the world’s most truly sustainable transport system with fossil-free alternatives for our commercial vehicles,” says Martin Lundstedt, President and CEO of the Volvo Group. “Samsung SDI is truly privileged to enter into a strategic alliance with the Volvo Group. As we stand at the crosscurrents of the mobility and transportation industry, we are convinced that this alliance will provide superior offerings pertaining to energy, safety and sustainability to the commercial vehicle industry and beyond. We are confident that this alliance will secure the market leadership of the two companies in the long-term,” says Young-Hyun Jun, CEO Samsung SDI. “We welcome the expertise Samsung SDI brings into the Volvo Group. With this collaboration we are well-positioned to meet the increased market demands. By utilizing Samsung SDI’s strong battery technology knowledge, we have strengthened our powerful electromobility technology even further,” says Andrea Fuder, Chief Purchasing Officer of the Volvo Group. Watch the video: https://www.youtube.com/watch?v=z5FfKseu-zs  2019-07-18 For further information, please contact Claes Eliasson, Volvo Group Media Relations,+46 31 323 72 29.   For more information, please visit volvogroup.com/press   The Volvo Group drives prosperity through transport solutions, offering trucks, buses, construction equipment, power solutions for marine and industrial applications, financing and services that increase our customers’ uptime and productivity. Founded in 1927, the Volvo Group is committed to shaping the future landscape of sustainable transport and infrastructure solutions. The Volvo Group is headquartered in Gothenburg, Sweden, employs 105,000 people and serves customers in more than 190 markets. In 2018, net sales amounted to about SEK 391 billion (EUR 38,1 billion). Volvo shares are listed on Nasdaq Stockholm.

Q2 2019 Interim report January-June

Q2 2019 highlights · Viaplay subscribers up 65k quarter on quarter to 1,421k representing 60% of total subscriber base · Sales of SEK 3,975m (3,719) with 6% organic growth · Operating income for the combined business segments of SEK 535m (508) · Total operating income of SEK 455m (415) including IAC of SEK 0m (-48) · Net income of SEK 348m (329) and basic earnings per share of SEK 5.17 (4.93) · Total net debt of SEK 4,210m, including net lease liabilities of SEK 636m, equivalent to 2.3x 12 month trailing EBITDA before IAC[1] +---------------------------------------+-------+-------+-------+-------+---------+|Financial overview | | | | |Full year|+---------------------------------------+-------+-------+-------+-------+---------+|(SEKm) |Q2 2019|Q2 2018|H1 2019|H1 2018| 2018|+---------------------------------------+-------+-------+-------+-------+---------+|Net sales | 3,975| 3,719| 7,702| 7,171| 14,568|+---------------------------------------+-------+-------+-------+-------+---------+|Organic growth | 5.8%| 5.8%| 5.9%| 6.0%| 3.8%|+---------------------------------------+-------+-------+-------+-------+---------+|Change in reported net sales | 6.9%| 8.7%| 7.4%| 8.0%| 6.4%|+---------------------------------------+-------+-------+-------+-------+---------+|   |   | |   |   |   |+---------------------------------------+-------+-------+-------+-------+---------+|Operating income - Business segments[2]| 535| 508| 853| 794| 1,706|+---------------------------------------+-------+-------+-------+-------+---------+|Central operations | -80| -44| -123| -59| -162|+---------------------------------------+-------+-------+-------+-------+---------+|Operating income before IAC | 455| 464| 729| 734| 1,544|+---------------------------------------+-------+-------+-------+-------+---------+|Items affecting comparability (IAC) | -| -48| -56| -48| -40|+---------------------------------------+-------+-------+-------+-------+---------+|Operating income | 455| 415| 673| 686| 1,504|+---------------------------------------+-------+-------+-------+-------+---------+|   |   | |   |   |   |+---------------------------------------+-------+-------+-------+-------+---------+|Operating margin before IAC | 11.4%| 12.5%| 9.5%| 10.2%| 10.6%|+---------------------------------------+-------+-------+-------+-------+---------+|Operating margin | 11.4%| 11.2%| 8.7%| 9.6%| 10.3%|+---------------------------------------+-------+-------+-------+-------+---------+|   |   | |   |   |   |+---------------------------------------+-------+-------+-------+-------+---------+|Net income | 348| 329| 515| 545| 1,292|+---------------------------------------+-------+-------+-------+-------+---------+|Basic earnings per share (SEK) | 5.17| 4.93| 7.66| 8.17| 19.24|+---------------------------------------+-------+-------+-------+-------+---------+|Diluted earnings per share (SEK) | 5.17| 4.88| 7.64| 8.09| 19.09|+---------------------------------------+-------+-------+-------+-------+---------+|Net debt | 4,210| -| 4,210| -| 3,944|+---------------------------------------+-------+-------+-------+-------+---------+ [1] 2018 figures included in the calculation of 12 month trailing EBITDA before IAC have been adjusted for the estimated effect as if IFRS 16 had been applied for the full period.[2] See page 16 for a reconciliation of business segments operating income. Alternative performance measures used in this report are explained and reconciled on pages 19-22.  President & CEO’s comments “We made substantial progress during Q2 to seize the significant opportunity we see in the Nordic streaming market. These results clearly demonstrate the strength of our strategy and the ecosystem that we have built. Organic sales were up, and both our operating segments delivered higher profits. We added 65k Viaplay subscribers in what has historically been a seasonally quiet quarter, and we have now grown the Viaplay sub base by over 20% in the last year” Group sales were up 6% on an organic basis, and operating income for our combined business segments was up 5%. Central operational costs were up significantly as anticipated due to extraordinary investments in our team, branding, culture and values. Our Broadcasting & Streaming operations delivered yet another quarter of profitable growth. Subscription & Other sales, which accounted for 60% of Group sales, were up 8%. We added 65k Viaplay subscribers in what has historically been a quiet quarter due to the seasonality in the sports subscriber base. We have now added 244k subscribers in the last twelve months and expect to have increased our market share. Viaplay’s 1,421k subscribers now represent 60% of our total subscriber base. The Viaplay intake was above our targets and driven by a combination of healthy gross intake, lower churn levels, and ground-breaking new B2B deals. We have added more original programming and acquired more content and live sports, which have all contributed to Viaplay’s growth, as have our ongoing technology and product developments. Advertising sales, which accounted for 26% of group sales, were down 3% as double-digit sales growth in both Viafree and Swedish Radio was offset by the fact that we did not have the Ice Hockey World Championship on our Swedish free-tv channels this year, and the continuing soft TV and Radio advertising markets. We have continued to invest in content, in order to drive our growth. We premiered 5 new Viaplay originals in the quarter, and announced the production of a further 6 new originals. We announced a number of important new sports rights agreements including exclusive coverage of Alpine and cross-country skiing from 2021, the Open golf championship until 2024, and Danish Superliga football until 2024. We have also further enhanced our Hollywood acquired portfolio with the MGM and NBCU deals that we announced earlier in the year, and we have continued to invest in access to high quality content by taking a minority stake in new LA-based studio Picturestart. We have also signed a series of large scale and long-term strategic distribution agreements with partners such as Tele2 and Telia, which will further extend the reach of our advertising and subscription funded services. NENT Studios, which accounted for 14% of Group sales, generated 37% sales growth on the back of high scripted drama sales. Operating profits were up significantly as a result. The production pipeline continues to look promising, and we have a high number of very interesting new development projects. NENT Group comes out of Q2 even better positioned to benefit from the shift to on-demand and online viewing. Scaling Viaplay is the best way to create long-term shareholder value, and we intend to do so while continuing to deliver profitable growth. This is possible because of our unique business model and the dedicated world class Team NENT. Anders JensenPresident & CEO Shareholder information 2019 Annual General Meeting The Annual General Meeting resolved to re-elect the Board members Anders Borg, David Chance, Henrik Clausen, Simon Duffy, Kristina Schauman and Natalie Tydeman. The Annual General Meeting also re-elected David Chance as Chairman of the Board. The Meeting approved the payment of an annual ordinary dividend of SEK 6.50 per share to the shareholders in two equal instalments of SEK 3.25 each. The record date for the first dividend payment was Friday 24 May 2019, and the record date for the second dividend payment will be Friday 11 October 2019. The Meeting further resolved to adopt a long-term incentive plan for key employees, including the authorisation of the Board to issue and repurchase Class C Shares and resolve on the transfer of its own Class B Shares to the participants in the incentive plan. The Annual General Meeting also resolved on a bonus issue, which will increase the share capital by SEK 134,184,488. The Annual General Meeting further resolved to amend the Articles of Association in order to carry out the resolutions regarding the hedged delivery of shares to participants in the long-term incentive plan (by introducing a new Class C share) and bonus issue (by increasing the limits for the share capital) and re-elected KPMG as auditor until the close of the 2020 Annual General Meeting. Joakim Thilstedt will continue as auditor-in-charge. Financial calendar 2019 Q3 interim report      24 October Questions? press@nentgroup.com (or Nicholas Smith, Acting Head of Public Relations; +46 73 699 26 95)investors@nentgroup.com (or Stefan Lycke, Head of Investor Relations; +46 73 699 27 14) Download high-resolution photos: Flickr Follow us: nentgroup.com  / Facebook  / Twitter  / LinkedIn  / Instagram   Conference call The company will host a conference call today at 09.00 Stockholm local time, 08.00 London local time and 03.00 New York local time. To participate in the conference call, please dial: Sweden:  +46 (0) 8 506 921 80UK:   +44 (0) 8 445 718 892US:   +1 6 315 107 495 The access pin code for the call is 1084102. To listen to the conference call online and for further information, please visit www.nentgroup.com NOTES TO EDITORS Nordic Entertainment Group AB (publ) (NENT Group) is the Nordic region’s leading entertainment provider. We entertain millions of people every day with our streaming services, TV channels and radio stations, and our production companies create content that is experienced around the world. We make life more entertaining by telling stories, touching lives and expanding worlds – from live sports, movies and series to music and original shows. Headquartered in Stockholm, NENT Group is listed on Nasdaq Stockholm (‘NENT A’ and ‘NENT B’). This information is information that Nordic Entertainment Group AB (publ) (NENT Group) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:30 CET on 18 July 2019.

INTERIM REPORT 1 JANUARY – 30 JUNE 2019

Launch preparations continue Second Quarter: 1 April–30 June 2019 · Net sales amounted to SEK 0.5 million (0.3). · The operating result totalled SEK -44.5 million (-35.7). · The company reported a loss after tax of SEK -44.0 million (-35.7). · Earnings per share amounted to SEK -1.92 (-2.41). · Cash flow from operating activities totalled SEK -40.9 million (-28.4). Period: 1 January–30 June 2019 · Net sales amounted to SEK 1.0 million (0.5). · The operating result totalled SEK -81.2 million (-59.6). · The company reported a loss after tax of SEK -80.3 million (-59.7). · Earnings per share amounted to SEK -3.50 (-4.51). · Cash flow from operating activities totalled SEK -81.9 million (-54.1). · At 30 June 2019, cash and cash equivalents amounted to SEK 19.4 million (354.4), short-term investments in fixed-income funds to SEK 250.1 million (150.0) and investments in listed bonds to SEK 151.8 million (0). Significant events in the second quarter of 2019 · The Annual General Meeting was held on 22 May 2019. Refer to “Other information” for information about the resolutions passed at the Annual General Meeting. · The Annual General Meeting resolved to re-elect directors Erika Kjellberg Eriksson, Mats Nilsson Bernitz, Ulf Landegren, Marcus Storch, Marianne Hansson, Per-Olof Wallström and Hans Johansson. Erika Kjellberg Eriksson was elected Chairperson of the Board. after the end of the period · The Board of Directors resolved to issue and repurchase 117,424 shares within the framework of the LTIP 2019 long-term incentive programme. Comments by the CEO Intensified partner discussions The second quarter of 2019 was characterised by feedback from potential customers following our participation in various conferences, preparations for regulatory studies and, last but not least, intensified discussions with several possible partners for the upcoming launch of ASTar. The European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) is the most important annual conference for Q-linea. This year it was held in Amsterdam on 13–16 April. I am proud of the fantastic feedback we received at ECCMID on ASTar. The same can be said for our participation in the American Society for Microbiology (ASM) Microbe in San Francisco on 20–24 June. We have received overwhelmingly positive feedback on our broad antibiotics panel, ASTar’s flexible but simple workflow and how easy it is to start using. Potential customers in Europe and the US are equally positive, but in the US we are encountering a somewhat different customer group. Customers in the US have more automated operations and more 24-hour labs. They are especially appreciative of the simplicity and the fully automated workflow, and it is particularly gratifying to be receiving positive feedback on our development process from future customers. Since customers are already starting to plan their budgets in order to purchase the system next year, it has been important for us to be able to present the final design of our ASTar system. When it comes to our regulatory studies, we achieved an important milestone in June when we submitted a pre-submission supplement to the US Food and Drug Administration (FDA), as planned. The supplement contained a detailed description of how we plan to design the US study and the specifics of the trial protocol and the ASTar system. We will have a meeting with the FDA in September to hear their views on the design of the study and we will thereafter adapt the study to meet their requirements. If everything goes according to plan, we should be able to start the study at the beginning of next year. Our goal is to obtain FDA approval to market and sell the system next year. I am happy to be leading the company and following its progress. We are methodically working through our goals and the impressive work that has been carried out throughout the company is now being reflected in our discussions with potential sales partners. These discussions intensified during the quarter and are now being conducted with some of the most attractive companies in the market. I look forward to our future partnership agreements with a sense of anticipation and optimism. To sum up, the feedback we are receiving both from potential customers and in discussions with possible partners is incredibly motivating in our continued work to prepare ASTar for approval and market launch next year. I hope and believe that Q-linea’s shareholders share our enthusiasm. Jonas Jarvius, President This report has been prepared in a Swedish original and an English translation. In the event of any discrepancies between the two, the Swedish version is to apply.This interim report has not been reviewed by the company’s auditor.    Presentation Q-linea invites investors, analysts and the media to an audiocast and teleconference (in English) today, 18 July, at 1:00 to 2:00 p.m. (CET). President Jonas Jarvius and CFO Anders Lundin will present Q-linea, com-ment on the interim report for the January to June 2019 period and respond to questions. Webcast: https://tv.streamfabriken.com/q-linea-q2-2019  Telephone number for the teleconference: SE: +46851999383 UK: +443333009262 US: +16467224956 Upcoming reporting dates 7 November 2019 Interim report, Q3 January to September 201913 February 2020 Year-end report, Q4 January to December 2019Week of 13 April 2020      Annual Report 2019        January to December 20197 May 2020 Interim report, Q1 January to March 202016 July 2020 Interim report, Q2 January to June 20205 November 2020 Interim report, Q3 January to September 2020  About the company Q-linea AB (publ) Corporate 556729-0217 RegistrationNumber:Registered Uppsala  office:     Contact:    Dag Hammarskjölds väg 52 A  www.qlinea.com  SE-752 37 Uppsala, Sweden E-mail: contact@qlinea.com  Tel: +46 18 444 3610 For questions about the report, contact:      Jonas Tel: +46 70 323 7760  E-mail: jonas.jarvius@qlinea.com Jarvius,PresidentAnders Tel: +46 70 600 1520 E-mail: anders.lundin@qlinea.comLundin, CFO& IR This information is information that Q-linea AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 18 July 2019 at 7:30 a.m. CET.  About Q-linea Q-linea is an innovative research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar™ is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Wärtsilä's Half year financial report January-June 2019

WÄRTSILÄ’S HALF YEAR FINANCIAL REPORT JANUARY-JUNE 2019 STABLE DEVELOPMENT IN NET SALES, EQUIPMENT PROFITABILITY CHALLENGING This release is a summary of Wärtsilä’s Half Year Report January-June 2019. The complete report is attached to this release as a pdf file. It is also available at http://www.wartsilareports.com/en-US/2019/q2/frontpage/ and on the company website at www.wartsila.com. HIGHLIGHTS OF THE SECOND QUARTER · Order intake decreased 11% to EUR 1,377 million (1,553) · Net sales decreased 2% to EUR 1,217 million (1,246) · Book-to-bill amounted to 1.13 (1.25) · Comparable operating result decreased 8% to EUR 113 million (123), which represents 9.3% of net sales (9.8) · Earnings per share decreased to 0.11 euro (0.13) · Cash flow from operating activities decreased to EUR -37 million (41) HIGHLIGHTS OF THE REVIEW PERIOD JANUARY-JUNE 2019 · Order intake decreased 9% to EUR 2,793 million (3,060) · Order book at the end of the period increased 10% to EUR 6,470 million (5,904) · Net sales increased 2% to EUR 2,368 million (2,312) · Book-to-bill amounted to 1.18 (1.32) · Comparable operating result increased 2% to EUR 215 million (211), which represents 9.1% of net sales (9.1) · Earnings per share decreased to 0.21 euro (0.22) · Cash flow from operating activities was stable at EUR -2 million (-1) WÄRTSILÄ’S PROSPECTS The demand for Wärtsilä’s services and solutions in the coming 12 months is expected to be somewhat below that of the previous 12 months (previously in-line). Demand by business area is anticipated to be as follows: · Soft in Wärtsilä Marine Business. The demand outlook has been downgraded from solid, due to lower vessel contracting volumes and an anticipated decline in the demand for scrubber solutions from last year’s exceptionally high level. Activity in the marine services market is expected to continue. · Soft in Wärtsilä Energy Business. The demand outlook has been downgraded from solid, as market conditions in the energy industry remain challenging, with geopolitical risks and economic uncertainty affecting customers’ appetite for investments. The demand for energy services remains healthy. Wärtsilä’s current order book for 2019 deliveries is EUR 2,613 million (2,336). Deliveries are expected to be concentrated to the last quarter of the year. JAAKKO ESKOLA, PRESIDENT AND CEO “While the first half of 2019 was generally marked by stable development in our net sales and profitability, our performance in the second quarter was burdened by fewer power plant deliveries, as well as an unfavourable project and equipment mix. Order intake for the first six months was below that of the previous year, largely resulting from the continued macroeconomic and geopolitical uncertainty that has prolonged customer decision-making in the energy markets. Orders received in the Marine Business remained stable during the same period, as newbuild contracting has favoured the more specialised vessel segments. Nevertheless, uncertainty regarding fuel price development has slowed scrubber orders, which, in combination with concerns related to lower overall vessel contracting volumes, has prompted us to lower our marine demand outlook for the coming twelve months. The outlook for the energy markets has also been lowered, as we expect market conditions to remain challenging in the near-term. In contrast to the softer demand trends in the equipment markets, I am pleased to note that the growth in services related sales has continued in both businesses throughout the second quarter. The phasing of the order book indicates that volume related challenges will continue in the coming months, followed by unusually strong deliveries in the fourth quarter. Successful delivery execution, the implementation of ongoing realignment actions, and finalising certain power plant contracts will be central to our financial performance this year. Looking beyond 2019, we are well placed to benefit from the demand for energy efficiency and the shift to low-carbon energy sources in both of our end-markets. We remain focused on improving operational efficiency and delivering increased lifecycle value to further strengthen our competitive position.” KEY FIGURES MEUR 4-6/ 4-6/ Change 1-6/ 1-6/ Change 2018 2019 2018 2019 2018Order intake 1 377 1 553 -11% 2 793 3 060 -9% 6 307of which services 622 592 5% 1 275 1 258 1% 2 598Order book, end of 6 470 5 904 10% 6 166periodNet sales 1 217 1 246 -2% 2 368 2 312 2% 5 174of which services 612 582 5% 1 184 1 117 6% 2 419Book-to-bill 1.13 1.25 1.18 1.32 1.22Operating result 96 111 -13% 187 196 -4% 543% of net sales 7.9 8.9 7.9 8.5 10.5Comparable operating 113 123 -8% 215 211 2% 577result*% of net sales 9.3 9.8 9.1 9.1 11.2Comparable adjusted 123 134 -8% 236 232 2% 621EBITA**% of net sales 10.1 10.7 10.0 10.0 12.0Profit before taxes 83 102 -18% 162 178 -9% 502Earnings/share, EUR 0.11 0.13 0.21 0.22 0.65Cash flow from -37 41 -2 -1 470operating activitiesNet interest-bearing 746 642 333debt, end ofperiod***Gross capital 54 232 306expenditureGearing 0.33 0.29 0.14Solvency, % 40.5 41.7 44.4Personnel, end of 19 239 19 231 0% 19 294period *Items affecting comparability in the second quarter of 2019 included costs related primarily to restructuring programmes of EUR 17 million (12). During January-June, items affecting comparability amounted to EUR 28 million (15).**Comparable adjusted EBITA excludes items affecting comparability and purchase price allocation amortisation.***The increase in net interest-bearing debt is largely related to the inclusion of lease liabilities on the balance sheet, as a result of the new IFRS 16 standard. As of the first quarter of 2019, Wärtsilä’s financial reporting has been amended to reflect its new organisational structure. The two business areas, Wärtsilä Marine Business and Wärtsilä Energy Business, constitute the reportable segments. Financial reporting for 2018 has been adjusted to reflect this change. Wärtsilä will additionally report the services related order intake and net sales for the two segments. In Wärtsilä Marine Business, order intake and net sales for retrofit scrubber projects have been transferred from services to new equipment. The comparison figures have been adjusted accordingly. Wärtsilä presents certain alternative performance measures in accordance with the guidance issued by the European Securities and Markets Authority (ESMA). The definition of these alternative performance measures is presented in the calculations of financial ratios at the end of this report. ANALYST AND PRESS CONFERENCEAn analyst and press conference will be held today, Thursday 18 July 2019, at 10:00 a.m. Finnish time (8:00 a.m. UK time), at Wärtsilä Helsinki Campus, located at Hiililaiturinkuja 2, Helsinki, Finland. The combined web- and teleconference will be held in English and can be viewed by registering on: http://www.mediaserver.fi/live/wartsila. To participate in the teleconference, please register at the following address: http://emea.directeventreg.com/registration/3683345. You will receive dial-in details by e-mail once you have registered. If problems occur, please press *0 for operator assistance. Please press *6 to mute your phone during the teleconference and to unmute.     A recording of the webcast will be available on the company website later during the day. For further information, please contact: Arjen BerendsExecutive Vice President & CFOTel: +358 10 709 5444arjen.berends@wartsila.com Natalia ValtasaariVice President, Investor RelationsTel: +358 10 709 5637natalia.valtasaari@wartsila.com For press information, please contact: Atte PalomäkiExecutive Vice President, Communications, Branding & MarketingTel: +358 10 709 5599atte.palomaki@wartsila.com Wärtsilä in briefWärtsilä is a global leader in smart technologies and complete lifecycle solutions for the marine and energy markets. By emphasising sustainable innovation, total efficiency and data analytics, Wärtsilä maximises the environmental and economic performance of the vessels and power plants of its customers. In 2018, Wärtsilä’s net sales totalled EUR 5.2 billion with approximately 19,000 employees. The company has operations in over 200 locations in more than 80 countries around the world. Wärtsilä is listed on Nasdaq Helsinki.www.wartsila.com

AQ Group AB (publ), interim report January - June, 2019

Second quarter, April-June 2019in brief ·  Strongly improved profit, good growth and acquisition of Trafotek ·  Net sales increased by 7.3% to SEK 1 313 million (1 224) ·  Operating profit (EBIT) increased by 61.6 % to SEK 93 million (58) ·  Profit after financial items (EBT) increased by 59.7 % to SEK 88 million (55) ·  Profit margin before tax (EBT %) was 6.7 % (4.5) ·  Cash flow from operating activities increased by 39.8 % to SEK 50 million (35) ·  Earnings per share after tax increased by 50.0 % to SEK 3.81 (2.54) ·  Equity ratio 49 % (54), 2019 affected by new IFRS 16 rules Six months, January-June 2019in brief ·  Net sales increased by 10.9% to SEK 2 566 million (2 314) ·  Operating profit (EBIT) increased by 46.2 % to SEK 189 million (129) ·  Profit after financial items (EBT) increased by 46.5 % to SEK 181 million (124) ·  Profit margin before tax (EBT %) was 7.1 % (5.4) ·  Cash flow from operating activities increased by 206.8 % to SEK 215 million (70) ·  Earnings per share after tax increased by 40.0 % to SEK 7.95 (5.68) A word form the CEO QuarterThe second quarter is the 99th consecutive quarter that AQ Group shows profit. Profit after financial items (EBT) was 59.7% better than last year and turnover was 7.3% higher. The profit improvement comes from higher sales and that we no longer have losses from the three units we restructured in 2018. Cash flow from operating activities was positively affected by our projects to increase inventory turnover, but other parts of working capital did not develop as strongly during the quarter. Here, we will continue our efforts to optimize our inventory and to reduce our overdue accounts receivable. On the other hand, cash flow from operating activities was good for the first half of the year. AcquisitionsDuring the quarter, we completed the acquisition of Trafotek. This company is a leading supplier in the design and manufacturing of inductive components for power electronics, such as reactors, transformers and filters. Trafotek's customers are mainly active in industrial automation, renewable energy and marine electrification. The fit between AQ and Trafotek is very good and we have no overlaps in terms of customers and geographical presence. We look forward to working with our new colleagues to develop the business with inductive components around the world. Just at the beginning of the third quarter, we also announced that one of our companies in Sweden, AQ Wiring Systems AB, has made a complementary acquisition of a company called MiniCon AB. This acquisition will strengthen our presence and expertise in wiring systems for demanding industrial customers in the Nordic region. Acquisitions like these will continue to be an important part of AQ's strategy. MarketThe organic growth for the quarter adjusted for currency, acquisitions and the larger unit we phased out last year was 8.9%. Our business with electrical cabinets for automation, inductive components for trains, wiring systems for commercial vehicles and assembly of complete machines for medical technology continue to be the strongest contributors of growth even in this quarter. In our role as a supplier, AQ is always ready for changes in demand. We need to be quick to change both in growth and when demand for our customers' products decreases. Delivery capabilityWe want to continue to develop into an even better supplier for our customers. We note that our delivery reliability has improved during the quarter, but we are not yet satisfied. In the last interim report, we mentioned that one third of our manufacturing units have unsatisfactory delivery precision. Approximately half of these have improved during the quarter and this work continues. We want to continuously develop our processes and standards to become even more robust and flexible during this and coming years. OrganizationAQ Group has a strong company culture with core values that are for real in customer focus, entrepreneurship, simplicity, cost efficiency, courage and respect. We run our business in decentralized companies with talented leaders and employees who work close to their customers and have a mandate to run the business. In this way, we can be quick and utilize all the opportunities available in the market. This is a strategy we will continue with. In addition, we are now also working to strengthen our business areas with common expertise in purchasing, processes and sales. Our ambition is to increase the intensity of our sales work and to identify more opportunities for cost savings in both purchasing and manufacturing. OutlookOur goal is to be a long-term stable, growing and profitable group with an operating margin (EBT) of 8% and a strong financial position. We like to do business with the customer in focus. Our employees and managers are doing a good job and it will be reflected in new business also in the future. With strong relationships with world-leading customers and committed employees, we will work hard to achieve a stable profit level, accomplish new acquisitions, continue organic growth and generate good cash flow. In the coming year, we will also focus on continued good integration of Trafotek, B3CG, Mecanova and Minicon. An important part of this is our core values and our efforts to be a long-term and "Reliable" supplier to leading industrial customers. Anders CarlssonCEO

Electrolux Q2 interim report 2019: Good price momentum and focus on innovation

· Net sales amounted to SEK 31,687m (31,354). Sales decline of 2.7%, driven by lower volumes. · Operating income amounted to SEK 1,619m (827), corresponding to a margin of 5.1% (2.6). The comparison period included non-recurring items of SEK -818m. · Price increases fully offset the headwinds from higher raw material costs, trade tariffs and currency as well as lower volumes. Mix improvements mitigated higher investments in marketing and R&D. · Operating cash flow after investments amounted to SEK 384m (1,805). · Income for the period increased to SEK 1,132m (517), and earnings per share was SEK 3.94 (1.80). · The Board has reconfirmed its plan to propose to the shareholders that the Professional Products business area is distributed to the shareholders with the aim to achieve listing on the Nasdaq Stockholm during the first quarter of 2020 or, at the latest, the second quarter of 2020. President and CEO Jonas Samuelson’s comment A strong focus on innovation to improve consumer experiences is our guiding compass and a key driver for profitable growth. It is therefore encouraging to see that we once again have a favorable earnings impact from improved mix by selling more high-margin products and we continue to invest in marketing to support the major launches we have this year. Concurrently, price increases continued to offset strong headwinds from higher raw material costs, trade tariffs and currency, and in this quarter also from volume decline. The lower volume was mainly caused by the U.S. private label sales drop. Underlying operating income was in line with last year. The earnings for our operations in Europe and Professional Products were once again solid and operating income in Latin America increased significantly. In North America, positive price and mix offset higher costs from raw materials and trade tariffs but not fully the volume decline. The business area Asia-Pacific, Middle East and Africa was impacted by currency headwind and weak sales in Australia. We re-confirm our market view for 2019 with the exception of Southeast Asia where we now estimate the demand in the region to be slightly positive. Based on current trade tariff levels, we estimate the negative year-over-year impact from raw materials, trade tariffs and currency to be approximately SEK 1.4-1.6bn in 2019, compared to the previous estimate of approximately SEK 1.7-1.9bn. In the first half of 2019, price has fully offset this headwind and we expect that to be the case also for 2019 as a whole. The uncertainty on trade tariffs continues to impact our visibility. The preparations for the intended separation and subsequent listing of the Professional Products business area are proceeding according to plan. As the previously announced reasons for the separation are still considered valid the Board has reconfirmed its plan to propose to the shareholders that the Professional Products business area is distributed to the shareholders with the aim to achieve listing on the Nasdaq Stockholm during the first quarter of 2020 or, at the latest, the second quarter of 2020. Electrolux 100th year is a product launch intensive year and I believe our innovation power will continue to strengthen our competiveness. In addition to significant kitchen range launches in Europe and Asia-Pacific, we have sharpened our offering by being the first to bring Air Fry technology built in to the cooker to the North American market. Looking ahead, I am confident that we are well positioned to create value through our profitable growth strategy. Telephone conference 09.00 CET A telephone conference is held at 09.00 CET today, July 18. Jonas Samuelson, President and CEO and Therese Friberg, CFO will comment on the report. Details for participation by telephone are as follows: Participants in Sweden: +46 8 566 426 51 Participants in UK/Europe: +44 3333 000 804 Participants in US: +1 631 9131 422 Pin code: 86381780# Slide presentation for download:  www.electroluxgroup.com/ir Link to webcast: https://edge.media-server.com/m6/p/ibk4cpkt

Munters second quarter 2019

Second quarter 2019 ·Order intake increased by 1% to SEKm 1,843 (1,826). ·Net sales increased by 1% to SEKm 1,964 (1,939). ·Operating profit (EBIT) amounted to SEKm 165 (170), including items affecting comparability of SEKm -39 (-) related to Munters Full Potential Program. ·Adjusted EBITA increased by 16% to SEKm 245 (211), corresponding to an adjusted EBITA margin of 12.5% (10.9). Excluding Data Centers Europe, based on Munters intention to leave the european Data Center market, the adjusted EBITA increased by 28% corresponding to an adjusted EBITA margin of 13.8% (11.9). ·Net income was SEKm 84 (122). ·Cash flow from operating activities was SEKm 168 (39). ·Earnings per share was SEK 0.46 (0.64). ·Klas Forsström was appointed as President and CEO and will assume his role on August 12. ·Annette Kumlien was appointed as Group Vice President and CFO and will assume her role on August 12. January – june 2019 ·Order intake increased by 10% to SEKm 3,792 (3,461). ·Net sales increased by 2% to SEKm 3,627 (3,539). ·Operating profit (EBIT) amounted to SEKm 179 (247), including items affecting comparability of SEKm -100 (-) related to Munters Full Potential Program. ·Adjusted EBITA increased by 8% to SEKm 352 (326), corresponding to an adjusted EBITA margin of 9.7% (9.2). Excluding Data Centers Europe, based on Munters intention to leave the european Data Center market, the adjusted EBITA increased by 26% corresponding to an adjusted EBITA margin of 11.2% (10.2). ·Net income was SEKm 63 (164). ·Cash flow from operating activities was SEKm 211 (38). ·Net debt increased by SEKm 429 and leverage increased by 0.2 as a consequence of the new accounting standard for leases, IFRS 16. ·Earnings per share was SEK 0.34 (0.86). ·Munters Full Potental program was launched in February. Realized savings at June 30 was SEKm 80 on an annual basis and well in line with targeted level. · Effective from the first quarter 2019, Munters is organized in two business segments, AirTech and FoodTech. A telephone conference will be held 18 July 09.00 CET. CEO Johan Ek and CFO Jonas Ågrup will present and comment on the second quarter 2019 report. Details for the telephone conference; SE: +46 8 505 583 58 UK: +44 333 300 927 US: +1 833 823 0586 The presentation can also be followed via webcast: https://tv.streamfabriken.com/munters-q2-2019 For further information, please contact: Johan Ek, CEO, Phone: +46 706 782 499 John Womack, Investor Relations, Phone: +46 706 782 499 This information is information that Munters Group AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on 18 July 2019. About Munters Munters is a global leader in energy efficient and sustainable air treatment solutions. Using innovative technologies, Munters creates the perfect climate for demanding industrial applications and has been defining the future of air treatment since 1955. Today, around 3,600 employees carry out manufacturing and sales in more than 30 countries. Munters has annual net sales of above SEK 7,2 billion and is listed on Nasdaq Stockholm. For more information, please visit www.munters.com.

Trading in Eco Wave Power’s share commences today on Nasdaq First North Stockholm

Prior to listing, Eco Wave Power completed a new share issue corresponding to approximately SEK 121.8 million. The proceeds will predominately be used for building Eco Wave Power’s first commercial wave farm, which will be a huge step towards the commercialization of wave energy and positioning it as an integral part of the world’s renewable energy mix. In addition, the funds will be used for expanding Eco Wave Power’s project pipeline, bringing more projects into the ready-to-build phase and for increasing sales and marketing activities. “We are committed to contribute in the fight against climate change and the listing of Eco Wave Power will strengthen the Company's market position and assist us in reaching our ambitious plans,” said Inna Braverman, CEO of Eco Wave Power. “We look forward to taking Eco Wave Power to the next level.” The issue in briefIssued amount: SEK 121,791,786Number of issued shares: 6,410,094Issue price: SEK 19.00 per shareShort name: EWPISIN: SE0012569663After the new share issue there are 35,249,344 shares in Eco Wave Power. AdvisorsNaventus Corporate Finance AB was the financial adviser in connection with the listing and new share issue. Avanza Bank AB and Nordnet Bank AB have been selling agents. Aktieinvest FK AB is the issuing agent. FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company’s Certified Adviser. For more information:Inna Braverman, CEOinna@ecowavepower.com+972 350 940 17 Andreas Kihlblom, CFOandreas@ecowavepower.com+46 (0)8 420 026 94 About Eco Wave PowerEco Wave Power has developed a patented, smart and cost-efficient technology for turning ocean and sea waves into green electricity. Eco Wave Power is the only wave energy company in the world, to own and operate a wave energy array, which is connected to the grid in accordance with a Power Purchase Agreement, PPA. Eco Wave Power is a Swedish company, founded in Tel Aviv, Israel, in 2011 Important informationThis document has not been approved by any regulatory authority. The document is a press release and not a prospectus and investors shall not subscribe or purchase securities referred to in this document except on the basis of the information contained in the prospectus approved by the Swedish Financial Supervisory Authority (Sw: Finansinspektionen) and made available on the Company's website. Distribution of this press release may in certain jurisdictions be subject to restrictions by law and persons who have access to this, or part of this, are required to inform themselves of, and comply with, such legal restrictions. Information in this press release shall not constitute an offer to sell shares, or a solicitation of any offer to purchase shares, nor shall there be any sale of the securities referred to herein, in any jurisdiction where such offer, solicitation of any offer to purchase, or sale would require preparing an additional prospectus or other offering documents or would not be lawful without registration or applicable exemption from registration under the securities laws of such jurisdiction. This press release does not constitute, or is part of, an offer or a solicitation of an offer to purchase or subscribe for securities in the United States. Securities referred to herein have not and will not be registered in accordance with the US Securities Act of 1933 (Securities Act) and may not be offered or sold within the United States without registration in accordance with the Securities Act, or an exemption therefrom. Securities referred to herein are not offered to the general public in the United States. Copies of this press release are not made and may not be distributed or sent, in whole or in part, directly or indirectly, to Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States or to any other jurisdiction where the distribution or issuance of this press release would be unlawful.

Interim report second quarter and first half of 2019

Second quarter 2019• Order intake rose 6% to SEK 4,653 million (4,391). For comparable units, order intake decreased by 1%.• Net sales rose 4% to SEK 4,587 million (4,390). For comparable units, net sales decreased by 1%.• Operating profit before amortisation of intangible non-current assets attributable to acquisitions (EBITA) rose 6% to SEK 574 million (543), corresponding to an EBITA margin of 12.5% (12.4%).• Profit for the quarter grew marginal to SEK 365 million (364) and earnings per share were SEK 3.02 (3.01).• Cash flow from operating activities totalled SEK 488 million (290).1 January – 30 June 2019• Order intake rose 8% to SEK 9,263 million (8,564). For comparable units the increase was 2%.• Net sales rose 8% to SEK 8,953 million (8,287). For comparable units the increase was 2%.• Operating profit before amortisation of intangible non-current assets attributable to acquisitions (EBITA) rose 12% to SEK 1,111 million (994), corresponding to an EBITA margin of 12.4% (12.0%).• Profit for the period grew 9% to SEK 715 million (657) and earnings per share were SEK 5.92 (5.43).• Cash flow from operating activities totalled SEK 656 million (294).CEO’s messageContinued good and stable demand with a high pace of acquisitions during the second quarter of 2019. Second quarterThe second quarter of 2019 was characterised by continued good and stable demand. The difference in demand between products, segments and markets has increased slightly, and in a number of segments development has levelled out, such as in construction and automotive.Order intake exceeded net sales by 1% and reached slightly more than SEK 4.6 billion, growing by a total of 6%. Sales increased by 4%. Many of our companies experienced continued favourable growth, and the UK business area had the strongest organic order growth during the quarter. However, uncertainty surrounding Brexit affected our British companies somewhat more than during the first quarter. The Measurement & Sensor Technology and Flow Technology business areas had good development driven in part by measurement technology and the marine segment. However, due to fewer investment-related projects and slightly weaker demand in certain segments, organic development for several business areas was dampened.Profitability developed favourably for most of our companies, and five of our eight business areas posted higher operating margins than in the same quarter a year ago. The EBITA margin for the Group as a whole improved slightly to 12.5% (12.4%). The strongest performance was shown in the Flow Technology and UK business areas, mainly driven by a high level of invoicing. Profitability for the Measurement & Sensor Technology business area decreased slightly and was affected by significantly lower demand in North America for one of the larger companies. Profitability remained at a good level.The market situation and the profitability continued to be challenging in the power generation segment in the Benelux business area. Work with both short-term and more strategic improvement measures continues according to plan.Cash flow from operating activities increased during the quarter to SEK 488 million (290). Tied-up capital remains at a somewhat high level as a result of high capacity utilisation in many of our companies, customers and suppliers.During the quarter Indutrade strengthened its long-term financing with a new credit facility, and a bond was issued. The Group’s financial strength creates stability and facilitates investments and acquisitions.We have continued to develop our sustainability work, and in 2019 we have carried out a training programme in sustainability for all of the Group’s managing directors. The ambition in 2019 is that all subsidiaries will conduct a materiality analysis and start defining relevant KPIs for their respective companies. AcquisitionsWe have maintained a high level of acquisition activity, and thus far during the year a total of ten acquisitions have been carried out. Five acquisitions were carried out during the second quarter: QbiQ Group (Netherlands), Adam Equipment and Datum Electronics (UK), Starke Arvid (Sweden), and Färber & Schmid (Switzerland). After the end of the quarter, the Norwegian instruments company Finisterra and the British company Natgraph, a manufacturer of customised drying and curing systems for industrial print applications, were also acquired.During 2019 we have acquired companies with combined annual sales of approximately SEK 1.2 billion. We have continued to deliver in line with our strategy by investing in successful, well-managed, marketing-leading niche companies with the potential to generate profitable growth. We have an opportunistic acquisition strategy where we pick the cream of the crop, and our future acquisition opportunities remain good.OutlookThe prevailing market situation continues to be stable, but with slightly higher variation and a flattening in demand in certain segments. We have a good spread of risk through our diversified structure with many small and flexible companies working in various niches and segments across many countries. Our MDs can independently make fast business decisions and adapt to their customers’ needs. We have a stable platform that gives us favourable prospects for sustainable, profitable growth going forward. Bo Annvik, President and CEO NoteThe information in this report is such that Indutrade AB is obligated to make public in accordance with the EU Market Abuse Act and the Swedish Securities Market Act. The information was submitted for publication by the agency of the following contact person at 8 a.m. (CEST) on 18 July 2019. This report will be commented upon as follows:The interim report will be presented via a webcast at 10.30 a.m. (CEST) on 18 July via the following link:https://event.on24.com/wcc/r/2038369/2D4C0C0BB7D88AE2860F48A2D156A068 To participate via conference call and ask questions, call:UK: +46 8 505 583 57SE: +44 333 300 9263US: +1 646 722 4904

Hansa Biopharma Interim Report January–June 2019

Highlights for the second quarter 2019 - At the 2019 American Transplant Congress (ATC), Dr. Edmund Huang of Cedars-Sinai Medical Center presented data demonstrating a significant reduction in time to transplant for highly sensitized patients treated with imlifidase over matched controls waiting under Kidney Allocations System (KAS). Dr. Huang’s session won ATC’s People’s Choice Award for the most impactful presentation. - Hansa Biopharma continued to advance imlifidase toward potential marketing authorization for enabling kidney transplantation in highly sensitized patients in the EU and the U.S. MAA is currently under review by EMA while complementary analyses are conducted in the U.S. to further illustrate the value of imlifidase over matched controls. Subsequent meeting with the FDA expected to take place in the second half of 2019. - CTA approvals received in Europe for a Phase 2 study with imlifidase in Guillain-Barré Syndrome (GBS). The initiation of the GBS study represents a continuation of the Company’s expansion outside the transplantation area into autoimmune diseases. - Divested the equity holding in Genovis, which generated gross proceeds of SEK 89m (USD 9.6m). - All resolutions passed at Hansa Biopharma’s 2019 Annual General Meeting. Two new board members, Eva Nilsagård and Mats Blom, appointed. - Spending in R&D and SG&A increased in the second quarter to SEK 46m (Q2’18 SEK 44m) and SEK 39m (Q2’18 SEK 15m) respectively as the Company continues to ramp-up in R&D and prepare for a potential launch of imlifidase in kidney transplantation. - Cash flow from operating activities for the second quarter ended at SEK -78m (SEK -49m); the Company’s cash position ended at SEK 763m end of June 2019. Cash flow was mainly driven by investments in activities related to the potential launch of imlifidase and the divestment of the Genovis equity holding. Financial Summary +-----------------------------+-----------+----------+----------+----------+|SEKm, unless otherwise stated| Q2 2019| Q2 2018| H1 2019| H1 2018|+-----------------------------+-----------+----------+----------+----------+|Net Revenue | 0.6| 0.9| 1.5| 1.5|+-----------------------------+-----------+----------+----------+----------+|SG&A expenses | -38.5| -14.8| -67.9| -30.0|+-----------------------------+-----------+----------+----------+----------+|R&D expenses | -45.6| -44.0| -88.1| -75.5|+-----------------------------+-----------+----------+----------+----------+|Other operating | -0.1| -0.8| -1.2| -1.0||income/expenses | | | | |+-----------------------------+-----------+----------+----------+----------+|Operating profit/loss | -83.7| -58.8| -156.4| -105.4|+-----------------------------+-----------+----------+----------+----------+|Net profit/loss | -82.4| -58.8| -154.9| -105.3|+-----------------------------+-----------+----------+----------+----------+|Cash flow from operating | -78.0 | -49.0| -179.6| -93.1||activities | | | | |+-----------------------------+-----------+----------+----------+----------+|Cash and short term | 762.7 | 534.2| 762.7| 534.2||investments June 30, 2019 | | | | |+-----------------------------+-----------+----------+----------+----------+|Shareholders’ equity, June | 755.4 | 543.0| 755.4| 543.0||30, 2019 | | | | |+-----------------------------+-----------+----------+----------+----------+|EPS before and after dilution| -2.06 | -1.55| -3.87| -2.77||June 30, 2019 (SEK) | | | | |+-----------------------------+-----------+----------+----------+----------+|Number of outstanding shares,|40,026,107 |38,083,125|40,026,107|38,083,125||June 30, 2019 | | | | |+-----------------------------+-----------+----------+----------+----------+|Weighted average number of |40,026,107 |37,976,440|40,014,056|37,962,440||shares before and after | | | | ||dilution | | | | |+-----------------------------+-----------+----------+----------+----------+|Number of employees, June 30,| 60 | 40| 60| 40||2019 | | | | |+-----------------------------+-----------+----------+----------+----------+ Søren Tulstrup, President and CEO, comments“Hansa Biopharma’s evolution into a commercial stage biopharmaceutical company continues according to plan. During the second quarter, our organization grew its footprint in both Europe and the U.S., and we continued to increase our engagement with the broader healthcare community within transplantation, autoimmune diseases and beyond. I recently returned from the 2019 American Transplant Congress (ATC) in Boston where I noted a high level of excitement around Hansa Biopharma, our technology platform and our pipeline. Imlifidase was highlighted in three presentations during the conference including a plenary presentation by Dr. Edmund Huang from Cedars-Sinai Medical Center in Los Angeles. Dr. Huang presented data demonstrating that imlifidase significantly reduces the time to transplant for patients treated with imlifidase compared to matched controls on the kidney transplantation waitlist. This session won the ATC’s People’s Choice Award as the most impactful to the transplant community, further validating the transformative potential of imlifidase and our technology. In the U.S., we are seeing signs from the current administration that increasing the kidney transplant rate and improving equity of access to this lifesaving therapy is high on the political agenda as part of a goal to significantly increase survival rate and quality of life for dialysis patients and at the same time reduce the > $100 billion spent annually by the U.S. government to treat chronic kidney disease and end-stage renal disease. If approved, imlifidase could be a key driver in helping thousands of highly sensitized patients get off of dialysis by enabling transplantation. The regulatory review process for imlifidase in Europe is progressing following the acceptance of our Marketing Authorization Application (MAA) in February. The timeline for the process is 210 working days plus clock stops, as we have communicated earlier. Meanwhile, in the U.S. we are conducting complementary analyses with respect to transplantability for the highly sensitized patients participating in the Phase 2 studies with imlifidase compared to matched controls from the U.S. transplant registry in order to further illustrate the value of imlifidase in the U.S. healthcare system. Once completed, we will schedule a subsequent meeting with the U.S. Food and Drug Administration, which is expected to take place in the second half of 2019. Overall, we continue to execute on our strategic agenda, with solid progress across our pipeline, including the recent initiation of two Phase 2 studies in Guillain-Barré Syndrome (GBS) and acute Antibody Mediated Rejection in kidney transplantation. In April, we decided to divest our equity holding in Genovis. The transaction provided a profitable exit from a non-core investment and generated funds that will help accelerate the development of our pipeline of clinical stage drug candidates as well as our next generation NiceR program for repeat dosing. We envision a world where all patients with rare immunologic diseases can lead long and healthy lives. To help achieve this vision we are building a high-performance organization to exploit our unique immunomodulating technology platform to develop innovative lifesaving and life altering therapies, bring these to the patients with rare diseases who need them, and generate value to society at large.” Søren TulstrupPresident and CEO of Hansa Biopharma This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below at 08:00am CET on July 18, 2019.

NENT Group becomes home of ISU ice skating for next four seasons

· NENT Group to show exclusive live coverage of ISU speed skating and figure skating events from autumn 2019 · Skating rights to complement NENT Group’s Alpine and Nordic winter sports rights from 2021 · NENT Group shows more than 50,000 hours of the world’s best live sporting action every year Nordic Entertainment Group (NENT Group), the Nordic region’s leading entertainment provider, has acquired the exclusive Nordic media rights to the main International Skating Union (ISU) competitions up to and including the 2022/2023 season. From autumn 2019, nearly 400 hours of world-class speed skating and figure skating from ISU events around the world will be shown live every season on NENT Group’s Viaplay and Viafree streaming services and Viasat pay-TV channels in combination with substantial exposure on NENT Group’s free-TV channels. NENT Group will offer viewers in Sweden, Norway, Finland and Denmark exclusive live coverage of the following ISU events: ·  ISU Speed Skating Championships ·  ISU World Cup Speed Skating ·  ISU Short Track Speed Skating Championships ·  ISU World Cup Short Track Speed Skating ·  ISU Figure Skating Championships ·  ISU Grand Prix of Figure Skating ·  ISU World Synchronised Skating Championships Skating attracts a large, passionate and growing audience across the Nordic region, which has produced some of the sport’s top stars. Norwegian speed skater Håvard Holmefjord Lorentzen won 500 metres gold and 1000 metres silver at the 2018 Pyeongchang Winter Olympics; Norwegian Sverre Lunde Pedersen won silver at the 2018 World Allround Speed Skating Championship; and Norway’s men’s team are the reigning Olympic team pursuit champions and 500 metres relay world champions. Johann Olav Koss, winner of three speed skating gold medals at the 1994 Lillehammer Winter Olympics, is one of Norway’s most famous athletes and was twice named Norwegian Sportsperson of the Year (1991 and 1994). Sweden’s Tomas Gustafson, meanwhile, dominated speed skating throughout the 1980s, winning three Olympic gold medals. In figure skating, Alexander Majorov and Anita Östlund from Sweden and Viveca Lindfors (a bronze medalist at the most recent European Championships) and Emmi Peltonen from Finland all currently participate at the highest level of ISU competition. The Nordic region is also set to host at least one ISU event in each of the coming seasons. Hamar in Norway will host the Combined ISU World Sprint & World Allround Speed Skating Championships in February 2020 and the ISU World Speed Skating Championships in March 2022, while Stockholm will host the ISU World Figure Skating Championships in March 2021. In April 2019 , NENT Group announced a long-term, pan-Nordic deal to become the home of Alpine and Nordic winter sports from 2021. Anders Jensen, NENT Group President and CEO: “This landmark agreement is yet another milestone for NENT Group as we continue to redefine the streaming and TV viewing experience for sports fans across the Nordic region. ISU skating attracts millions of viewers and is an ideal complement to our recently acquired winter sports rights. The planet’s fastest and most skilled skaters, at least three ISU competitions in the Nordic region, and NENT Group’s world-class commentary and production capabilities mean our viewers have even more to look forward to over the next four seasons.” Bruno Marty, Senior Vice President of Winter Sports at Infront, the brokers of the agreement: “This marks one of our first deals in our new partnership with ISU. We are proud to have brought NENT Group on board, who with their intensifying commitment to winter sports and diversity of platforms and outlets will surely help us further elevate interest in these thrilling sports. The distribution on NENT Group’s streaming platforms and substantial exposure on free-TV will enable access to a large, passionate and growing audience across the Nordic region.” NENT Group brings millions of fans closer to the sports they love – every shot, every goal, every touchdown, every putt, every punch, every lap, every time. NENT Group shows more than 50,000 hours of the world’s best live sporting action every year on its streaming services and TV channels, including NHL and KHL ice hockey, UEFA Champions League, Premier League, Bundesliga and Ligue 1 football, Formula 1, IndyCar, NFL American football, boxing, UFC, tennis, basketball, handball and golf. **** NOTES TO EDITORS Nordic Entertainment Group AB (publ) (NENT Group) is the Nordic region’s leading entertainment provider. We entertain millions of people every day with our streaming services, TV channels and radio stations, and our production companies create content that is experienced around the world. We make life more entertaining by telling stories, touching lives and expanding worlds – from live sports, movies and series to music and original shows. Headquartered in Stockholm, NENT Group is listed on Nasdaq Stockholm (‘NENT A’ and ‘NENT B’). Contact us:press@nentgroup.com (or Nicholas Smith, Acting Head of Public Relations; +46 73 699 26 95)investors@nentgroup.com (or Stefan Lycke, Head of Investor Relations; +46 73 699 27 14)Download high-resolution photos: Flickr Follow us:nentgroup.com  / Facebook  / Twitter  / LinkedIn  / Instagram Privacy policy:To read NENT Group’s privacy policy, click here 

HAMLET Pharma Announces Results of First Major Clinical Trial for a New Cancer Killing Molecule

Alpha1H triggered significant shedding of cells in all tumor patients, who received the treatment (p< 0.0001). In addition, Alpha1H triggered the excretion of whole tumor fragments into the urine (p<0.0001), illustrating the potent effect compared to the placebo group.  Alpha1H triggered cell death in the tumor, as shown by cytolysis and apoptosis, a beneficial form of cell death. These findings support the key mechanisms of action of Alpha1H discovered in the laboratory and the successful translation from the laboratory to the clinic.  Carefully selected safety variables were recorded according to safety guidelines. The effects of Alpha1H occurred without drug-related side effects in the patients, consistent with the lack of toxicity observed in animal models of bladder cancer.   The clinical trial of 40 patients (20 placebo and 20 with treatment who received 6 infusions over 22 days) has been a technical success, due to the competence and commitment of the different study teams involved. A team of experts at the Motol University Hospital in Prague handled patient enrolment, clinical care, pathology assessments and treatment. The study was monitored by a highly renowned, clinical trial CRO in Prague. Scientific coordination was from Lund University, where research sample analysis was handled and molecular information obtained. Additional study variables will be communicated as soon as data is available. “ This is a bench-to-bedside moment and we are grateful to all, who have made this possible. The results inspire us to continue the efforts making Alpha1H available to cancer patients” says Catharina Svanborg, founder, CMO and chairman of the board of Hamlet Pharma Ltd.   “ This is a very important milestone for the company. We need more evidence but hopefully this could be the gentle chemotherapy of the future,” says Mats Persson, CEO of Hamlet Pharma Ltd.  

Half-year Financial Report of KONE Corporation for January-June 2019

KONE Corporation, stock exchange release, July 18, 2019 at 12.30 p.m. EEST Half-year Financial Report of KONE Corporation for January-June 2019 Continued strong orders received, well on track to meet full-year targets April-June 2019 -       Orders received grew by 9.0% to EUR 2,310 (4–6/2018: 2,119) million. At comparable exchange rates, orders grew by 8.1%. -       Sales grew by 9.0% to EUR 2,541 (2,331) million. At comparable exchange rates, sales grew by 7.9%. -       Operating income (EBIT) was EUR 306.5 (280.5) million or 12.1% (12.0%) of sales. The adjusted EBIT was EUR 319.6 (300.4) million or 12.6% (12.9%) of sales.* IFRS 16 had a positive impact of EUR 2 million to the operating income. -       Cash flow from operations (before financing items and taxes) was EUR 323.5 (366.2) million. IFRS 16 had a positive impact of EUR 29 million to the cash flow from operations. January-June 2019 -       Orders received grew by 9.4% to EUR 4,404 (1–6/2018: 4,027) million. At comparable exchange rates, orders grew by 8.0%. -       Sales grew by 9.2% to EUR 4,740 (4,339) million. At comparable exchange rates, sales grew by 7.7%. -       Operating income (EBIT) was EUR 521.8 (492.0) million or 11.0% (11.3%) of sales. The adjusted EBIT was EUR 548.0 (518.7) million or 11.6% (12.0%) of sales.* IFRS 16 had a positive impact of EUR 4 million to the operating income. -       Cash flow from operations (before financing items and taxes) was EUR 701.1 (545.2) million. IFRS 16 had a positive impact of EUR 58 million to the cash flow from operations. KONE has adopted the new IFRS 16 and IFRIC 23 effective January 1, 2019 using the modified retrospective approach and the comparative figures have not been restated. Business outlook (specified) In 2019, KONE’s sales is estimated to grow by 4–7% at comparable exchange rates as compared to 2018. The adjusted EBIT is expected to be in the range of EUR 1,170–1,250 million, assuming that foreign exchange rates would remain at the July 2019 level. Foreign exchange rates are estimated to impact EBIT positively by around EUR 20 million. KONE previously estimated its sales to grow by 3–7% at comparable exchange rates as compared to 2018. The adjusted EBIT was expected to be in the range of EUR 1,160–1,260 million, assuming that foreign exchange rates would have remained at the April 2019 level. Foreign exchange rates were estimated to impact EBIT positively by around EUR 30 million. Key figures Key figures  4–6/2019 4–6/2018 Change 1–6/ 1–6/ Change 1–12 2019 2018 /2018 Orders received MEUR 2,310.1 2,118.6 9.0% 4,404.1 4,027.2 9.4% 7,797.0Order book MEUR 8,407.1 7,915.3 6.2% 8,407.1 7,915.3 6.2% 7,950.7Sales MEUR 2,540.8 2,330.6 9.0% 4,739.6 4,338.6 9.2% 9,070.7Operating income MEUR 306.5 280.5 9.3% 521.8 492.0 6.1% 1,042.4(EBIT)Operating income % 12.1 12.0 11.0 11.3 11.5margin (EBITmargin)Adjusted EBIT* MEUR 319.6 300.4 6.4% 548.0 518.7 5.6% 1,112.1Adjusted EBIT % 12.6 12.9 11.6 12.0 12.3margin*Income before tax MEUR 310.2 290.5 6.8% 530.6 514.1 3.2% 1,087.2Net income MEUR 238.8 223.7 6.8% 408.6 395.9 3.2% 845.2Basic earnings EUR 0.46 0.43 5.8% 0.78 0.77 2.3% 1.63per shareCash flow from MEUR 323.5 366.2 701.1 545.2 1,150.1operations(beforefinancingitems and taxes)Interest-bearing MEUR -973.3 -1,254.8 -973.3 -1,254.8 -1,704.0net debt Equity ratio % 42.2 45.5 42.2 45.5 49.9Return on equity % 28.6 28.0 28.6 28.0 27.7Net working MEUR -805.4 -725.7 -805.4 -725.7 -757.8capital(includingfinancing itemsand taxes)Gearing % -36.6 -47.7 -36.6 -47.7 -55.3 * In September 2017, KONE introduced a new alternative performance measure, adjusted EBIT, to enhance comparability of the business performance between reporting periods during the Accelerate program. Restructuring costs related to the Accelerate program are excluded from the calculation of the adjusted EBIT. Henrik Ehrnrooth, President and CEO: “In the second quarter, we had a good performance on many fronts. I’m especially pleased that our orders received continued to grow at a very good rate and that the margin of orders is now improving. Sales growth was balanced with all businesses and regions contributing to the positive development. We have returned to a solid growth path in adjusted EBIT this year and the actions we have taken to improve our margins are starting to produce results. While our adjusted EBIT margin was still slightly below that of last year, we are going in the right direction. Overall, our results were in line with our expectations and consistent with our full-year targets. The solid growth in orders received, combined with the improving margin of orders received, is a demonstration of our overall competitiveness. We have continued to make good progress in driving improved differentiation with our solutions and services. In addition to our strong offering, one of our competitive edges continues to be consistent project execution as well as the service mindset of our people. We have continued to build on these capabilities with the objective to be the preferred partner for our customers. This year, we have focused among other things on further improving the quality of our field operations. We have developed our installation resource and project management, processes and tools to ensure that we can consistently do what we promise for our customers with improved quality and productivity. We have also continued to strengthen our network of training facilities, so that our employees have the necessary competences to deliver increasingly complex projects. I want to thank all KONE employees, for their hard work and accountability in strengthening these competitive advantages. We have now half a year behind us with strong development in both orders received and sales. As a result, we can specify our full year guidance. We expect sales to grow by 4–7% at comparable exchange rates and the adjusted EBIT to be in the range of EUR 1,170–1,250 million in 2019. Our industry has faced several headwinds over past years. Our industry has faced several headwinds over past years. I’m pleased that the actions that we have taken and our strategic direction have strengthened us in this environment, and our result is again improving.” Operating environment in April-June 2019 The global new equipment market grew slightly in units compared to the second quarter of 2018. In Asia-Pacific, the new equipment market grew slightly. In China, infrastructure segment developed positively while residential segment was rather stable and nonresidential segment declined. Government continued to balance between supporting the economic activity and curbing speculation in the residential market. Overall, the Chinese new equipment market grew slightly in units. In the rest of Asia-Pacific, the new equipment markets were stable with growth in some Southeast Asian countries and in India and a decline in Australia. In the EMEA region, the new equipment market was stable. The new equipment market in Central and North Europe grew slightly from a high level. In South Europe, the market declined slightly with varying development among the countries. In the Middle East, the market declined driven by Turkey, in particular. In North America, the new equipment market was stable on a high level. Global service markets continued to develop positively. Both the maintenance and the modernization markets saw growth across the regions, with the strongest rate of growth seen in Asia-Pacific and a more moderate development in Europe and North America. Pricing trends remained varied during April–June. In China, competition remained intense but pricing was rather stable in the new equipment market. In the EMEA region, the pricing environment was mixed. The Middle East region continued to be characterized by intense competition, while there were some signs of improving pricing environment in Europe. In North America, competition intensified somewhat. Operating environment in January-June 2019 The global new equipment market grew slightly in units compared to the first half of 2018. In Asia-Pacific, the new equipment market grew slightly. In China, infrastructure segment developed positively while residential segment was rather stable and non-residential segment declined. Government continued to balance between supporting the economic activity and curbing speculation in the residential market. Overall, the Chinese new equipment market grew slightly in units. In the rest of Asia-Pacific, the new equipment markets were stable with growth in some Southeast Asian countries and in India and a decline in Australia. In the EMEA region, the new equipment market was stable. The new equipment market in Central and North Europe grew slightly from a high level. In South Europe, the market was stable. In the Middle East, the market continued to decline. In North America, the new equipment market was stable on a high level. Global service markets continued to develop positively. Both the maintenance and the modernization markets saw growth across the regions, with the strongest rate of growth seen in Asia-Pacific and a more moderate development in Europe and North America. Pricing trends remained varied during January–June. In China, competition remained intense but pricing was rather stable in the new equipment market. In the EMEA region, the pricing environment was mixed. The Middle East region continued to be characterized by intense competition, while there were some signs of improving pricing environment in Europe. In North America, competition intensified somewhat. Market outlook 2019 The new equipment market is expected to be relatively stable or to grow slightly. In China the market is expected to be relatively stable or to grow slightly in units ordered, while in the rest of the Asia-Pacific, the market is expected to grow slightly. The new equipment markets in North America and the Europe, Middle East and Africa region are expected to be rather stable. Maintenance markets are expected to see the strongest growth rate in Asia-Pacific and to grow slightly in other regions. The modernization market is expected to grow slightly in North America and in the Europe, Middle East and Africa region and to develop strongly in Asia-Pacific. Business outlook 2019 (specified) In 2019, KONE’s sales is estimated to grow by 4–7% at comparable exchange rates as compared to 2018. The adjusted EBIT is expected to be in the range of EUR 1,170–1,250 million, assuming that foreign exchange rates would remain at the July 2019 level. Foreign exchange rates are estimated to impact EBIT positively by around EUR 20 million. The outlook is based on KONE’s maintenance base and order book as well as the market outlook. KONE has a solid order book for 2019 in the new equipment business and the service business is expected to continue to grow. Targeted pricing and productivity improvement actions are expected to support profitability together with the savings from the Accelerate program. High component and labor costs together with trade tariffs are the main headwinds for the adjusted EBIT in 2019. The impact of high raw material prices and trade tariffs is estimated to be less than EUR 50 million. KONE previously estimated its sales to grow by 3–7% at comparable exchange rates as compared to 2018. The adjusted EBIT was expected to be in the range of EUR 1,160–1,260 million, assuming that foreign exchange rates would have remained at the April 2019 level. Foreign exchange rates were estimated to impact EBIT positively by around EUR 30 million. Press and analyst meetings A meeting for the press, conducted in Finnish, will be held on Thursday, July 18, 2019 at 2:15 p.m. EEST. A meeting for analysts, conducted in English, will begin at 3:45 p.m. EEST and will be available as a live webcast on www.kone.com/investors. An on-demand version of the webcast will be available later the same day. The meeting can also be joined via a telephone conference. U.S.: +1 323-794-2551UK: +44 (0)330 336 9105Finland: +358 (0)9 7479 0361Participant code: 9926738 Both meetings will take place in KONE Building, located at Keilasatama 3, Espoo, Finland. For further information, please contact: Sanna Kaje, Vice President, Investor Relations, tel. +358 204 75 4705 Sender: KONE Corporation Henrik EhrnroothPresident and CEO Ilkka HaraCFO About KONE At KONE, our mission is to improve the flow of urban life. As a global leader in the elevator and escalator industry, KONE provides elevators, escalators and automatic building doors, as well as solutions for maintenance and modernization to add value to buildings throughout their life cycle. Through more effective People Flow®, we make people's journeys safe, convenient and reliable, in taller, smarter buildings. In 2018, KONE had annual sales of EUR 9.1 billion, and at the end of the year over 57,000 employees. KONE class B shares are listed on the Nasdaq Helsinki Ltd. in Finland. www.kone.com

Epiroc interim report Q2

CEO comments  Record-breaking quarterThe second quarter 2019 continued with positive deve-lopment for revenues and profit. Revenues increased 8% to an all-time high at SEK 10,626 million with an organic growth of 3%. The operating profit reached a record of SEK 2,263 million, up 25% compared to the previous year. The operating margin was 21.3% and excluding change in provision for long-term incentive programs, the operating margin was 21.7%. The organic growth and our efficiency actions had positive effects on our operating profit and margin, and our flow-through improved. We also continue to have tailwind from currency. Operating cash flow improved both compared to the previous quarter and year-on-year. Demand expected to remain at a good levelThe activity and production in the mining industry continued to be robust at a high level and our customers are investing in new equipment, even if they continue to be cautious on larger investments. The demand from the infrastructure industry was also healthy.Orders received were record high at SEK 10,553 million, supported by acquisitions and currency. Organic order intake declined 4% compared to the strong Q2 2018. As expected, the order volumes for Epiroc’s equipment remained at a similar level as in the last three quarters, but did not reach the high level of Q2 2018. The aftermarket business continued to be strong, reflecting the activity level in the market, both in mining and infrastructure. The service business had an organic order growth of 7% and Tools & Attachments had a solid order intake.Going forward, we do not see any clear signs that the current market situation will change. Hence, we reiterate our view that the demand will remain at the current level in the near term, however noting that Q3 in general is slightly weaker than Q2. Actions to improve performanceWe are saddened by a tragic work-related fatal accident in India. Safety is always a priority and the injury frequency rate is decreasing. To further improve, we have launched a global safety awareness initiativeIn Tools & Attachments, we continued to see positive effects from our efficiency actions. In line with our stated ambition to continuously prune our product portfolio and exit non-core areas, we have signed an agreement to divest our geotechnical consumables product line. Our supply-chain program for parts and consumables is progressing according to plan with gradual improvement of availability, transport costs and inventory levels. In the quarter, we decided to invest in a new heat treatment plant for rock drills in Örebro, Sweden, to ensure that we continue to improve rock drill quality and performance. The plant will also increase capacity and reduce costs. Leadership in automation andbattery-electric vehiclesWe have a market-leading offering in automation, connectivity and battery-electric vehicles and the customer interest in, and demand for these solutions is growing quickly. In the quarter, we launched 6th Sense. This is our new offering of solutions to enable customers to optimize processes by connecting machines, systems and people using automation, information management and system integration, and to achieve higher production at lower operating costs.Currently we have more than 2,500 connected machines, a number that is increasing rapidly. For example, for production drill rigs, the number of connected machines have doubled in the last year. We also see that connectivity is an enabler for increased utilization. In underground drilling more than 550 of our drill rigs are equipped for complete automation of the drilling process. In surface drilling, we have the largest installed base of autonomous rotary drill rigs, and the world’s first fully autonomous SmartROC D65 down-the-hole drill rig is now operating in Canada. Also, the interest in our next generation under-ground battery-electric vehicles continues to be strong and we received more orders for these machines in the quarter. First anniversaryOn June 18, we celebrated our 1-year anniversary as a listed company. We recently concluded our first employee survey, which showed that our employees are engaged and view Epiroc as a great place to work. I am proud of the drive and commitment of our organization as we continue to strengthen our customer offerings and im-prove our efficiency, agility and resilience. Per LindbergPresident and CEOA presentation and teleconference will be held today at 14.00 CEST. Information is available at epirocgroup.com/en/investors .

Sobi completes acquisition of emapalumab and related assets

Following approvals from relevant competition authorities Swedish Orphan Biovitrum AB (publ)  (Sobi™) (STO:SOBI) has completed the acquisition of the newly established company owning emapalumab and related assets, as announced on 12 June 2019. The acquisition means that the previously announced exclusive licence agreement with Novimmune will be superseded. Through the acquisition of emapalumab, Sobi gains access to: · All assets relating to emapalumab including intellectual property, patent rights, data and know-how · All relevant and highly experienced employees involved in the clinical and biopharmaceutical development of emapalumab · Options for the shared financial rights to NI-1701 and NI-1801, two product candidates in the field of immuno-oncology · A priority review voucher within the US Food & Drug Administration’s priority review programme, which offers companies investing in orphan drugs a cost reduction for the application fee for future products and shortens the review period. The voucher can be used or sold by Sobi. The consideration for the acquisition is CHF 515 M (SEK 4,897 M), of which CHF 400 M was previously committed in the exclusive licence agreement for emapalumab. The acquisition is expected to be earnings neutral in 2019. The acquisition is debt-financed, with new credit facilities made available by BNP Paribas, Danske Bank, Skandinaviska Enskilda Banken and Svenska Handelsbanken. ---- About emapalumabEmapalumab is a monoclonal antibody (mAb) that binds to and neutralises interferon gamma (IFNγ). In the US, emapalumab is indicated for paediatric (newborn and older) and adult primary haemophagocytic lymphohistiocytosis (HLH) patients with refractory, recurrent or progressive disease, or intolerance to conventional HLH therapy. Emapalumab is the first and only medicine approved in the US for primary HLH, a rare syndrome of hyperinflammation that usually occurs within the first year of life and can rapidly become fatal unless diagnosed and treated. The FDA approval is based on data from the phase 2/3 studies (NCT01818492 and NCT02069899). Emapalumab is indicated to be administered through intravenous (IV) infusion over one hour twice per week until haematopoietic stem cell transplant (HSCT). Visit www.gamifant.com for more information, including full US prescribing Information. Emapalumab was developed and submitted for approval to the FDA by Novimmune. Sobi acquired the global rights to emapalumab from Novimmune through an exclusive licensing agreement announced in July 2018, which is now superseded by the above announced acquisition. About SobiAt Sobi, we are transforming the lives of people affected by rare diseases. As a specialised international biopharmaceutical company, we provide sustainable access to innovative therapies in the areas of haematology, immunology and specialty care. We bring something rare to rare diseases – a belief in the strength of focus, the power of agility and the potential of the people we are dedicated to serving. The hard work and dedication of our approximately 1,050 employees around the globe has been instrumental in our success across Europe, North America, the Middle East, Russia and North Africa, leading to total revenues of SEK 9.1 billion in 2018. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at www.sobi.com. For more information please contact Paula Treutiger, Head of Communication & Investor Relations0733 666 599paula.treutiger@sobi.com Linda Holmström, Corporate Communication & Investor Relations0708 734 095linda.holmstrom@sobi.com

Interim report April - June 2019

“During the second quarter of the year, sales increased by 7 percent, of which acquired units contributed 3 percentage points. Organic sales were unchanged compared with the year-earlier quarter, with variations between geographies. North and South America generally continued to perform well for us during the quarter, while the trend in Europe and Asia was more tentative, with increased uncertainty. Overall, The Group's earnings trend was stable, with the underlying EBIT increasing by 2 percentage points. The rate of investment remained at a high level, which reflects the ambition to further sharpen our market positions in most segments. The trend shifted during the period: the quarter began cautiously in April, an improvement was noted in May, while there was a downturn once again in June. Our interpretation is that intensified political tension and escalated global trade conflicts are increasingly impacting the sentiment in several markets, meaning that the near future is difficult to forecast. Our understanding is that we will see increasing differences in the development between various market segments, but that overall demand will remain at the same level for the next quarter. In this scenario, however, we anticipate a disadvantageous sales mix for us, which is expected to have a somewhat negative impact on the earnings trend. To address an expected decline in demand in parts of the Group, we took a proactive approach at the end of the quarter and initiated measures to reduce costs, primarily through targeted personnel reductions. These initiatives will generate nonrecurring costs and our estimate is that the restructuring costs for the year will amount to approximately SEK 500 M, which is an increase of about SEK 250 M compared with information provided earlier. Our largest business area, Trelleborg Sealing Solutions, noted unchanged organic sales, but with distinct differences between various segments. Deliveries to the automotive industry were declining, sales to the aerospace industry and the healthcare & medical segment remained strong, while sales to general industry were slightly weaker than during the first quarter of the year. Demand for tires for the agriculture sector declined during the quarter, probably impacted by the intensified trade conflicts, but also by the weather conditions in certain markets. The market statistics published after the end of the period displayed a significant decline in the European aftermarket for agricultural tires during the quarter. Generally, we continued to grow our market shares, particularly in the OE segment, but this did not offset the decline in the aftermarket and also created a negative sales mix for Trelleborg Wheel Systems. Accordingly, the business area initiated targeted activities during the quarter to adapt to the lower level of demand. Trelleborg Industrial Solutions continues to note healthy growth, and most market segments performed positively. As previously forecast, profitability continued to be affected by inefficiency in a Czech production unit. Work is continuing to improve the situation, through targeted investments and cost adaptations. Our oil & gas operation and major infrastructure construction projects are now recovering after a prolonged period of weak market conditions. Order intake was favorable during the quarter and our evaluation stands that the business area will recognize a positive organic sales trend in the second half of the year and achieve profit during the fourth quarter. For the third quarter, our overall assessment is that demand will be in line with the second quarter of the year, but with a disadvantageous sales mix that is expected to have a somewhat negative effect on earnings. We are continuing to carefully monitor economic developments and maintain a high level of preparedness to manage fluctuating market conditions,” says Peter Nilsson, President and CEO. Second quarterNet sales for the second quarter of 2019 rose 7 percent to SEK 9,361 M (8,786). Organic sales were in line with the preceding year for the Group in its entirety, and declined 1 percent, excluding project deliveries. EBIT, excluding items affecting comparability, amounted to SEK 1,321 M (1,293), which was equivalent to an EBIT margin of 14.1 percent (14.7). Items affecting comparability for the quarter were a negative SEK 118 M (neg: 32) and pertained to restructuring costs. At the end of the quarter, an action program was launched to address an anticipated downturn in certain market segments. Restructuring costs for the full year will amount to approximately SEK 500 M, an increase of about SEK 250 M compared with information provided earlier. Earnings per share, excluding items affecting comparability, totaled SEK 3.36 (3.40). For the Group in its entirety, earnings per share amounted to SEK 2.98 (3.31). Operating cash flow amounted to SEK 1,052 M (1,074). The cash conversion ratio was 69 percent (83). Market outlook for the third quarter 2019Demand is expected to be on a par with the second quarter of 2019, adjusted for seasonal variations. Market outlook from the interim report published on April 26, 2019, relating to the second quarter of 2019Demand is expected to be on a par with the first quarter of 2019, adjusted for seasonal variations. For further information, please contact: Media: Vice President Media Relations Karin Larsson, +46 (0)410 67015, +46 (0)733 747015, karin.larsson@trelleborg.comInvestors/analysts: Vice President IR Christofer Sjögren, +46 (0)410 67068, +46 (0)708 665140, christofer.sjogren@trelleborg.comThis information is information that Trelleborg AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 1:00 p.m. CET on July 18, 2019. This is a translation of the company’s Interim Report in Swedish. 

Nolato Q2 2019: Normalised inventory situation at Integrated Solutions

Nolato AB has today published its interim report for the second quarter of 2019. · Sales totalled SEK 1,987 million (2,302) · Operating profit (EBITA) was SEK 233 million (266) · EBITA margin of 11.7% (11.6) · Profit after tax was SEK 180 million (204) · Basic earnings per share totalled SEK 6.82 (7.75) · Cash flow after investments amounted to SEK 178 million (352) · Sustained strong financial position Medical Solutions sales rose to SEK 634 million (562). Adjusted for currency, sales increased by a strong 9%. Operating profit (EBITA) rose to SEK 82 million (73). The EBITA margin was 12.9% (13.0). “Volumes increased in both the Medical Devices and Pharma Packaging sectors, and most product areas experienced positive growth,” commented Nolato President and CEO Christer Wahlquist. Integrated Solutions sales decreased to SEK 821 million (1,186); adjusted for currency, this was a decrease of 35%. Operating profit (EBITA) decreased to SEK 107 million (140). The EBITA margin grew to a very strong 13.0% (11.8). “Following inventory adjustments in Vaporiser Heating Products (VHP) late last year and in the first quarter of this year, the inventory situation for VHP has now normalised,” noted Christer Wahlquist. “Growth in the EMC area was excellent, while volumes for mobile phones were weak in the quarter.” Industrial Solutions sales were SEK 541 million (554); adjusted for currency and Group structure, this was a decrease of 3%. Operating profit (EBITA) decreased to SEK 46 million (55) and the EBITA margin to 8.5% (9.9). “The lower margin was due to continued unsatisfactory efficiency of one production facility, combined with lower volumes in the hygiene area,” said Christer Wahlquist. “Measures implemented to enhance efficiency are gradually leading to an improvement in the margin.” Nolato retains a healthy financial position, with an equity/assets ratio of 47% (43) and net financial assets of SEK 190 million (253). –––––– For further information, please contact:Christer Wahlquist, President and CEO, +46 (0)705 804848Per-Ola Holmström, CFO, +46 (0)705 763340 Nolato is a Swedish group with operations in Europe, Asia and North America. We develop and manufacture products in polymer materials such as plastic, silicone and TPE for leading customers within medical technology, pharmaceuticals, consumer electronics, telecom, automotive, hygiene and other selected industrial sectors. Nolato’s shares are listed on Nasdaq Stockholm in the Large Cap segment, where they are included in the Industrials sector. www.nolato.com  Prior to publication this information constituted inside information that Nolato AB is obliged to publish pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. This information was submitted through the agency of the above contact persons for publication on 18 July 2019 at 2.00 p.m. CET.

TOMRA: 2Q 2019 - Sound performance in both Collection and Sorting

The second quarter 2019 was a robust quarter, fueled by strong momentum in Recycling for TOMRA Sorting Solutions and growth in newly entered deposit markets for TOMRA Collection Solutions. Revenues in the second quarter 2019 amounted to 2,318 MNOK up from 2,128 MNOK in second quarter last year, representing a growth of 8%. Organic, currency adjusted revenues were up 6% for the group, stable for TOMRA Collection Solutions and 11% for TOMRA Sorting Solutions. Gross margin was 45% in the quarter, up from 43% in second quarter 2018, due to improved margins for both TOMRA Collection Solutions and TOMRA Sorting Solutions. Operating expenses totaled 689 MNOK in the second quarter, up from 609 MNOK in second quarter last year. The increase was related to higher general business activity, future oriented ramp-up activities and currencies. EBITA was 352 MNOK in second quarter 2019 versus 307 MNOK in second quarter 2018. Cash flow from operations in second quarter 2019 equaled 45 MNOK, compared to 126 MNOK in second quarter 2018, with 69 MNOK in positive effect from IFRS 16. “We are overconsuming our planet’s resources and drastic measures must be taken to move away from a “take, make and dispose” mentality. TOMRA has a clear vision for our contribution to building a circular economy, combining the use of technology for automated collection systems and advanced sorting solutions. However, technology alone is not enough, various stakeholder groups must join forces to make real impact. That is why TOMRA is taking a thought leadership role by facilitating industry collaboration through our own initiatives such as TOMRA Leads and being core members of global initiatives such as Alliance to End Plastic Waste”, says Stefan Ranstrand, TOMRA President and CEO. Collection Solutions: Stable business with upside from Australia Revenues in the business area equaled 1,088 MNOK in the second quarter, up from 1055 MNOK in second quarter last year. After adjustment for currency changes, revenues were unchanged. Gross margin was 43%, up from 42% from last year. Operating expenses amounted to 288 MNOK, up from 259 MNOK last year, due to currencies and preparations for new markets. EBITA was 183 MNOK compared to 182 MNOK second quarter last year. On 12 June 2019, the EU Single Use Plastic Directive was published in the official journal of the EU, which included a 90% recycling target on plastic bottles by 2029. The member states now have two years to transpose the directive into their national laws. Sorting Solutions: Solid revenue and margin growth Revenues equaled 1,230 MNOK in second quarter 2019, up 11% in local currencies. Gross margin was 46%, up from 44% same period last year due to improved margins in all business streams. Operating expenses were up from 330 MNOK to 377 MNOK, due to higher activity and currency. EBITA increased from 145 MNOK in second quarter 2018 to 193 MNOK in second quarter 2019, positively influenced by higher revenues and improved gross margin. Order intake amounted to 1,111 MNOK, compared to 1,144 MNOK same period last year. The order intake was slightly up in Recycling and somewhat weaker in Food. The order backlog ended at 1,345 MNOK, a decrease from 1,585 MNOK at the end of second quarter last year. Asker, 19 July 2019 TOMRA Systems ASA For questions, please contact: Espen Gundersen, Deputy CEO/CFO: +47 66 79 92 42 / +47 97 68 73 01 Bing Zhao, Director Investor Relations & Strategy: +47 40 21 08 19 Webcast link: https://events.webcast.no/tomra/kvartalspresentasjoner/tomra-systems-asa-q2-presentation-2019 There will be a Q&A after the presentation and the recorded webcast will be made available on TOMRA’s webpage www.TOMRA.com. 

Stefan Syrén Appointed New President and CEO of the Gunnebo Group and Changes in the Group Executive Team

Stefan Syrén has been employed by Gunnebo since May 2018 with responsibility for the Business Units Safe Storage and Integrated Security. In the last year, he has successfully participated in driving the implementation of the new Business Units structure of Gunnebo Group. Stefan Syrén will take up the position as President and CEO latest during November 2019, in addition to his current responsibilities. He succeeds Henrik Lange, who has decided to resign. Robert Hermans has been employed by the Gunnebo Group since 1996 and has been responsible for Entrance Control since 2010. He will, in addition to his current position, be appointed Executive Vice President of the Gunnebo Group and Deputy CEO, which will take place simultaneously with the shift of President and CEO.    “First and foremost, I would like to thank Henrik Lange for the profound change agenda he has been initiating and driving in the past years,” says Gunnebo’s Chairman of the Board Martin Svalstedt. “His valuable contribution in transforming the organization to new Business Units, with end-to-end responsibilities, will have a long-lasting positive effect on the company for many years to come.” “The Board is pleased to appoint Stefan Syrén as the new President and CEO of Gunnebo. In this journey of change towards focus by product offering in our Business Units, we must continue to drive innovation based on our customers’ need, while at the same time work to improve our cost structure and efficiency. These are competencies that Stefan, with success, has demonstrated both in his current role in Gunnebo and in previous roles in other companies." "Robert Hermans has successfully developed our fastest growing Business Unit Entrance Control and it is equally pleasing to appoint Robert as Executive Vice President Gunnebo Group and Deputy CEO." Other changes to Gunnebo's Group Executive TeamIn connection with the transition to a global Business Unit structure that Gunnebo began in 2018, the regional structure for Asia-Pacific and Americas will cease to exist at year-end 2019. Sacha de La Noë, SVP Asia-Pacific, Middle East and Africa and Dan Schroeder, SVP Region Americas, who are currently in Gunnebo's Group Executive Team, will leave Gunnebo and the Group Executive Team at the end of the year due to these changes. Gunnebo AB (publ)Communications For more information, please contact:Martin Svalstedt, Chairman of the Board for Gunnebo AB tel. +46 704 855 371, orHenrik Lange, President and CEO Gunnebo AB, tel. +46 766 105 128, orStefan Syrén, incoming President and CEO Gunnebo AB, tel. +46 721 864 044, orKarin Wallström Nordén, SVP Marketing and Communications Gunnebo AB, tel. +46 708283 339 This information is information that Gunnebo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07.21 CET on 19 July 2019. 

Saab’s Results January-June 2019

Statement by the President and CEO Håkan Buskhe: Sales growth remains strong and operating margin improved During the first half of 2019, Saabs sales increased by 8 per cent and the operating margin improved. Saab continues to drive internationalisation of the business and several steps were taken in the first half of the year to strengthen the local presence. A clear example of this is the decision to establish a new U.S. development and production facility in West Lafayette, Indiana, where Saab will manufacture its parts for the T-X advanced jet trainer ordered by the U.S. Air Force. Orders Order bookings during the first half of 2019 amounted to SEK 9.7 billion (12.7). During the period, an order was received from the U.S. Coast Guard for the Sea Giraffe Multi Mode Radar, and the United Kingdom Royal Navy ordered an anti-submarine training system. The business area Dynamics saw continued strong demand. Two major framework agreements were signed for the Carl-Gustaf multi-purpose weapon system and AT4 disposable weapon system. Small orders increased strongly compared to the same period in 2018. Market demand remains strong and during the remaining part of the year, Saab see substantial business opportunities. Sales and operating income Sales in the first half year amounted to SEK 16,941 million (15,719) with organic growth of 7 per cent.  The increase in sales is primarily related to higher level of deliveries within business area Dynamics and a higher activity level within business area Industrial Products and Services. Operating income amounted to SEK 1,221 million (905) with an operating margin of 7.2 per cent (5.8).  Measures taken to increase productivity contributed to improved margin in the period. Saab has a strong focus on securing delivery of milestones in major projects. The HMS Gotland was relaunched in the second quarter, which means that two of Sweden’s Gotland-class submarines have now concluded comprehensive mid-life upgrades. Development and production of the Gripen E fighter continued according to plan and during the period a third aircraft performed its first flight. Efforts to adapt the product portfolio, increase marketing efficiency and accelerate the pace of automation and digitisation in operations continues. Operational cash flow Operational cash flow amounted to SEK -2,702 million (-2,750). Cash flow was negative mainly due to increased working capital within the business area Aeronautics, where preparations for the first deliveries of Gripen E to Brazil and Sweden continue. Saab expects operational cash flow to be negative for the full-year 2019, but at a better level than 2018. Operational cash flow will continue to be affected during the year by timing differences in payments for major projects with a high activity level. Outlook statement We estimate that sales growth in 2019 will be in line with Saab’s long-term financial goal: annual organic sales growth of 5 per cent. The operating margin in 2019, excluding material non-recurring items, is expected to improve compared to 2018, bringing Saab a step closer to its long-term financial goal: an operating margin of 10 per cent per year over a business cycle. Financial highlights MSEK  Jan-Jun Jan-Jun Change, Q2 2019 Q2 2018  Full year 2019  2018  % 2018 Order 9,710 12,664 -23 5,228 6,529 27,975bookingsOrder backlog 94,236 104,473 -10 102,184Sales 16,941 15,719 8 8,445 7,953 33,156Gross income 3,788 3,537 7 1,937 1,799 7,764Gross margin, 22.4 22.5 22.9 22.6 23.4%EBITDA 1,893 1,323 43 974 669 3,182EBITDA 11.2 8.4 11.5 8.4 9.6-margin, %Operating 1,221 905 35 630 458 2,266income (EBIT)Operating 7.2 5.8 7.5 5.8 6.8margin, %Adjusted 1,221 905 35 630 458 2,564operatingincomeAdjusted 7.2 5.8 7.5 5.8 7.7operatingmargin, %Net income 826 450 84 429 199 1,366Of which 831 425 96 433 183 1,313ParentCompany’sshareholders’interestEarnings per 6.20 3.65 3.23 1.57 11.21share afterdilution, SEK1)Return on 10.5 9.7 8.1equity, % 2)Operational -2,702 -2,750 -779 -539 -2,424cash flowFree cashflow -3,126 -3,192 -989 -781 -3,195Free cashflow -23.32 -27.38 -7.38 -6.70 -27.27per shareafterdilution, SEK1) Average 134,064,875 116,563,375 134,039,937 116,610,780 117,144,915number ofshares afterdilution2) Return onequity ismeasured overa rolling12-monthperiod  Press and analyst meeting Saab is pleased to invite press, investors and financial analysts to a press and analyst meeting where CEO Håkan Buskhe and CFO Magnus Örnberg present the Saab interim report for January-June 2019. Date:            Friday, 19 July at 11.30 (CET). Address:     Saab, Olof Palmes Gata 17, 5th floor, Stockholm, Sweden The report is published at 07.30 a.m. (CET) the same day.  You are welcome to participate on site at Saab, watch the live webcast or dial in to the conference call. It is possible to post questions also over the web and conference call.  Live webcast: http://saab-interimreport.creo.se/190719 Conference call: Please, dial in using one  of the numbers below. Sweden:                    +46 8 566 42705 United Kingdom:      +44 3333009031 United States:           +1 8338230590 The interim report, the presentation material and the webcast will be available on http://www.saabgroup.com/investor-relations. R.S.V.P.  E-mail: marie.bergstrom@saabgroup.com Tel: +46 8 463 02 45 For further information, please contact: Saab Press Centre Ann Wolgers, Press Officer +46 (0)734 180 018 presscentre@saabgroup.com  Saab Investor Relations Ann-Sofi Jönsson, +46 (0) 734 187 214 www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab   Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs.  The information is such that Saab AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on 19 July 2019 at 07.30 (CET).

Evolution Gaming: Interim report January-June 2019

Second quarter of 2019 (Q2 2018)  · Operating revenues increased by 45% to EUR 85.7 million (59.3) · EBITDA increased by 63% to EUR 42.7 million (26.2), corresponding to a margin of 49.8% (44.2) · Profit for the period amounted to EUR 34.5 million (20.1) · Earnings per share amounted to EUR 0.19 (0.11) January-June 2019 (1H 2018)  · Operating revenues increased by 49% to EUR 165.0 million (110.8) · EBITDA increased by 63% to EUR 78.6 million (48.1), corresponding to a margin of 47.7% (43.4) · Profit for the period amounted to EUR 63.1 million (36.7) · Earnings per share amounted to EUR 0.35 (0.20) Comments from CEO Martin Carlesund: Evolution’s strong development continues, and we can report continued high growth and further improved margin in the second quarter. 2019 is a year of product and innovation, and during the period, we have launched all this year’s new games. The response has been instant, and we are overwhelmed by the positive reception among both players and operators. Our aim in the development has been to create games that attract new player types and to expand the Live vertical into new segments, and so far, we are very happy with the outcome. All games, from the new titles within the Game Show category to the dice games, find their audiences and we see a significant increase in the number of players. The new games are not as staff intensive as the traditional table games, which in combination with a generally high efficiency in all studios contribute to the margin development. The extended portfolio also contributes to the revenue growth, but it is important to note that most of our revenues continue to derive from our core games and that the new games are still in an early stage post-launch. However, all new titles contribute to a generally higher interest in Live Casino and we believe that the Live vertical will continue to grow its share of the total online casino market. When the Live vertical grows, we take market shares – as do our customers with access to the new games. Revenues amounted to EUR 85.7 million, which is 45 percent higher than the corresponding quarter last year. EBITDA amounted to EUR 42.7 million with a margin of 49.8 percent, which is the highest margin recorded so far in a single quarter. In the first half of the year, the margin was 47.7 percent, and we expect to be able to sustain this level in the second half as well which is why we increase our expected margin range to 47-49 percent for the 2019 full year. The positive market development continues. The Nordics are growing, however at a somewhat slower pace as the Swedish market now is normalising following the intense start to the year as a result of the new gaming legislation. The UK continues to stabilise and is growing compared to the corresponding quarter last year. Both Rest of Europe and Rest of World also exhibit favourable growth. Going forward, we will continue to invest in the development of both additional game shows and other innovative product types, as well as table games to meet the overall demand for Live. We also continue to invest in our studios. During the quarter, we have transferred the first tables to the new Malta studio, while also expanding the studio in Georgia. In addition, we have initiated a doubling of the capacity in New Jersey. We will also strengthen our presence in the US further and have started the planning for the construction of a studio in Pennsylvania. All in all, investments for the 2019 full year in absolute numbers will be somewhat higher than in 2018. It is imperative for us to meet the demand for Live, to continue to enable innovation within the company and to constantly increase the gap to competition. Connected to this, it is important to remember that in a case where we must prioritise, we will always put growth before margins. During the first half of the year, we have laid the foundation for Evolution’s continued leadership in Live Casino. A proof of this was when we received the award as Live Casino Supplier of the Year for the tenth consecutive year at the EGR B2B Awards in June. The award goes straight to all our employees. I am immensely proud of everyone’s achievements so far this year, and the innovation power they possess creates confidence for the future. Since Evolution’s inception, we have had a paranoid approach to our development, and given all achievements so far in 2019 I would like to conclude these comments by pointing out that we are never fully satisfied, we never sit back and each day, we fight to become a little bit better. Presentation for investors, analysts and the media CEO Martin Carlesund and CFO Jacob Kaplan will present the report and answer questions on Friday, 19 July 2019 at 09:00 a.m. CET via a telephone conference. The presentation will be in English and can also be followed online. Number for participation by telephone: +46 8 566 42 692 / +44 3333 00 9272 / +1 833 526 8396. Follow the presentation at https://tv.streamfabriken.com/evolution-gaming-group-q2-2019.

Tobii Interim Report following the Second Quarter of 2019

Tobii AB (publ) today announced its interim report following the second quarter of 2019. Comment by Tobii’s CEO Henrik Eskilsson: “Strong sales growth for Tobii Tech and important customer launches.Sales in the quarter increased 21 percent, or 13 percent adjusted for currency effects, compared to the second quarter of 2018. External sales in Tobii Tech grew by 87% and we have in the quarter seen several interesting initiatives and launches related to eye tracking from important players in the ecosystem.” Second quarter April-June 2019 · The Group’s net sales increased by 21% to SEK 372 million (307) compared with the first quarter of 2018. Adjusted for currency effects, the increase was 13%. · The gross margin was 69% (70%). · The Group's operating loss amounted to SEK -51 million (-59).Tobii Dynavox contributed SEK 21 million (22) and Tobii Pro SEK -3 million (1) to earnings, while investments in Tobii Tech had an impact of SEK -72 million (-82) on the Group's operating loss · Earnings per share amounted to SEK -0.59 (-0.41). · The Group has applied IFRS 16 Leases since January 1. This has had a positive impact in the second quarter of SEK 7 million on consolidated EBITDA and SEK 1 million on EBIT. Please see the tables on page 17 for more information. Significant events ·  Dell launched its Alienware m15 and m17 gaming laptops with integrated eye tracking from Tobii. ·  Qualcomm launched its new Smart Viewer reference design with integrated eye-tracking technology from Tobii.  ·  The British competition regulator CMA announced the provisional findings of its investigation of the Smartbox acquisition and continues to hold the position that the acquisition may result in a lessening of competition in the UK. ·  After the end of the quarter the Company announced that Anand Srivatsa joins Tobii as the new CEO of the Tobii Tech division. ·  At the Annual General Meeting of Shareholders, Jörgen Lantto and Mårten Skogö were elected to serve as new members of the Board of Directors Events after the end of the period · After the end of the quarter the Company announced that Anand Srivatsa joins Tobii as the new CEO of the Tobii Tech division. Comments from the CEO Sales in the quarter increased 21 percent, or 13 percent adjusted for currency effects, compared to the second quarter of 2018. External sales in Tobii Tech grew by 87% and we have in the quarter seen several interesting initiatives and launches related to eye tracking from important players in the ecosystem. Tobii Dynavox grew sales with 24% compared with the second quarter of 2018. The increase can be attributed to the acquisition of Smartbox, favorable currency effects and robust underlying demand, but was offset by delays in our administrative process of handling customer funding cases together with insurance companies in the US. Adjusted for acquisitions and currency effects, sales growth was 3 percent in the second quarter and 7 percent for the first half of the year. The value of ongoing, but not completed, customer funding cases during the quarter increased by over 10%, corresponding to about SEK 15 million. I expect that both this backlog of customer funding cases and the flow in our process will normalize during the second half of the year. Investments in product and market development continue. We have several important products under development and during the quarter we trained an additional approximately 9,000 prescribers, therapists and other key individuals worldwide. On May 30 the UK Competition and Markets Authority (CMA) announced its provisional findings from the second phase of the investigation regarding our acquisition of Smartbox. In summary, the CMA continues to hold the position that the acquisition of Smartbox may result in a reduction of competition in the UK. On the contrary, Tobii believes that the acquisition benefits users. We expect more information from CMA in late July and work with several scenarios and action plans in parallel. In the last two quarters, Tobii Pro has delivered strong results, but this quarter was weaker. Sales growth was 1 percent compared with the second quarter the previous year and –5 percent adjusted for currency effects. The second quarter is usually seasonally weaker for Tobii Pro, but this quarter’s low sales growth is mainly attributed to an increased order backlog since a larger proportion of the orders consisted of services and larger solutions with longer delivery times. In addition, we saw lower order income in certain geographic regions. Naturally we are not satisfied with the result, but remain positive about the market development and opportunities for Tobii Pro. In order to provide better support to our customers we launched an updated version of Tobii Pro Lab during the quarter, with increased support for website studies. We also adapted Tobii Pro’s VR Analytics software to work together with HTC Vive Pro Eye. We are maintaining a high rate of investment in product development and look forward to several important product launches. Tobii Pro has also continued to strengthen its local presence and opened a new sales office in Chile to more pro-actively address the Latin American market. In Tobii Tech, sales to external customers increased by 87 percent, and by 50 percent overall, adjusted for currency effects. The primary focus is on the three segments PC, VR and Niche Applications. At the Computex trade show Dell launched its Alienware m15 and m17 gaming laptops with integrated eye tracking from Tobii, which means that Tobii’s IS5 eye-tracking platform is now integrated in the entire Alienware family of next-generation gaming laptops. At the same trade show Intel launched the specifications for “Project Athena”, the next generation of ultraportable laptops, where advanced sensor technologies are key components for making laptops more intuitive and user-friendly. This is of course positive for our business opportunities in PC, both for our Tobii Aware software and for our eye-tracking sensors. HTC’s new VR headset Vive Pro Eye, with built-in eye tracking from Tobii, started selling during the quarter. Qualcomm also launched its new Smart Viewer reference design in which Tobii’s eye-tracking technology is integrated, contributing to an enhanced user experience and lower energy consumption using “foveated rendering”. As previously announced, we have ongoing integration projects with a handful of customers in VR. During the quarter, Tobii took important steps forward in the field with one new design win and good progress in ongoing collaborations.   In Niche Applications we received a couple of new design wins during the quarter. Sales in this segment is rising sharply, and the segment contributes positively to the result of the division. I am very happy to welcome Anand Srivatsa as the new Division CEO of Tobii Tech. Anand has an excellent background for taking over the helm at Tobii Tech and continuing to achieve strong growth in this division. Anand worked most recently at Intel, where he was Vice President and General Manager of Intel’s entire Desktop, Systems and Channels Group. In summary, we saw a continued sales increase for the Group and I am especially pleased with the increased external sales of Tobii Tech. Overall, the trends are also truly positive for eye tracking, which has been particularly apparent during the quarter in relation to PC and VR in Tobii Tech. I am however not satisfied with the result for Tobii Pro, although we have a robust underlying demand and an increased backlog of orders. I also strongly feel that Anand Srivatsa will be the perfect addition to strengthen the Group Management and I look forward to once again being able to fully devote myself to the Tobii Group as a whole. Conference callToday at 2:00 p.m. CEST, Tobii will host a conference call with web cast presentation for media, analyst and investors. Please find dial-in details on Tobii’s website under Calendar . This information is inside information that Tobii AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and to the Securities Market Act. The information was submitted for publication, through the agency of the contact person set out below, at 07.30 CET on July 19, 2019.

Report for the second quarter 2019: Major result improvement in SSAB Americas, decline in SSAB Europe

Comments by the CEO SSAB’s operating profit for the second quarter of 2019 was SEK 1,316 million, down SEK 314 million compared with the second quarter of 2018. Lower earnings were attributable to SSAB Europe, which was affected primarily by higher iron ore costs. Group operating cash flow increased to SEK 1,696 (1,325) million. Demand for SSAB Special Steels was good during the quarter. Operating profit was somewhat higher than a year earlier at SEK 544 (522) million. Higher realized prices were largely counteracted by higher iron ore costs. Demand in Europe weakened during the second quarter and SSAB Europe’s shipments were down compared to last year. This was primarily due to weaker demand from the automotive industry. Operating profit dropped to SEK 66 (907) million. A sharp rise in iron ore prices and weaker steel prices have resulted in exceptional pressure on margins on the European market. Second quarter operating profit for SSAB Americas rose to SEK 872 (365) million. This improvement was driven by significantly higher realized prices and lower scrap metal prices compared to the second quarter last year. Demand was good in most customer segments, although the sentiment at distributors is cautious. There is some uncertainty as to how the business cycle will develop looking ahead. Weaker steel prices on our home markets, Europe and the USA, imply a cautious sentiment at distributors and demand is expected to be seasonally weaker during the third quarter. The current staffing level is aligned with a relatively high production rate, with a large number of temporary employees, which gives us flexibility when the market slows down. During the third quarter, the production volume will be lower and the number of temporary employees will be reduced accordingly. Among other things, the smaller blast furnace in Oxelösund will be idled. In addition, already planned measures to cut other costs in all divisions are being carried out. At the same time, our strong balance sheet gives us a sound basis to continue to develop the company, regardless of business conditions.  Invitation to SSAB’s second quarter 2019 results briefing SSAB invites you to a presentation of the quarterly report today at 10.30am CEST.The interim report for the second quarter of 2019 will be presented by SSAB’s President and CEO Martin Lindqvist, and CFO Håkan Folin.The press conference will be held in English and live webcast on SSAB’s website www.ssab.com. It is also possible to participate in the briefing via telephone. The conference starts at 10.30am CEST. Telephone numbers:+ 46 8 5664 2651 (Sweden),+ 44 33 3300 0804 (UK),+ 1 63 1913 1422 (USA). PIN: 55 13 29 99# Link to webcast   For further information, please contact:                                                               Investor Relations: Per Hillström, Head of IR,per.hillstrom@ssab.com, +46 70 2952 912 Media: Viktoria Karsberg, Head of Corporate Identity and Communications,viktoria.karsberg@ssab.com, +46 8 4545 734 This information is inside information that SSAB AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 7.30am CEST on July 19, 2019.

Episurf Medical enters into its first strategic partnership regarding its AI-based imaging technology

Episurf Medical (NASDAQ: EPIS B) today announces that it has entered into a Letter of Intent with a US-based orthopaedic company related to Episurf Medical’s proprietary and patented imaging technology, now to be applied for the allograft industry. While the details and financial considerations of the Letter of Intent are currently confidential, both parties have the intention to collaborate using Episurf Medical’s Epioscopy® technology platform for surgery planning within allograft joint surgery. In September 2018, Episurf Medical announced that the company had CE-marked its visualisation tool, Epioscopy®, which is based on Artificial Intelligence (AI) and translates MR images into a 3D model of the knee joint. Now, the first strategic partnership has been initiated which confirms the demand of this technology. By this partnership, Episurf Medical is establishing its third commercial leg of its business, which further comprises the Episealer® knee implant technology and the Episealer® Talus (ankle) implant technology which is under development. "Allografts is a biological treatment alternative for cartilage lesions in the knee, and as for the orthopaedic industry in large, the US is the main market for this market segment. We are very happy for this important step. It shows that we are able to leverage on our core competencies around image segmentation and damage assessment, and it provides commercial opportunities for us globally. In fact, we are broadening our addressable market to include patients outside the treatment gap. We are continuing to position our technology for commercial success, now in three areas" says Pål Ryfors, CEO Episurf Medical. For more information, please contact: Pål Ryfors, CEO, Episurf MedicalTel:+46 (0) 709 62 36 69Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CEST on 19 July 2019.

Fortum Half-year Financial Report 2019 - Improved results in all business segments and strong cash flow

FORTUM CORPORATION HALF-YEAR FINANCIAL REPORT JANUARY-JUNE 2019 19 JULY 2019 AT 9:00 EEST Release category: Half-year financial report This release is a summary of Fortum’s Half-year Financial Report 2019. The complete report is attached to this release as a pdf-file. It is also available on the company's website at www.fortum.com/investors. April-June 2019 · Comparable EBITDA was EUR 372 (282) million, +32% · Comparable operating profit was EUR 232 (153) million, +52% · Operating profit was EUR 184 (256) million, -28% · Share of profits of associated companies and joint ventures was EUR 461 (24) million, mainly due to Fortum’s share of Uniper’s profit · Earnings per share were EUR 0.69 (0.24), of which EUR -0.05 (0.11) related to items affecting comparability and 0.45 (-) to Uniper. In 2018, capital gain from the sale of the 10% stake in Hafslund Produksjon were EUR 0.09 · Strong cash flow from operating activities totalled EUR 740 (361) million, mainly related to dividends received of EUR 229 million and the change in settlements for futures · The purchase price allocation of the Uniper investment was finalised January-June 2019 · Comparable EBITDA was EUR 918 (820) million, +12% · Comparable operating profit was EUR 640 (558) million, +15% · Operating profit was EUR 542 (738) million, -27% · Share of profits of associated companies and joint ventures was EUR 572 (70) million, mainly due to Fortum’s share of Uniper’s profit · Earnings per share were EUR 1.07 (0.68), of which EUR -0.09 (0.18) related to items affecting comparability and 0.50 (-) to Uniper. In 2018, capital gain from the sale of the 10% stake in Hafslund Produksjon were EUR 0.09 · Strong cash flow from operating activities totalled EUR 1,491 (634) million, mainly due to the change in settlements for futures and dividends received Summary of outlook · The Generation segment's Nordic generation hedges: approximately 80% hedged at EUR 33 per MWh for the remainder of 2019 and approximately 60% at EUR 31 per MWh for 2020 · Capital expenditure, including maintenance but excluding acquisitions, is expected to be in the range of EUR 600-650 million in 2019. In 2020, capital expenditure is expected to decline Key financial ratios +-----------------------------+----+---+|EUR million |2018|LTM|+-----------------------------+----+---+|Return on capital employed, %|6.7 |8.4|+-----------------------------+----+---+|Comparable net debt/EBITDA |3.6 |3.3|+-----------------------------+----+---+ Key figures +--------------------------+-----+-----+-------+-------+-----+-----+|EUR million |II/19|II/18|I-II/19|I-II/18|2018 |LTM |+--------------------------+-----+-----+-------+-------+-----+-----+|Sales |1,144|1,087|2,834 |2,672 |5,242|5,404|+--------------------------+-----+-----+-------+-------+-----+-----+|Comparable EBITDA |372 |282 |918 |820 |1,523|1,621|+--------------------------+-----+-----+-------+-------+-----+-----+|Comparable operating |232 |153 |640 |558 |987 |1,069||profit | | | | | | |+--------------------------+-----+-----+-------+-------+-----+-----+|Operating profit |184 |256 |542 |738 |1,138|942 |+--------------------------+-----+-----+-------+-------+-----+-----+|Share of profits of |461 |24 |572 |70 |38 |540 ||associates and | | | | | | ||joint ventures | | | | | | |+--------------------------+-----+-----+-------+-------+-----+-----+|Profit before income taxes|652 |241 |1,076 |734 |1,040|1,382|+--------------------------+-----+-----+-------+-------+-----+-----+|Earnings per share, EUR |0.69 |0.24 |1.07 |0.68 |0.95 |1.34 |+--------------------------+-----+-----+-------+-------+-----+-----+|Net cash from operating |740 |361 |1,491 |634 |804 |1,661||activities | | | | | | |+--------------------------+-----+-----+-------+-------+-----+-----+|Shareholders’ equity per | | |13.93 |13.34 |13.33| ||share, EUR | | | | | | |+--------------------------+-----+-----+-------+-------+-----+-----+|Interest-bearing net debt | | |5,422 |5,271 |5,509| ||(at the end of the period)| | | | | | |+--------------------------+-----+-----+-------+-------+-----+-----+ Fortum's President and CEO Pekka Lundmark: "The second quarter of 2019 was a good quarter for Fortum. Results improved in all business segments, cash flow was strong and there was continued focus on strengthening the balance sheet. The higher achieved power price and the higher hydro and nuclear volumes were the main drivers for the clear result improvement in the Generation segment. The results of the Russia segment improved, with higher electricity margins and capacity prices as the main drivers. Part of the improvement was related to high bad-debt provisions in the second quarter of last year. The weather was warmer than normal in most heating areas, but not as warm as last year. Although seasonally loss-making, the results of the City Solutions segment improved due to higher heat sales, favourable power prices, and better results in our recycling and waste business. Consumer Solutions showed a clear result improvement for the second quarter in a row, after a weaker year in 2018. Roughly half of the result improvement was due to higher margins; the other half was of a more temporary nature. In the second quarter, Fortum received dividends from Uniper for the first time. The dividend of EUR 165 million strongly contributed to Fortum’s cash flow. Fortum’s EUR 399 million share of Uniper’s profits clearly increased Fortum’s net profit and had a EUR 0.45 positive effect on Fortum’s earnings per share. We remain convinced that Fortum and Uniper together can take a leading role in the European energy transition. Working in close alignment, we would be stronger and better positioned to address the key challenges of the future energy landscape: affordability, sustainability, and security of supply. The talks we held with Uniper during the spring only strengthened our conviction. Following the controversy around the Uniper annual general meeting in May, we have met with Uniper employee representatives, the new members of the Management Board and the Supervisory Board. I am pleased that we have now agreed that discussions will continue. In June, the new Finnish Government presented its political programme. I am glad to see that the new government has indicated its commitment to an ambitious climate policy. The programme contains several positive tax-related proposals to support decarbonisation and electrification, but also increased taxes for heating fuels that overlap with the EU ETS. Similarly as in Sweden, also the Finnish Government proposes the introduction of a tax on waste incineration. Such a tax would be inefficient, as it would hardly steer towards efficient recycling and reuse. It is essential that rejects from sorting of non-recyclable waste and hazardous waste would be excluded from such a tax." Espoo, 18 July 2019 Fortum CorporationBoard of Directors News conference The joint news conference for media, investors and analysts will be held on 19 July 2019 at 11.00 EEST at Fortum Head office in Keilalahdentie 2-4, Espoo. The conference is available as a live webcast on Fortum's website at www.fortum.com/investors. To participate in the teleconference, please dial in approximately 5 minutes before the beginning of the event using the numbers below: FI +358  9 81 710 310UK +44 333 300 0804US +185 585 706 86 Pin: 90793343# The webcast, together with the transcript after the event, will be recorded and published on Fortum's website at www.fortum.com/investors. Further information: Investor Relations and Financial Communications: Ingela Ulfves, tel. +358 40 515 1531, Måns Holmberg, tel. +358 44 518 1518, Rauno Tiihonen, tel. +358 10 453 6150, Pirjo Lifländer, tel. +358 40 643 3317, and investors@fortum.com Media: Pauliina Vuosio, tel. +358 50 453 2383  Financial calendar in 2019: January-September 2019 Interim Report on 24 October at approximately 9:00 EEST. Distribution: Nasdaq HelsinkiKey mediawww.fortum.com More information, including detailed quarterly information, is available on Fortum’s website at www.fortum.com/investors

INTERIM REPORT JANUARY – JUNE 2019

·Net sales amounted to MSEK 808.2 (756.5), whereof the second quarter MSEK 387.4 (489.4). This corresponds to an increase for the period of 7% and a decrease for the quarter of 21%. Excluding one-off income in the second quarter of 2018, net sales in the second quarter decreased by 4%. ·Adjusted EBITDA amounted to MSEK 290.8 (234.4), whereof the second quarter MSEK 137.8 (145.7). During the second quarter of 2019, the company has also had non-recurring costs related to the acquisition of Trimb and restructuring costs of MSEK 35.3. During the second quarter of 2018, the company had one-off incomes of MSEK 86.6 in the form of a milestone payment. ·The gross margin was 55.2% (55.8%) for the period, and 54.5% (55.1%) for the second quarter. Including one-off income, the gross margin in 2018 was 60.8% during the period and 63.1% during the quarter. ·Cash flow from operating activities amounted to MSEK 203.6 (136.7), whereof the second quarter was MSEK 111.8 (95.2). ·Earnings per share were SEK 0.21 (5.07), of which the second quarter amounted to SEK -0.04 (3.86). For 2019, earnings per share are affected by costs affecting comparability and for 2018 by a milestone payment from Pfizer and recognition of deferred tax assets on loss carry forwards (417,7 MSEK). ·Cash and short-term investments at period end amounted to MSEK 561.2 (398.6 as of December 31, 2018). ·On April 3, it was announced that Karo Pharma’s Board had appointed Christoffer Lorenzen as the new CEO of Karo Pharma. He replaces Peter Blom. Christoffer took up his new position on July 1, 2019. During the period April 3 through June 30, Ulf Mattson served as acting CEO. ·On June 21, Karo Pharma announced that it had agreed to acquire all shares in Trimb Holding AB from Avista Capital Partners and other shareholders, for MSEK 3,400. The transaction is expected to enhance Karo Pharma’s market position and is expected to create a stable platform for Karo Pharma’s continued growth. The combined company had annual sales in 2018 of about MSEK 2,640. ·A rights issue of approximately MSEK 1,500 is planned. The Board of Directors of Karo Pharma intends to propose that the company’s shareholders at an extraordinary general meeting resolves to authorize the Board to decide on the rights issue. Notice to the extraordinary general meeting where the authorization will be resolved upon will be published separately and will also be available on Karo Pharma’s website.   COMMENT ON OPERATIONS In the second quarter of 2019, Karo Pharma continued to develop in line with the long-term strategy of advancing the company by growing through acquisitions as a complement to organic growth. On June 21, we announced the acquisition of Trimb Holding AB for MSEK 3,400 on a cash and debt free basis (Enterprise Value). Trimb is a prominent company in self-care drugs and healthcare products, which over the past few years successfully has built a Nordic business with growing presence in northern Europe. Trimb complements Karo Pharma well, both in terms of geographical presence, sales channels and product range. The merged company had annual sales in 2018 of approximately MSEK 2,640 and becomes a clear leader in its field in the Nordic region. Regarding the development of Karo Pharma’s existing business, adjusted for a milestone payment in Q2 2018, we saw a negative development in the second quarter by 4 percent. Excluding discontinued business relationships in a number of smaller markets that were obtained through the acquisition of the product portfolio from LEO Pharma, sales declined organically by 2 percent. Adjusted for currency effects, sales decreased by 3 percent. Developments in the various markets varied, and while we saw a positive development in Denmark and Finland, the trend was negative in Sweden and Norway. In other European markets, sales increased, while we saw a negative trend in markets outside Europe primarily driven by discontinued business relationships in a number of smaller markets. The period and the second quarter have been affected by an ongoing change of contract manufacturer, which has meant some delays and delivery problems especially in the Norwegian market. However, we expect these changes to improve our profitability and business in the long term. Unrelated thereto we faced supply issues after the close of the second quarter related to a specific product, Lithionit, which now have been resolved. The quarter was also affected by restructuring costs as well as costs related to the acquisition of Trimb. Christoffer LorenzenCEO  SIGNIFICANT EVENTS AFTER PERIOD ENDChristoffer Lorenzen took over as President and CEO on July 1.Christoffer Lorenzen, born 1975, has been a member of Group Management and a member of the Executive Board of Chr. Hansen Holding A / S, which is listed on the Copenhagen Stock Exchange. He holds a master's degree in marketing from Copenhagen Business School and is a board member of Hamlet Protein A / S and in Schultz Holding A / S. He has previously been Head of Corporate Strategy at H. Lundbeck A / S. In February this year, he was elected to Karo Pharma's Board of Directors, a positioned he left in connection with Karo Pharma’s Annual General Meeting.  AUDITORS REVIEWThis report has not been subject to auditor’s review.  FINANCIAL CALENDAR Interim report Jan-Sept           Nov 1, 2019Year-end report 2019 Feb 13, 2019 FOR FURTHER INFORMATION, PLEASE CONTACTChristoffer Lorenzen, CEO, + 46 73 501 76 20, christoffer.lorenzen@karopharma.seMats-Olof Wallin, CFO, + 46 76 002 60 10, mats-olof.wallin@karopharma.se   (mats-olof.wallin@karopharma.se) ABOUT KARO PHARMAKaro Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment. The information in this report is such that Karo Pharma is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on July 19, 2019 at 8.00 a.m. CET. 

Stora Enso evaluates expansion in Wood Products

Stora Enso has initiated feasibility studies for a possible cross laminated timber (CLT) unit in connection with its Ždírec mill in the Czech Republic and a new construction beam unit to be located at the Ybbs mill in Austria. Stora Enso also plans to consolidate production to increase focus on efficiency and to streamline the asset base. Stora Enso continues its transformation into a leading provider of innovative wood-based solutions. The transformation in Wood Products includes both selected growth in added-value businesses and consolidation of production to increase focus on efficient integrated production. The proposed expansion in Ždírec would add a total annual capacity of approximately 120 000 m3of CLT. It would be Stora Enso’s fourth CLT unit, following the inauguration of the Gruvön CLT unit in Sweden earlier this year. The study is expected to be completed by the end of 2019. In Ybbs, the planned expansion would add a total annual capacity of 60 000 m3of construction beams. The new beam product would be offered to Building Solutions’ customers and sold as a solution together with CLT and LVL. The feasibility study is expected to be completed by the end of the first quarter of 2020. If the investments are approved following the feasibility studies, the capital expenditure is estimated to be approximately EUR 90 million. The transformation in Wood Products also includes the earlier announced plans to close the Kitee sawmill with a possible consolidation of spruce production to Varkaus, as well as the divestment of assets related to Thermowood production at Uimaharju sawmill in Finland. Stora Enso will consolidate the Thermowood production to Launkalne mill in Latvia. “We see extensive potential for our engineered wooden materials in the market, and an opportunity for further growth in the multi-storey building segment. Our products substitute fossil-based materials and demand for our premium, renewable products, our proven massive wood components as well as our building concepts is constantly increasing. Consolidation would enhance cost efficiency, optimised raw material usage, efficient automatised production, synergies between mills and a strong market driven portfolio of products and services,” says Jari Suominen, Executive Vice President of Stora Enso’s Wood Products division. For further information, please contact:Cathrine WalleniusSVP, Communications and Marketing, Wood Productstel. +46 70 2092429Investor enquiries:Ulla PaajanenSVP, Investor Relationstel. +358 40 763 8767 Part of the bioeconomy, Stora Enso is a leading global provider of renewable solutions in packaging, biomaterials, wooden constructions and paper. We believe that everything that is made from fossil-based materials today can be made from a tree tomorrow. Stora Enso has some 26 000 employees in over 30 countries. Our sales in 2018 were EUR 10.5 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com  STORA ENSO OYJ 

Stora Enso invests in producing bio-based carbon materials for energy storage

Stora Enso is investing EUR 10 million to build a pilot facility for producing bio-based carbon materials based on lignin. Wood-based carbon can be utilised as a crucial component in batteries typically used in consumer electronics, the automotive industry and large-scale energy storage systems. The pilot plant will be located at Stora Enso’s Sunila Mill in Finland. The investment in making carbon materials for energy storage further strengthens Stora Enso’s opportunities to replace fossil-based and mined raw materials as well as to connect sustainable materials to ongoing technology innovations.Lignin is one of the main building blocks of a tree. Today, the lignin produced at Sunila Mill, Lineo™ by Stora Enso, is used, for example, to replace fossil-based components in phenols for adhesives. With the new investment, Stora Enso will pilot the processing of lignin into a carbon intermediate for electrode materials. This lignin will be converted into so called hard carbon anode materials for lithium-ion batteries with properties similar to graphite. Such batteries are used daily in mobile phones and similar portable devices, power tools, electric vehicles, in industrial applications, in stationary energy storage and grid units, and so on.“This investment is another step on our transformation journey to explore new ways to replace fossil-based, scarce and high-cost materials with renewable alternatives. Using wood-based lignin for technical carbon material offers an exciting opportunity. With the pilot facility we will continue to build on our long-term work in extracting lignin from biomass to create more value from it. We will target the rapidly growing battery market in which companies are looking for high-quality, attractively priced and sustainable materials,” says Markus Mannström, Executive Vice President of Stora Enso’s Biomaterials division.The construction of the pilot facility will begin before the end of 2019 and is estimated to be complete by early 2021. Decisions about commercialisation will follow after evaluating the results of the pilot-scale production. Stora Enso has been producing lignin industrially at its Sunila Mill in Finland since 2015. The mill’s annual production capacity is 50 000 tonnes making Stora Enso the largest kraft lignin producer in the world.For further information, please contact:Ingrid PeuraSVP, Communications, Biomaterialstel. +358 50 307 0026Investor enquiries:Ulla PaajanenSVP, Investor Relationstel. +358 40 763 8767 Part of the bioeconomy, Stora Enso is a leading global provider of renewable solutions in packaging, biomaterials, wooden constructions and paper. We believe that everything that is made from fossil-based materials today can be made from a tree tomorrow. Stora Enso has some 26 000 employees in over 30 countries. Our sales in 2018 were EUR 10.5 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com  STORA ENSO OYJ 

INTERIM REPORT 1 APRIL– 30 JUNE 2019

“We will continue to explore commercialization opportunities for our imaging technology, and we took a first, and very important, step very recently though our first strategic partnership. The orthopaedic industry is dominated by a small number of large, global players. As we have previously communicated, at the right time the company is open to seeking a partnership for some or all of its products in key markets.” Second quarter 2019 compared to 2018, Group » Gross order intake amounted to SEK 1.3m (1.1) an increase of 21.0% » Order backlog amounted to SEK 0.7m (1.1) » 14,0% increase in orders for Episealer® knee implants during the quarter with 49 (43) approved orders » Group net sales Increased by 35.5% to SEK 1.1m (0.8) » Loss before tax amounted to SEK -18.9m (-16.2) » Earnings per share (weighted average) amounted to SEK -0.42 (-0.45) Significant events during the second quarter » Episurf Medical announced and conducted a rights issue and raised approximately SEK 75.2m prior to transaction costs » Episurf Medical announced that the EPIC-Knee study now is available at ClinicalTrials.gov and that the patient recruitment in the US was ready to start » Prof. Niek van Dijk joined Episurf Medical’s Clinical Advisory Board » The Episealer® implant was highlighted in three scientific publications » Clinical data for Episealer ® was accepted for presentation at a global scientific congress » US, Japanese and European patent approvals for Episurf Medical » Professor Mats Brittberg, Göteborg’s University, presented the Episealer ® at the ICRS Focus Meeting “One Step Cartilage Repair” in Rome, 5-7 June » The Company’s COO Jeanette Spångberg left the company on June 1 and the Company’s Chief Regulatory Officer – Regulatory Affairs, Quality and IP, Katarina Flodström, was appointed as new COO. In conjunction to these changes, Michael Näsström was appointed Acting Quality Manager » Episurf Medical announced that the Company will terminate the financing agreement with European Select Growth Opportunities Fund Significant events after the second quarter » Canadian patent approval for Episurf Medical » Episurf Medical enters into its first strategic partnership regarding its AI-based imaging technology For more  information, please contact: Pål Ryfors, CEO, Episurf MedicalTel:+46 (0) 709 62 36 69Email: pal.ryfors@episurf.com Veronica Wallin, CFO, Episurf MedicalTel:+46 (0) 700 37 48 95Email: veronica.wallin@episurf.com (pal.ryfors@episurf.com) About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 19 July 2019.

Stora Enso Oyj Half-year Report January–June 2019

Fit for the future, protecting profit and cash flowBergvik Skog transaction completedQ2/2019 (compared with Q2/2018) · Sales decreased by 2.1% to EUR 2 608 (2 664) million. · Operational EBIT margin was 11.0% (12.3%), above 10% for the eighth consecutive quarter. Operational EBIT was EUR 287 (327) million. · Operating profit (IFRS) was EUR 142 (317) million. · EPS decreased to EUR 0.08 (0.28) and EPS excl. IAC was EUR 0.22 (0.31). · Strong cash flow from operations amounted to EUR 548 (357) million. · The net debt to operational EBITDA ratio at 2.2 (1.3) increased temporarily slightly over the target level of 2.0, due to the restructuring of Bergvik Skog (impact 0.6) and the adoption of IFRS 16 Leases (impact 0.3). · Operational ROCE was 11.3% (15.5%) Q1–Q2/2019 (year-on-year) · Sales were EUR 5 242 (5 243) million, similar to the comparison period. · Operational EBIT of EUR 610 million decreased by 12.3%, mainly due to increased wood costs. Outlook for 2019Further deteriorating trading conditions caused by geopolitical uncertainties related to trade wars and a possible hard Brexit are expected to impact Stora Enso negatively. Demand growth is forecast to slow down for Stora Enso’s businesses in general and demand decline is escalating for European paper. Costs are forecast to increase in 2019 compared to 2018. Stora Enso will implement additional Profit Protection measures to mitigate these cost increases and the geopolitical uncertainties. Due to the current uncertainties in the business environment Stora Enso will not comment on estimated sales development in the outlook.Guidance for Q3/2019Q3/2019 operational EBIT is expected to be in the range of EUR 200–280 million. During the third quarter, there will be annual maintenance shutdown at the Beihai, Imatra, Heinola, Ostrołęka, Enocell and Veitsiluoto mills. The total maintenance impact is estimated to be on the same level as in Q3/2018 and EUR 30 million more than in Q2/2019. Key figures EUR million Q2/19  Q2/18  Change Q1/19  Change Q1–Q2/1 Q1–Q2/1 Change 2018 % % % Q1 Q2/19–Q Q2/19–Q -Q2/19– 9  8 2/18 1/19 Q1     -Q2/18Sales 2 608  2 664 -2.1% 2 635 -1.0% 5 242 5 243 0.0% 10 486Operational 435 466 -6.6% 471 -7.6% 907 970 -6.5% 1 878EBITDAOperational 287  327 -12.3% 324 -11.4% 610 696 -12.3% 1 325EBITOperational 11.0% 12.3% 12.3% 11.6% 13.3% 12.6%EBIT marginOperating 142 317 -55.3% 313 -54.7% 454 672 -32.4% 1 390profit(IFRS)Profit 214 285 -25.0% 286 -25.2% 499 618 -19.2% 1 190before taxexcl.IACProfit 93 257 -63.8% 282 -66.9% 375 590 -36.5% 1 210before tax(IFRS)Net profit 52 213 -75.6% 226 -76.9% 278 486 -42.9% 988for theperiod(IFRS)Net 3 973  2 442 62.7% 3 093 28.4% 3 973 2 442 62.7% 2 092interest-bearingliabilitiesOperational 11.3% 15.5% 14.0% 12.5% 16.5% 15.5%ROCEEarnings 0.22 0.31 -27.5% 0.30 -25.8% 0.52 0.66 -21.7% 1.29pershare (EPS)excl. IAC,EUREPS 0.08 0.28 -73.2% 0.29 -74.5% 0.37 0.63 -41.2% 1.28(basic),EURNet 2.2  1.3 1.7 2.2 1.3 1.1debt/last12months’operationalEBITDAratioAverage 26 553  26 155 1.5% 26 036 2.0% 26 352 25 798 2.1% 26 067number ofemployees Stora Enso’s CEO Karl-Henrik Sundström comments on the second quarter 2019 results:“We continued our transformation with two major steps during the quarter. Firstly, we finalised restructuring of our Swedish forest holdings by dividing Bergvik Skog with its shareholders. Currently we have a direct holding of 1.4 million hectares of forest in Sweden. This transaction increased our forestland holding by over 250 000 hectares and gives us better access to competitive raw material supply for the future. The direct ownership of forestlands improves our opportunities to further develop sustainable forest management, thus strengthening our competitiveness and self-sufficiency. This is important for us, as we strongly believe in the bioeconomy and the future business opportunities it offers to us. The average value per hectare in our balance sheet is 2 000 euros in Sweden. In the restructuring of Bergvik Skog AB, we decided to increase our part of the Swedish forest holdings, while one of the other major owners recently decided to sell with the price of 3 700 euros per hectare. Further, using the price statistics from LRF Konsult for smaller lots, the price per hectare has been 5 700 euros.The second major step in the transformation was our announcement of converting Oulu paper mill to kraftliner packaging board production. This is another action that shows our determination to grow in the packaging sector and reduce our exposure in the declining paper business. We have quite recently completed a similar project successfully when we converted one paper machine at Varkaus Mill to kraftliner. We have a proven track record in machine conversions.We reached double-digit operational EBIT margin for the eighth consecutive quarter, despite the further geopolitical uncertainty that impacted Stora Enso’s trading conditions. This materialised in a sales decline, and we have decided to intensify our profit protection measures. We increased the profit protection programme's target from EUR 120 million to EUR 200 million. I am impressed by the actions we have taken throughout the organisation. The programme is proceeding ahead of plan, and EUR 60 million of the cost savings have already been achieved.Our cash flow from operations was strong at EUR 548 million and we will continue on this path. We have intensified working capital management, addressing inventories is important in this economic environment. The focus on profit protection and cash generation is an opportunity to make us more fit for the future.The Consumer Board division improved its profitability year-on-year mainly due to successful selling price increases. The other divisions were clearly impacted by deteriorated trading conditions and they are addressing costs vigorously. The Biomaterials and Wood Products divisions were able to reach their strategic operating capital targets during the quarter. This was an especially great achievement as Stora Enso is facing challenging markets.We continue our proactive portfolio management and evaluate expansion in Wood Products to respond to the renewable materials construction demand in line with the global megatrend of green building. Stora Enso has initiated a feasibility study for a possible cross laminated timber (CLT) unit with 120 000 m³ capacity in connection with our Ždírec sawmill in the Czech Republic and a new 60 000 m³ construction beam mill located at the Ybbs sawmill in Austria.We are also investing in bio-based carbon materials for energy storage in Biomaterials division at Sunila Mill in Finland. We are building a pilot facility for producing bio-based carbon materials based on lignin. Wood-based carbon can be utilised as a crucial component in batteries typically used in consumer electronics, the automotive industry and large-scale energy storage systems.In Consumer Board we introduced DuraSense White and Cupforma Natura Solo. DuraSense is a biocomposite with a lower carbon footprint suitable for replacing plastic packaging components as such caps, lids and other types of food contact closures. Cupforma Natura Solo is a new renewable paperboard for paper cups. It is applicable for hot and cold drinking cups, as well as for ice cream packaging. It is produced without a traditional plastic coating layer and designed for full fibre recovery in a recycling process. These are two good examples of replacing fossil-based materials with renewable ones in the bioeconomy.As regards sustainability, Stora Enso was featured as a world leader in societal impact in a report by BCG (Boston Consulting Group).As always, I would like to thank our customers for their business, our employees for their dedication, and our investors for their trust." Events today1) Webcast and press conference in Helsinki at 11.00 EESTThe webcast and press conference for media will take place at 11.00 EEST (10.00 CEST, 09.00 UK time, 04.00 EDT) at Stora Enso’s Head Office, Kanavaranta 1, Helsinki. The event will be held in English and it will be hosted by CEO Karl-Henrik Sundström, CFO Seppo Parvi, and SVP, Communications Satu Härkönen. The webcast may be accessed at https://storaenso.videosync.fi/2019-q2-results  2) Webcast and conference call for analysts and investors at 14.00 EESTThe webcast and conference call for analysts and investors will take place at 14.00 EEST (13.00 CEST, 12.00 UK time, 07.00 EDT). It will be hosted by CEO Karl-Henrik Sundström, CFO Seppo Parvi, and SVP, Head of InvestorRelations Ulla Paajanen, and may be accessed at https://edge.media-server.com/m6/p/ueyp9oce.Those analysts and investors who wish to ask questions should join the conference call (details below). All participants can follow the presentation over the webcast. Live event at 14.00 EEST UK  +44 (0)2071 928 000 Finland  +358 (0)9 4245 0806 Sweden  +46 (0)8 5069 2180 USA  +1 631 510 7495 Confirmation Code:  6959688 The links to the webcasts are also available on the Stora Enso website: storaenso.com/investors .This release is a summary of Stora Enso’s Half-year Report January–June 2019. The complete report is attached to this release as a pdf file. It is also available on the company website at storaenso.com/investors .  For further information, please contact:Satu HärkönenSVP, Communicationstel. +358 40 832 7458 Investor enquiries:Ulla PaajanenSVP, Investor Relationstel. +358 40 763 8767 Part of the bioeconomy, Stora Enso is a leading global provider of renewable solutions in packaging, biomaterials, wooden constructions and paper. We believe that everything that is made from fossil-based materials today can be made from a tree tomorrow. Stora Enso has some 26 000 employees in over 30 countries. Our sales in 2018 were EUR 10.5 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com   STORA ENSO OYJ 

Intrum announces launch of offering of EUR 600 million Senior Notes due 2026

Today, Intrum announced that it has launched an offering (the “Offering”) of EUR 600 million in aggregate principal amount of fixed rate senior notes due 2026 (the “Notes”). The proceeds from the Offering will be used to refinance Intrum’s outstanding EUR 300 million senior floating rate notes due 2022 and SEK 3,000 million senior floating rate notes due 2022. Any excess proceeds will be used to repay amounts outstanding under Intrum’s revolving credit facility. For further information, please contact:Emil Folkesson, Group Treasury Director+46 (0) 8 546 102 02 Viktor Lindeberg, Head of Investor Relations+46 (0) 8 546 102 02 Cautionary StatementThe Offering is being made by means of an offering memorandum. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful. The Notes have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States, or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. Accordingly, the Notes are being offered and sold in the United States only to qualified institutional buyers in accordance with Rule 144A under the Securities Act and to non-U.S. persons outside the United States in accordance with Regulation S under the Securities Act. Promotion of the Notes in the United Kingdom is restricted by the Financial Services and Markets Act 2000 (the “FSMA”), and accordingly, the Notes are not being promoted to the general public in the United Kingdom. This announcement is only addressed to and directed at persons who (i) are outside the United Kingdom, (ii) have professional experience in matters relating to investments (being investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order”)), (iii) fall within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations, etc.”) of the Financial Promotion Order, or (iv) to the extent that doing so does not prejudice the lawful distribution of the announcement to the foregoing, are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any Notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “relevant persons”). The Notes will only be available to relevant persons and this announcement must not be acted on or relied on by anyone who is not a relevant person. This announcement does not constitute and shall not, in any circumstances, constitute a public offering nor an invitation to the public in connection with any offer within the meaning of the Directive 2010/73/EU of the Parliament and Council of November 4, 2003 as implemented by the Member States of the European Economic Area (as amended, including by Directive 2010/73/EU, or superseded, including by Prospectus Regulation (2017/1126) of 14 June 2017, the “Prospectus Directive”). The offer and sale of the Notes will be made pursuant to an exemption under the Prospectus Directive, as implemented in Member States of the European Economic Area, from the requirement to produce a prospectus for offers of securities. Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail investors in EEA. This press release may include “forward looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward looking statements can be identified by the use of forward looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will” or “should” or, in each case, their negative, or other variations or comparable terminology. These forward looking statements include all matters that are not historical facts and include statements regarding Intrum or its affiliates’ intentions, beliefs or current expectations concerning, among other things, the Offering. By their nature, forward looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward looking statements are not guarantees of future performance and that Intrum and its affiliates’ actual results of operations, financial condition and liquidity, and the development of the industry in which they operate may differ materially from those made in or suggested by the forward looking statements contained in this press release. In addition, even if Intrum or its affiliates’ results of operations, financial condition and liquidity, and the development of the industry in which Intrum operate are consistent with the forward looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. Given these risks and uncertainties, you should not rely on forward looking statements as a prediction of actual results. This information was submitted for publication, through the agency of the contact person set out above, at 11.00 CET on July 19, 2019. 

Financial Report April – June 2019

Q2 2019: Navigating through challenging conditions  Financial highlights Q2 2019 $2,155m consolidated sales1.5% organic sales growth*7.9% operating margin8.5% adj. operating margin*$1.25 EPS - a decline of 43%$1.38 adj. EPS* - a decline of 38% Full Year 2019 indications1% to 3% organic sales growth(1)% to 1% consolidated sales growth9.0% to 9.5% adj. operating margin Key business developments in the second quarter of 2019 · Organic growth outperformed global light vehicle production by 9.1pp mainly due to Americas and China.Key business developments in the second quarter of 2019 · Profitability continued to be impacted by severe global LVP decline and high raw material costs. · Accelerated cost improvement actions. Total workforce declined by 1,208 in the quarter, mainly direct labor. Initiated actions to reduce indirect headcount by about 5%. Additional restructuring measures are being evaluated. · *For non-U.S. GAAP measures see enclosed reconciliation tables. All figures herein refer to continued operations, excluding former Electronics segment, unless stated otherwise. All change figures in this document compare to the same period of previous year, except when stated otherwise. Key Figures +-----------------------+------+------+-------+------+------+--------+|(Dollars in millions, | Q2| Q2| Change| H1| H1| Change||except per share data) | 2019| 2018| | 2019| 2018| |+-----------------------+------+------+-------+------+------+--------+|Net sales |$2,155|$2,212| (2.6)%|$4,329|$4,452| (2.8)%|+-----------------------+------+------+-------+------+------+--------+|Operating income | $170| $229| (26)%| $343| $473| (28)%|+-----------------------+------+------+-------+------+------+--------+|Adjusted operating | $183| $230| (20)%| $350| $475| (26)%||income[1]  | | | | | | |+-----------------------+------+------+-------+------+------+--------+|Adjusted operating | 8.5%| 10.4%|(1.9)pp| 8.1%| 10.7%| (2.6)pp||margin[1] | | | | | | |+-----------------------+------+------+-------+------+------+--------+|Earnings per share, | $1.25| $2.20| (43)% |$2.52 |$4.02 | (37)% ||diluted[2], [3]  | | | | | | |+-----------------------+------+------+-------+------+------+--------+|Adjusted earnings per | $1.38| $2.22| (38)%| $2.57| $4.04| (36)%||share, diluted[1], [2],| | | | | | ||[3] | | | | | | |+-----------------------+------+------+-------+------+------+--------+|Operating cash flow[4] | $(21)| $201|(110)% | $133 | $282 | (53)% |+-----------------------+------+------+-------+------+------+--------+|Return on capital | 18.3%| 21.2%|(2.9)pp|18.9% |21.5% |(2.6)pp ||employed[5] | | | | | | |+-----------------------+------+------+-------+------+------+--------+|[1] Excluding costs for ||capacity alignment and ||antitrust related ||matters. [2] Assuming ||dilution and net of ||treasury shares. [3] ||Participating share ||awards with right to ||receive dividend ||equivalents are (under ||the two-class method) ||excluded from the EPS ||calculation. [4] For Q2 ||2018 and H1 2018 ||management estimate for ||Continuing Operations ||derived from cash flow ||including Discontinued ||Operations. [5] ||Operating income and ||income from equity ||method investments, ||relative to average ||capital employed. |+-----------------------+------+------+-------+------+------+--------+ Comments from Mikael Bratt, President & CEO  We experienced another challenging quarter dominated by severe weakness in global light vehicle markets and high raw material costs with reduced profitability as a consequence. The uncertainty remains high in a falling market and we currently do not see any signs of a turnaround in light vehicle demand. Therefore we now indicate a lower full year 2019 sales and profitability. As market weakness has continued in the second quarter, we have stepped up the cost improvement actions, including targeting a reduction of our indirect workforce by approximately 5% and implementing a sharpened purchasing process. We already see effects from our current cost reduction actions, with total headcount declining by around 1,200 in the second quarter and launch related costs continuing to decline vs. the first quarter. I am generally pleased with how we managed the sharp decline in global LVP by the cost reduction actions we implemented and are planning. Furthermore, I see both room and need for additional improvements in certain areas. Our sales continued to develop significantly better than LVP, with organic growth* outperforming LVP in all regions except Japan, where we expect outperformance to begin later in the year. In North America and China, our organic growth was 14pp higher than LVP growth, while it was 9pp above global LVP growth. Order intake continued on a good level, securing a strong order book and a prolonged outperformance vs. LVP. In addition to our near term focused cost reduction actions, we have accelerated our efforts on building the foundation for improving the entire value chain. This includes increased flexible automation, digitalization and R,D&E efficiency. We are well positioned to navigate through significant challenges from LVP volatility and geopolitical uncertainty by forcefully implementing necessary near-term cost reductions and investing for longer term margin improvement, while as always having quality as our first priority.   Conference call and webcast An earnings conference call will be held at 2:00 p.m. CET today, July 19, 2019. Information regarding how to participate is available on www.autoliv.com. The presentation slides for the conference call will be available on our website shortly after the publication of this financial report. Inquiries: Investors and Analysts Anders TrappVice President Investor RelationsTel +46 (0)8 58 72 06 71 Henrik KaarDirector Investor RelationsTel +46 (0)8 58 72 06 14 Inquiries: Media  Stina ThormanVice President CommunicationsTel +46 (0)8 58 72 06 50  This information is information that Autoliv, Inc. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the VP of Investor Relations set out above, at 12.00 CET on July 19, 2019.